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Abstract 
Background 
 In recent years there has been a substantial increase in research 
examining the role of subjective memory complaints (SMC) in cognitive 
function and Alzheimer’s disease.  These studies have related SMC to many 
different cognitive outcomes, such as retaining normal cognitive function, a 
fluctuating cognitive performance and the development of Alzheimer’s 
disease.  Most of these studies have focused on older populations and have 
employed a limited assessment of cognitive function.  This limits the 
available evidence regarding the clinical utility of SMC.  The literature on the 
role of SMC in younger subjects is scarce.  It is not known whether memory 
complaints are useful in predicting future cases of Alzheimer’s disease in 
younger community-based subjects. 
 
Aims 
The main aim of the present study was to determine whether SMC 
predict the development of cognitive impairment in a younger cohort of 
subjects, many of whom were under the age of 70 years (73%), based on 
their risk profile and neuropsychological assessment.  A further aim was to 
ascertain whether the DRS or 7MS are sensitive screening tools for MCI and 
examine whether the presence of SMC affects the 3-year cognitive outcome 
of subjects. 
To address these aims, this study consisted of two parts: a cross-
sectional design and a longitudinal follow-up component.  
 vii 
Methods 
This study was carried out with 86 community-dwelling subjects 
recruited via advertisement within the catchment area of Central Sydney 
Area Health Service.  The mean age of the subjects was 63.1 years 
(SD=8.4).  Subjective memory complaints were assessed using a single 
question.  Cognitive function was assessed using a comprehensive battery of 
tests, selected on the basis of their sensitivity to identifying cognitive 
impairment typically associated with Alzheimer’s disease.  After the initial 
analysis between those with SMC and without SMC, subjects were further 
classified according to their performance on an episodic memory task (i.e., 
delayed verbal recall, Rey, 1964) as having normal memory function, SMC or 
aMCI. 
 
Results  
Part 1 
Subjective memory complaints (SMC) were reported by 63% of the 
sample.  The initial analysis between subjects with SMC (n=54) and without 
SMC (n=32) suggested an initial relationship between SMC and cognitive 
functioning.  Subjects with SMC had impaired global cognitive functioning on 
two brief screening tests (7MS and DRS), working memory, verbal recall and 
visuomotor speed. 
However, subsequent screening with the delayed verbal recall test 
showed that 12 of the 54 subjects with SMC demonstrated significant 
cognitive impairment, scoring 2 SD below the control group mean.  After 
 viii 
these subjects were removed to form the aMCI group, the cognitive 
differences between subjects with SMC and without SMC were no longer 
apparent.  Subjects with aMCI showed evidence of multiple cognitive deficits 
(below 1 SD of control group mean) with a high percentage of subjects 
demonstrating impairment on tests of verbal learning, verbal recall, verbal 
ability and visuomotor speed. 
Further analysis showed a significant association between age and 
subjects identified as having SMC (r=-.581, p<.001) and aMCI (r=.692, 
p<.001).  From the age of 60 onwards, both the SMC and aMCI groups 
demonstrated a more rapid cognitive decline with increasing age in several 
cognitive domains.   
 
Part 2 
 After a mean interval of 3.2 years, 43 subjects were followed up.  
Subjects with aMCI showed evidence of greater decline on both screening 
tests (7MS; DRS), whilst the SMC group had significantly higher scores.  This 
trend was also apparent with other neuropsychological testing.  The analysis 
of change over time in cognitive function showed that the majority of 
subjects (both SMC aMCI) either remained stable or improved their cognitive 
performance.  It is likely that the small sample size and short follow-up 
interval of the present study contributed to the present observation of no 
change in cognitive function over time.   
 
 
 ix 
Discussion 
 The present findings suggest that subjective memory complaints are a 
poor predictor of cognitive function.  In isolation, SMC are unlikely to be 
useful for identifying cases with significant cognitive impairment.  This is 
particularly relevant for subjects under the age of 70 years.  However, for 
subjects over the age of 70 years, SMC are likely to identify significant cases 
with neuropsychological assessment (such as animal fluency and delayed 
recall).   
 
Conclusion 
The present study showed that SMC are a poor predictor of cognitive 
function in subjects under the age of 70 years.  This study provided evidence 
that selected and relatively quick to administer formal neuropsychological 
tests of cognitive function (in particular tests of animal fluency and delayed 
recall) are better able to identify those at risk of developing cognitive 
impairment associated with Alzheimer’s disease, at an earlier age.  This 
would thus allow exposure to earlier treatment options, such as donepezil, 
aricept, vitamin E, and memantine”. 
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Chapter 1: 
Alzheimer’s disease and 
current challenges 
 
 
1.1 Synopsis  
In 1907, the German physician Alois Alzheimer published the first 
paper describing the symptoms of a 51 year old female named Auguste D. 
with what has come to be known as Alzheimer’s disease (Maurer, et al., 
1997).  Auguste presented with a cluster of symptoms and signs including a 
rapidly deteriorating memory, language difficulties, disorientation and 
psychotic features.  This cluster did not fit any known diagnosis of the time.  
After Auguste’s death, Dr. Alzheimer performed an autopsy.  He found 
shrinkage of the brain and two types of protein deposits he described as 
senile plaques and neurofibrillary tangles.  Today these features are 
considered neuropathological hallmarks of Alzheimer’s disease.  Over the last 
few decades, there has been a substantial increase in Alzheimer research 
and a resultant increase in publications on this topic.  A basic medline search 
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(using the term Alzheimer*) will illustrate the explosion of Alzheimer 
research over the last 40 years.  There were 14 publications in 1970, 113 in 
1980, 1381 in 1990.  By 2000 and 2008, it was 3163 and 3856, respectfully. 
Slowing the progression or delaying the onset of Alzheimer’s disease 
is urgent from a patient, carer, and economic perspective.  A delay in onset 
of 5 years would reduce the overall prevalence by 50% (Cummings et al., 
2007).  The most recent information indicates that maximum benefits will be 
obtained if treatment is initiated early in the course of the disease process 
before symptoms occur or when mild symptoms first appear.  Thus, 
identifying patients early in the disease processes poses a major challenge to 
clinicians and the greater scientific community.  The introductory chapters 
review some of the major challenges associated with identification of early 
treatment populations, risk factors, treatment options and diagnostic issues 
relating to Alzheimer’s disease.  
Before beginning any study into Alzheimer’s disease, it is important to 
clarify the existing confusion between dementia and Alzheimer’s disease.  
Often in the literature the terms can be confused, as they may be used 
interchangeably.  Clearly, Alzheimer’s disease is the most common type of 
dementia in the elderly, accounting for more than half of all dementia cases 
(Brookmeyer et al., 2007), whereas dementia is a clinical syndrome with 
multiple aetiologies.  Also, other dementias, in particular those of vascular 
aetiology, may co-exist with underlying Alzheimer’s disease neuropathology.  
In the present thesis, the term ‘Alzheimer’s disease’ will be used because it is 
the most likely cause of dementia in 50 to 70% of cases (Alzheimer’s 
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Association, 2009).  The term ‘dementia’ is used when it is not clear from the 
literature the exact underlying aetiology of the dementia syndrome. 
 
1.2. Definition 
Dementia is a term used to describe a group of disorders which cause 
a progressive decline in memory and other cognitive functions that interfere 
with social and occupational functioning (APA, 2000).  It is frequently 
accompanied by neuropsychiatric symptoms, such as depression, psychosis 
or behavioural problems (Kelley and Petersen, 2007).   
Alzheimer’s disease is a progressive neurodegenerative brain disease.  
It is clinically characterized by cognitive deficits in memory, executive 
functioning and loss of language skills.  There are associated impaired 
activities of daily living and a range of behavioural and psychological 
symptoms; all with severe debilitating consequences (Bäckman et al., 2004b; 
Twamley et al., 2006).  
The typical early neuropsychological profile of Alzheimer’s sufferers 
consists of prominent complaints of memory difficulty.  This is accompanied 
by deficits in new learning and a disproportionate decline in memory function 
relative to other cognitive domains.  This is a hallmark feature of the disease 
(Hodges, 2006).  The major impairment early in the disease is in 
anterograde episodic memory.  Patients show poor recall of stories, and/or 
complex figures (Complex Figure Test; Rey, 1964) along with impaired 
recognition memory for previously studied words and faces (Geldmacher, 
2004). 
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1.3 Epidemiology 
Prevalence  
A Delphi consensus study (Ferri et al., 2005) estimates that there are 
24 million people worldwide with dementia.  New cases per year total 4.6 
million (i.e. one new case every 7 seconds).  By 2016, dementia will surpass 
depression as the largest cause of disability burden in Australia.  It will 
become the major public health issue in this country (Brodaty et al., 2005).  
In Australia, estimates indicate that more than 200,000 are living with 
dementia (Jorm, 2005). In the absence of a cure, adequate prevention 
strategies or means to slow its progression, the prevalence of dementia in all 
of Australia is expected to more than triple (Jorm, 2005). 
 
Incidence 
By 2050, over 175,000 new cases of dementia will be diagnosed each 
year in Australia.  Of these, almost half will have Alzheimer’s disease.  The 
incidence increases exponentially with age and more than half of all cases of 
Alzheimer’s disease are expected to occur among people older than 75 years 
(Jorm and Jolly, 1998).  Thus, the incidence of Alzheimer’s disease is 
predicted to increase at a faster rate than both the total population and the 
elderly population (Jorm et al., 2005a), (see Figure 1.1).  
By 2050, almost one in five Australians will be 65 years or older.  
After the age of 65, the probability of developing Alzheimer’s disease doubles 
every 5 years (Brookmeyer et al., 2007).  As the population is ageing the 
number of people affected by the Alzheimer’s disease will also increase 
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(Henderson and Jorm, 1998).  The very old (>80 years) (who are most likely 
to suffer from Alzheimer’s disease), are expected to increase at a faster rate 
than either the total population or the young old (55 to 75 years) (Jorm, 
2005).   
This scenario will be evident worldwide as the numbers of people 
affected with dementia (including those with Alzheimer’s disease) will double 
every 20 years to reach 81 million by the year 2040 (Ferri et al., 2005).   
Australia
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Figure 1.1 Projected increase in dementia cases, elderly population and total population for 
Australia, 2000-2050.  Adapted from Jorm et al. (2005a). 
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1.4 Clinical diagnosis 
During the lifetime of the patient, Alzheimer’s disease is a clinical 
diagnosis requiring the patient to have dementia with no other disease 
established as the cause of the disorder.  A brain biopsy may support the 
clinical findings of Alzheimer’s disease; however this diagnostic procedure is 
very rarely used.  A definitive diagnosis is made on the basis of 
neuropathological findings at autopsy.  The hallmarks of Alzheimer’s disease 
are two principal pathological features, namely plaques and neurofibrillary 
tangles.  Both are required for a neuropathological diagnosis of Alzheimer’s 
disease.  In-vivo, the diagnosis is based on clinical criteria and there are 
biological markers available which can help with diagnosing Alzheimer’s 
disease, e.g. brain imaging (Amyloid-Positron Emission Tomography, 
Flurodeoxyglucose Positron Emission Tomography, Single-Photon Emission 
Computerised Tomography, Magnetic Resonance Imaging, Computerised 
Tomography) as well as Cerebrospinal Fluid concentration of tau and b-
amyloid. 
The most widely used diagnostic systems for Alzheimer’s disease are 
the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders IV-TR, 
published by the American Psychiatric Association 2000), the ICD-10 
(International Classification of Diseases) endorsed by the World Health 
Organization (1992), and the NINCDS-ADRDA criteria of the National 
Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s Disease and Related Disorders Associations (McKhann et al. 
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1984).  These systems are used by clinicians to improve reliability and 
uniformity of diagnosis. 
In research settings, the NINCDS-ADRDA criteria are the most widely 
used to determine the diagnosis of Alzheimer’s disease.  According to the 
NINCDS-ADRDA criteria, Alzheimer’s disease can be diagnosed at three 
different levels of certainty (“definite AD”; “probable AD” and “possible AD”).  
The clinical diagnostic accuracy has been reported to exceed 90% with 
patients who are in the mid to late stages of the disease (Dubois et al., 
2007).  However, it should be emphasized that the diagnostic accuracy of 
Alzheimer’s disease varies greatly depending on where the diagnosis is done, 
e.g. research memory clinic versus rural areas, general practitioners and 
general hospital. 
In clinical settings, the DSM-IV-TR criteria for dementia of the 
Alzheimer’s type requires the development of memory impairment to be 
accompanied by impairment in one or more other cognitive domains, (being 
aphasia, apraxia, agnosia, or executive function, see Table 1.1).  The 
cognitive impairments are gradually progressive, of sufficient severity to 
impair functional abilities, and exclude other neurologic or psychiatric 
disturbances, in particular major depressive disorder.  Delirium (usually an 
acute confusional state of sudden onset) also requires exclusion.  
The ICD-10 criteria for dementia include an acquired and significant 
decline of memory and learning function plus the decline in at least one 
other cognitive domain (e.g., thinking, language abilities, visuospatial 
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orientation and concentration).  The condition needs to be present for at 
least 6 months and an acute confusional state should be excluded.  
Table 1.1 DSM-IV-TR diagnostic criteria for Dementia of the Alzheimer’s Type 
(DAT) 
A. Memory impairment in learning or recall and 
      One or more of the following 
1. Aphasia: language difficulties 
2. Apraxia: difficulty performing purposeful movements 
3. Agnosia: difficulty recognising people or objects 
4. executive dysfunction 
B. Cognitive deficits of sufficient severity to affect social or occupational  
      functioning, representing a significant decline from a previous level 
C. Clinical course with gradual onset and progression 
D. Other causes for dementia have been excluded 
1. No alternative central nervous system explanation (e.g., stroke,   
                       Parkinson’s disease) 
2. No alternative systemic conditions 
3. Not due to the effects of substance use 
E. Not caused by delirium 
F. Not better accounted for by another Axis I disorder (e.g., Major Depression, 
Schizophrenia) 
Adapted from the American Psychiatric Association (2000). Diagnostic and Statistical Manual 
of Mental Disorders, 4th edition-text revision. APA Press: Washington, D.C. 
 
1.5 Clinical course 
Clinically, the course of Alzheimer’s disease is typically divided into 
three stages, each with different patterns of cognitive and 
functionalimpairment (Cummings, 2004).  The course of the illness varies, as 
each individual progresses through the disease and may in fact retain some 
of their abilities.  However, the end stage of the disease is very similar.   
For research purposes, Alzheimer’s disease is considered to have a 
predementia phase lasting a number of years during which mild cognitive 
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deficits are apparent on formal testing (Bäckman et al., 2004b; Amieva et al., 
2005).  During this phase, the person may complain about their memory, 
however they are able to function independently in the community.  A more 
detailed review of the pre-dementia phase of Alzheimer’s disease is 
discussed in Chapter 3, as it has particular relevance to this study.  
 
The three stages are: 
Stage 1. Mild 
In the mild stage of clinical AD, there is amnesia for recent events and 
complaints about memory.  The amnesia is characterized by forgetfulness 
 (e.g., asking repetitive questions, misplacing items) and an inability to learn 
new information (e.g., recalling recent events).  In contrast, the retrieval of 
old information and long-term memory is usually unimpaired.  Attention 
deficits have also been identified (e.g., Chen et al., 2001).  The memory 
deficit has been attributed to pathology of the medial temporal lobe 
(hippocampus and entorhinal cortex) and the deficit in attention as the first 
clinical manifestation of a significant involvement of the parietal cortex 
(Chen, 2001).  
These deficits become evident when the patient is exposed to new 
conditions.  Personality change and depressive symptoms, such as 
disinterest and social withdrawal are also apparent.  During this stage, the 
person is still able to manage independently. 
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Stage 2. Moderate 
In the moderate stage, patients tend to lose things and repeatedly 
ask the same questions.  Language is characterised by an impoverished 
vocabulary of semantically empty words (e.g., ‘thing’, ‘stuff’), 
circumlocutions, excessive use of pronouns, gestures, and semantic 
paraphasias are used to overcome word-finding difficulties in order to 
maintain the fluency of conversation.  Reading and writing are progressively 
forgotten.  Orientation to time and place is poor.  Agnosia, apraxia, and 
deterioration of executive functions become evident, followed by an inability 
to perform activities of daily living.  The memory problems worsen, and the 
person may not recognise close relatives.  Previously intact long-term 
memory shows impairment.  
In the moderate stage, behaviour changes are the norm and patients 
also manifest labile affect, restlessness, irritability, agitation, aggression and 
wandering.  In many cases the behavioural problems seen in stage 3 are 
related to the involvement of the frontal lobes.  The patient is partly 
dependent on help from others, especially when faced with new situations or 
problems.  
 
Stage 3: Severe 
In the advanced stage of clinical AD, language is reduced to simple 
phrases or even single words.  However, many patients can receive and 
return emotional signals long after the loss of verbal language.  Patients 
commonly manifest behavioural problems, apathy, restlessness and 
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exhaustion.  Neurological symptoms, such as apraxia and extrapyramidal 
disorders are common.  The patient needs help and guidance in all basic 
functions in their everyday life.  Patients will ultimately not be able to 
perform the simplest of tasks independently.  They are likely to develop 
other illnesses and infections. 
Deterioration of muscle and mobility will develop, leading the patient 
to become bedridden and lose the ability to feed them self.  Death is usually 
not due to the disease itself, but rather to a secondary infection such as 
pneumonia or urinary tract infections.  The course of the disease is a gradual 
and progressive decline with an average duration from diagnosis to death of 
8 years (Brookmeyer et al., 2002).  
 
The role of medications during the course of Alzheimer’s disease 
 The role of medication in the management of dementia is multifaceted 
as it may prevent or delay the onset of the disease by slowing the 
progression or treating memory problems and reducing secondary symptoms 
such as depression and hallucinations.  A two-year study of vitamin E in 
patients with Alzheimer’s disease showed a significant delay in functional 
decline, and nursing home placement, compared to selegiline and placebo 
(Sano et al., 1997).  Primary symptoms are often treated with cholinesterase 
inhibitors (e.g. donepezil, rivastigmine and galantamine), memantine and 
ginkgo biloba.  One RCT study showed that donepezil significantly delayed 
the progression to dementia in a subgroup of depressed aMCI patients by 
1.7 to 2.2 years (Lu et al., 2009) compared to placebo controls.  Early 
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initiation of cholinesterase treatment may temporarily stabilize or delay 
disease progression (Farlow et al., 2007).  These mediations stop the 
breakdown of acetylcholine and show a modest improvement in cognitive 
function and behavioural symptoms.  Current medications to treat secondary 
symptoms (e.g., depression and agitation) include anti-depressants, anti-
psychotics and mood stabilizers.     
 
Conversion to dementia 
 It is difficult to pinpoint the precise point at which a person converts 
to dementia, hence the rapid growth in research into MCI.  The boundary 
between normal ageing, mild cognitive impairment and dementia remain 
unclear and contentious as noted in Chapter 3.  Importantly, longitudinal 
studies of cognitive ageing do not identify a single point of transition 
between ‘normal’ ageing and dementia. When several cognitive domains are 
used to predict later onset of dementia, cognitive decline is typically non-
uniform across domains (Amieva et al., 2005). 
 
1.6 Differential diagnosis 
 Differentiating among the many causes of cognitive impairment that 
resemble the clinical state of dementia is vital in terms of treatment and 
prognosis.  The identification of potentially reversible conditions, such as 
delirium and depression is absolutely necessary.  Differential diagnosis 
begins by conducting a careful history (particularly from significant others), a 
thorough mental state and physical examination as well as appropriate 
laboratory investigations to exclude delirium, depression and potentially 
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medically treatable conditions such as hypothyroidism or vitamin B12 
deficiencies.  It is essential to exclude delirium.  The distinguishing feature is 
an impairment of consciousness, which occurs in delirium and not in 
dementia.  However, a delirium may be superimposed on an underlying 
dementia (Rahkonen et al., 2000). 
The distinction between major depression (“pseudo-dementia”) and 
dementia is also essential.  As with delirium, a major depression may also be 
concurrent with an underlying dementia of the Alzheimer’s type (Greenwald 
et al., 1989).  This section discusses differences between major depression 
and Alzheimer’s disease.  
       Table 1.2 Criteria for Major Depressive Disorder 
 
A. In addition to the presence of depressed mood and/or loss of interest or pleasure,  
    the DSM-IV-TR requires the presence of at least five of the following symptoms to  
    have been present during the same 2-week period. 
 
1.   Depressed mood most of the day, nearly every day 
1. Markedly diminished interest or pleasure in activities 
2. Significant weight loss when not dieting or weight gain 
3. Insomnia or hypersomnia nearly every day 
4. Observable psychomotor agitation or retardation nearly every day 
5. Fatigue or loss of energy nearly every day 
6. Feelings of worthlessness or excessive or inappropriate guilt 
7. Diminished ability to think or concentrate, or indecisiveness 
8. Recurrent thoughts of death, plans or suicide attempts 
   The symptoms: 
B. Do not meet criteria for a Mixed Episode 
C. Cause significant impairment in social or occupational functioning 
D. Are not due to the effects of substance use or a medical condition 
E. Are not better accounted for by bereavement 
       Adapted from the American Psychiatric Association (2000). Diagnostic and Statistical  
      Manual of Mental Disorders, 4th ed text revision. APA Press: Washington, D.C. 
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Depression 
According to DSM-IV-TR criteria, major depressive episode or disorder 
(major depression) is a mood disorder that produces profound sadness, loss 
of interest in life, disturbed sleep, appetite change, impaired thinking and 
energy levels (APA, 2000).  An exact definition is adapted from DSM-IV-TR 
(see Table 1.2).  
Depression co-occurs in a number of psychiatric disorders, and is 
frequently present in dementia.  The depression may or may not be “major” 
in type.  When “major”, it will often significantly affect cognitive functioning 
(Steffens and Potter, 2008).  In the initial stages, it is often difficult to 
distinguish between major depression and Alzheimer’s disease.  Many 
features of major depression overlap with those found in dementia, such as 
memory problems, low mood, loss of interest, withdrawal, fatigue, 
concentration difficulties and sleep difficulties.  Further, complicating the 
distinction is the realization that in 25% to 50% of cases, depression and 
dementia co-exist (Greenwald et al., 1989). 
However, there are some important clinical and neuropsychological 
differences between patients with major depression and those with early 
Alzheimer’s disease (see Table 1.3). 
As shown in Table 1.3, depressed patients typically report more 
memory complaints.  This is likely to reflect the distinct features of major 
depression, such as negativity, self deprecation along with impaired 
concentration.  Patients with AD frequently underestimate their impairments 
and engage in confabulation (Geldmacher, 2004) due to the loss of insight 
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 Table 1.3. Clinical and cognitive presentations of Major Depression compared to 
Alzheimer’s disease  
Feature Major Depression Alzheimer’s disease 
Age of onset Above or below 60 Uncommon below 60 
Rate and course of cognitive 
change 
Acute; mood congruent 
changes; either improve with 
remission or persist 
Insidious;  progressive 
decline 
Subjective memory 
complaints 
Overestimate Underestimate 
Affect Sadness > apathy Apathy > sadness in the 
presence of mood changes; 
apathy may exist in isolation 
Sleep-wake cycle Disturbed Variable 
Memory  Learning improves with 
repeated exposure 
Cueing improves recall 
 
Fewer intrusion errors in 
recall 
Learning does not improve 
despite repeated exposure 
Rapid forgetting; cueing 
does not improves recall 
Greater intrusion errors in 
recall 
Aphasia; Apraxia; Agnosia Uncommon Common 
Executive functions Initially impaired; improves 
when depression lifts  
May be initially 
compromised; declines later 
in disease 
Information processing 
speed 
Slowed Normal in early stage 
Psychomotor speed Slowed  Normal in early stage  
Effort  Impairment on effortful 
cognitive tasks 
Normal effort in response to 
cognitive demands of task 
Adapted from Steffens and Potter (2008).  
known to occur in patients with Alzheimer’s disease (Clement et al., 2008; 
Kim et al., 2006).  Depressed patients typically demonstrate psychomotor 
slowing combined with poor effort and cooperation on cognitive testing (e.g., 
producing incomplete answers).  In contrast, decreased performance on 
cognitively demanding tasks reflects the AD patient’s genuine inability to 
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perform the task, rather than a lack of effort.  Moreover, on episodic 
memory tests; patients with Alzheimer’s disease do not benefit from cueing 
to facilitate remembering, whereas depressed patients benefit from cueing.  
Major depression as a risk factor for Alzheimer’s disease is discussed in 
Chapter 2. 
 
Diagnostic types 
To assist with differential diagnosis, key early presentations of 
different dementias are listed in Table 1.4 and reviewed in the text. 
 
Vascular Dementia  
Vascular dementia involves the loss of cognitive function resulting 
from ischaemic, hypoperfusive or hemorrhagic brain lesions due to 
cerebrovascular disease or cardiovascular pathology (Geldmacher, 2004; 
Roman, 2004).  Vascular dementia is a common cause of dementia, second 
in prevalence only to Alzheimer’s disease (Gorelick et al., 2004).  Alzheimer’s 
disease and vascular dementia frequently co-exist and account for up to 
35% of all dementia cases (Geldmacher, 2004; Zekry et al., 2002).  The 
onset of vascular dementia is typically abrupt, followed by a stepwise 
deterioration or progressively worsening condition (Schindler, 2005).  
Patients typically have deficits in encoding or retrieval, but their performance 
improves with cues, and recognition may be normal.  Rapid forgetting is 
atypical.  They are prone to slowed mental processing and disturbances in 
executive functioning; frequently accompanied by depression.  Vascular 
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dementia has a higher prevalence in men than women, and onset is usually 
after the age of 70 years.  
 
Table 1.4 Essential differences between Alzheimer’s disease and other dementias 
 AD VaD FTD DLB 
Onset 
 
Insidious Sudden, 
staggered or 
insidious 
Insidious Insidious 
Course 
 
Slowly 
progressive 
Stepwise, 
fluctuating, 
variable or 
insidious  
Gradual 
progression 
Often rapidly 
progressive and 
may fluctuate 
on a daily basis 
Cognitive 
deficits 
 
Multiple 
cognitive 
deficits 
Focal deficits;  
mental 
slowness;  
 
Cognition 
reasonably 
preserved in 
early stages; 
language more 
affected earlier 
than AD 
Visuo-
perceptual skills 
+ attention;  
+letter fluency 
Functional/     
Behavioural 
findings 
 
Executive 
dysfunction; 
apathy; loss of 
insight; 
emotional 
withdrawal 
Incontinence; 
executive 
dysfunction; 
preserved 
insight; gait 
disturbances;  
depression 
Disinhibition; 
apathy; loss of 
insight; 
emotional 
blunting 
 
Executive 
dysfunction; 
apathy; 
depression; 
Psychosis (esp. 
visual 
hallucinations) 
more common 
than AD; 
Parkinsonian 
features  
AD=Alzheimer’s disease; VaD=Vascular Dementia; FTD=Frontotemporal Dementia; 
DLB=Dementia with Lewy bodies. 
Adapted from APA (2000); Ferman et al. (2006); Hodges et al. (1992); Geldmacher (2004); 
McKeith (2007); Neary et al. (1998). 
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Frontotemporal dementia  
Frontotemporal dementia describes a group of clinical syndromes 
associated with damage to the prefrontal and anterior temporal lobes and 
presents with non-Alzheimer type pathology (Hodges et al., 1992; Neary et 
al., 1998; Mesulam, 2001).  In the early stages, frontotemporal dementia is 
frequently misdiagnosed as a psychiatric disorder or Alzheimer’s disease 
(McKhann et al., 2001).  Frontotemporal dementia can present as either the 
behavioural/frontal variant or aphasic variant.  Symptoms indicating the 
behavioural variant include; disinhibition, impulsivity, apathy, obsessive 
compulsive disorder in the context of good cognitive skills.  Patients also 
experience emotional blunting and loss of insight resulting in disturbed in 
social comportment (Liscic et al., 2007).  Communication abilities remain 
preserved until later stages of the disease.  Frontotemporal dementia occurs 
between 45 and 65, at an age when many patients are still employed, but in 
a quarter of cases the onset is over the age of 65 years (Hodges, 2001).  
The aphasic variant can be further divided into two subtypes: 
Semantic Dementia and progressive non-fluent aphasia. 
 
a. Semantic Dementia 
Semantic dementia was initially coined by Snowden et al. (1989) to 
describe a form of frontotemporal dementia, associated with deterioration of 
semantic memory as a consequence of focal atrophy of the left temporal 
lobe.  Patients with semantic dementia typically have fluent, effortless, 
grammatical speech which lacks content.  Patients with semantic dementia 
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can be identified by their high endorsement of semantic complaints not 
found in other patient groups (Ahmed et al., 2008).  They often experience 
difficulty retrieving words, understanding the meaning of words and visual 
information.  These deficits are often accompanied by surface dyslexia 
and/or dysgraphia, and visual recognition deficits for faces and objects 
(Hodges, 2001).  In contrast, episodic memory remains intact, with normal 
performance on recognition-based tests with visual material and preservation 
of recent autobiographical memory (Hodges and Graham, 1998). 
 
b. Progressive Non-fluent Aphasia  
 Progressive non-fluent aphasia is characterised by progressive 
language deficits in the absence of memory, visual processing, and 
personality changes in the early stages (Mesulam, 2001).  Initial language 
deficits typically include difficulties with effortful speech production, errors in 
grammar and phonological production, and difficulties with word retrieval.  
In contrast, semantic comprehension remains well preserved.  However, as 
the disease progresses, language further deteriorates to the point where the 
patient may use unintelligible grunts to communicate, or may become mute 
(Mesulam, 2001). 
 
3. Dementia with Lewy bodies  
Dementia with Lewy bodies consists of primary dementia 
characterised by visuoperceptual and executive dysfunction, accompanied by 
prominent visual hallucinations, fluctuating attention and Parkinsonian 
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(McKeith, 2007).  In contrast to Alzheimer’s disease, visual hallucinations 
may become evident early in the course and deficits in executive function 
are among the earliest cognitive problems (Geldmacher, 2004).  The 
cognitive/behavioural and Parkinsonian signs typically evolve within one year 
of each other (McKeith, 2007).  Compared to pathologically proven 
Alzheimer’s patients, patients with Dementia with Lewy bodies have better 
performance on memory and object naming tasks and greater deficits in 
attention, letter fluency and visuo-spatial abilities (Ferman et al., 2006).  
Visuospatial disturbances are prominent and other changes include general 
slowness of thought and action and rigidity.  Apathy and depression are also 
common features.  
Table 1.4 identified several types of dementia syndromes.  However, 
it is important to recognise that this table is not exclusive and that there are 
many other types of dementias.  Some of these include: Creutzfeld Jacob 
Disease (a prion disease), Korsakoff’s dementia, (an amnestic disorder 
secondary to thiamine deficiency) and Progressive Supranuclear Palsy.  
Whilst some of these are easier to distinguish from Alzheimer’s disease (e.g., 
Creutzfeld Jacob Disease, Korsakoff’s dementia due to the underlying cause), 
others such as Progressive Supranuclear Palsy are more clinically challenging.   
 
1.7 Disease mechanisms/Pathophysiology 
 There are a number of possible mechanisms for the aetiology of 
Alzheimer’s disease (Bertram et al., 2008; Eckman and Eckman, 2007; 
Ertekin-Taner, 2007).  The classical ones are discussed here.   
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Neuropathology 
Examination of the AD brain reveals cortical atrophy that exceeds that 
observed in a normal elderly brain (McEvoy et al., 2009).  This is an 
important characteristic feature of Alzheimer’s disease.  The two key 
neuropathological features of Alzheimer’s disease, first described by 
Alzheimer in 1906 are amyloid plaques and neurofibrillary tangles.  These 
features are thought to underpin much of the clinical and behavioural 
observations of the disease.  However, these two features have been 
implicated in normal ageing and in patients with mild cognitive impairment 
(e.g., Aizenstein et al., 2008; Morris, 2006).  Other notable changes 
associated with Alzheimer’s disease include neuronal degeneration in the 
nucleus basalis of Meynert (Rosengarten et al., 2006) and decreased levels 
of acetycholine (Eggers et al., 2006).  
According to Braak et al. (1991; 1995) the distribution of amyloid 
plaques varies among patients with no specific evolution of the pattern over 
the course of the disease.  However, the distribution of tangles follows a 
specific pattern.  Tangles are prominent in the hippocampal and entorhinal 
regions during the early stages of Alzheimer’s disease.  They then spread to 
limbic structures and cortical association areas, (predominantly the parietal 
and temporal lobes) and later to the frontal lobes.  
 
The Amyloid Cascade Hypothesis 
The deposition of extracellular amyloid plaques is probably an early 
pathologic event, preceding the clinical symptoms of Alzheimer’s disease 
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(Engler et al., 2006; Jack et al., 2008).  Plaques consist mainly of aggregates 
of the amyloid β-peptide (Glenner and Wong, 1984; Masters et al., 1985) 
and have been found to induce neuronal death (apoptosis). 
It is still uncertain whether amyloid plaques or tau proteins are the 
more important lesion in Alzheimer’s disease (Eckman and Eckman, 2007; 
Tiraboschi, 2004).  Initially the amyloid cascade hypothesis suggested that 
abnormal accumulation of amyloid β-peptide caused Alzheimer’s disease 
(Hardy et al., 1992).  As cognitive decline is not well correlated to the 
amount of amyloid deposits in the brain (McKee et al., 1991), this theory has 
not been supported.  Levels of soluble amyloid β-peptide may be better 
correlated to both synaptic density and cognitive decline (McLean et al., 
1999).  There is growing evidence that they might be the principal 
neurotoxic agent in Alzheimer’s disease, whereas insoluble fibrils are 
relatively inert or even protective (Walsh and Selkoe, 2007).  Therefore, the 
main focus of the theory today is amyloid β-peptide aggregation rather than 
plaques, as the primary cause of Alzheimer’s disease (Hardy et al., 2006; 
Masters, 2006).  
Neurofibrillary tangles consist mostly of aggregated hyper-
phosphorylated tau protein that forms inside the neuron.  The normal 
function of tau is to bind tubulin and thereby stabilize microtubules in 
neuronal axons, allowing nutrients and neurotransmitters to be transported 
along the axons between the cell body and the synapses.  Tau is a non-
specific bio-marker which is elevated in other brain diseases as well.  In 
Alzheimer’s disease, hyperphosphorylated tau detaches from the 
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microtubules and aggregates into paired helical filaments and neurofibrillary 
tangles (Iqbal et al., 1986).  Support for the amyloid hypothesis, which looks 
at amyloid β-peptide as the common initiating factor for Alzheimer’s disease, 
is that studies on a transgenic mouse model for Alzheimer’s disease, tangles 
appear to be an event secondary to amyloid β-peptide plaques, where 
amyloid β-peptide might induce or aggravate the aggregation of tau (Oddo 
et al., 2004). 
 
Amyloid Precursor Protein  
Glenner and Wong (1984) published the purification and sequence of 
the protein, now referred to as amyloid β-peptide, from cerebrovascular 
amyloidosis in patients with Alzheimer’s disease.  The amyloid β-peptide was 
shown to be derived from a larger precursor protein, the amyloid precursor 
or APP mapped to chromosome 21 (Kang et al., 1987).  Amyloid precursor 
protein consists of multiple structural and functional domains.  It has been 
proposed to function as a cell surface receptor, and is involved in cell 
adhesion and synaptic plasticity (Zheng and Koo, 2006).  Homozygous APP 
knock-out mice are viable and fertile, but are smaller and less active than 
wild type mice (Zeng et al., 1995). 
St George-Hyslop et al. (1987) subsequently demonstrated a linkage 
to the same region of chromosome 21 in four early onset Alzheimer’s disease 
families.  Goate et al. (1991) demonstrated the first mutation in the APP 
gene causing familial Alzheimer’s disease.  Mutations within the APP 
sequence are all in exons 16 or 17, where the sequence for amyloid β-
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peptide is located.  Mutations affecting the y-secretase cleavage site alter 
the processing of APP into more amyloid β-peptide 42, whereas mutations 
affecting the β-secretase cleavage site lead to the production of more total 
amyloid β-peptide.  There are also mutations located within the amyloid β-
peptide sequence that increase the aggregation rate of amyloid β-peptide. 
The observation that patients with Down's syndrome (who have 
trisomy of chromosome 21) frequently, develop Alzheimer-like 
neuropathology by middle age (Olson and Shaw, 1969) supports a theory 
that chromosome 21 abnormalities may underlie Alzheimer’s disease.  Once 
the APP gene was mapped to chromosome 21, the co-occurrence of Down’s 
syndrome and early-onset Alzheimer’s disease could be explained by a gene 
dose effect due to the extra copy of the APP gene.  Recent reports have 
indicated that duplications of APP, in the absence of trisomy 21, can cause 
familial early-onset Alzheimer’s disease with cerebral amyloid angiopathy 
(Sleegers et al., 2006).  There are also reports that polymorphisms in the 
promoter of the APP gene affecting expression levels are associated with 
Alzheimer’s disease (Theuns et al., 2006).  These findings demonstrate that 
an increased expression of APP is sufficient enough to cause Alzheimer’s 
disease, even when the sequence of APP is not altered.  For further 
discussion of the genetics of Alzheimer’s disease see Chapter 2. 
 
1.8 Treatment  
There is no cure for Alzheimer’s disease and currently available 
treatments remain symptomatic with no beneficial effect on the disease 
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process (Sano, 2003).  At present, treatment often involves cholinesterase 
inhibitors (donepezil, galantamine, rivastigmine, or rarely tacrine); and in 
moderate to severe cases, memantine, an NMDA (N-methyl-D-aspartate) 
antagonist (Lipton, 2006; Walker et al., 2005).  
Slowing cognitive decline and hence postponing functional and 
behavioural impairment is important in the treatment of Alzheimer’s disease 
(Hermann and Gauthier, 2008).  Cholinesterase inhibitors work by increasing 
synaptic concentrations of the neurotransmitter acetylcholine (Stahl, 2000). 
They can modestly improve cognitive performance or delay cognitive decline 
in many patients.  In some patients, cognitive performance is improved to 
levels observed 6 to 12 months earlier.  Evidence suggests that early 
treatment with these medications may provide greater benefits over the long 
term, such as slowing the progression of the disease and reducing the risk of 
institutionalization (Lopez et al., 2005). 
The behavioural and psychological symptoms of dementia (BPSD, 
such as aggression and psychosis can be treated with neuroleptic 
antipsychotic drugs (Sink et al. 2005).  Whilst these drugs have been shown 
to modestly reduce these behavioural problems, serious side-effects of, 
cerebrovascular events, movement difficulties, or cognitive decline, often 
limit their use in clinical practice (Sink et al., 2005).  It should be highlighted 
here that the current guidelines, e.g. from the International Psychogeriatric 
Association (IPA) are not to treat behavioural problems with antipsychotic as 
first line treatment, but with non-pharmacological interventions should and 
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only if they fail or there is acute risk involved should medication be 
considered.   
Several new agents are being developed as molecular targets for 
treating or even preventing Alzheimer’s disease (Cummings et al., 2007).  
These exciting developments include: 1) antiamyloid agents, which target 
the toxicity associated with Aβ peptide, 2) neuroprotective agents.  These 
may reduce the damage associated with processing abnormal amyloid 
protein.  Examples are antioxidants, anti-inflammatory agents or tau-related 
therapies, and 3) neurorestorative approaches, such as neurotrophic and 
nerve growth strategies, transplantations, and stem-cell related interventions 
(Cummings et al., 2007).  These new approaches offer some hope in the 
future treatment of Alzheimer’s disease.  However, as a rule treatment needs 
to be initiated early in order to achieve the maximum benefits (Cummings et 
al., 2007). 
 
1.9 Summary 
This introductory chapter reviewed some of the challenges involved 
with identification of early treatment populations, and diagnostic issues 
related to Alzheimer’s disease, and treatment options.  The next chapter 
provides information on risk factors associated with Alzheimer’s disease, 
including genetic as well as environmental factors that may help to identify 
subjects with a high risk of developing Alzheimer’s disease and cognitive 
disorders in later life. 
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Chapter 2: 
Risk factors for 
Alzheimer’s disease 
______________________ 
 
2.1 Introduction 
Alzheimer’s disease is considered to be a multi-factorial disease, 
resulting fro a complex interplay of different factors (Borenstein et al., 2006).  
Recent studies suggest that various genetic and environmental factors are 
likely to contribute to the risk of dementia, including early-life brain 
development, body growth, socioeconomic conditions, environmental 
enrichment, head injury, and education status (Borenstein et al., 2006; 
Fratiglioni and Wang, 2007).  Many studies have considered the importance 
of these factors in their attempts to identify causes of Alzheimer’s disease or 
identify high-risk individuals for treatment.  
This section reviews the literature on well known risk factors for 
Alzheimer’s disease; some of which are modifiable by lifestyle changes or 
medical treatment (obesity, hypertension, diabetes).  For ease of reference, 
the term dementia will be used unless findings specifically refer to 
Alzheimer’s disease.  
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2.2 Age 
 Advancing age is considered to be the principal risk factor for 
Alzheimer’s disease.  The prevalence of the disease increases exponentially 
between the ages of 65 and 85, doubling every five years after the age of 60 
(Bondi et al., 2008).  Several studies have identified the age of 70 as a 
critical turning point for significant cognitive decline and dementia (Arauz et 
al., 2005; Ritchie and Kilda, 1995; Wang et al., 2004a).  A number of studies 
suggest that women have a slightly greater risk for Alzheimer’s disease than 
men (Heun et al., 2006).  This has been attributed to women’s longer life 
expectancy, hormones and genes.  
It has been proposed that dementia might be an inevitable 
consequence should one live long enough (Drachman, 1994).  However, 
some studies indicate that dementia is “age-related” rather than an “ageing-
related” disorder (Ritchie and Kilda, 1995).  These authors reported a fall in 
the prevalence of dementia in the age range 80 to 84, and around 95 years 
of age the prevalence levelled off to about 40%.  Thus, the very elderly have 
a reduced risk of dementia, having survived the period when dementia 
presents.  This supports the hypothesis that dementia is not a normal part of 
ageing. 
 
2.3 Lifestyle and environmental factors 
There is increasing awareness that lifestyle factors contribute 
significantly to an increased risk of dementia.  The Western lifestyle which 
includes an excessive consumption of unhealthy food and a lack of exercise 
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is known to contribute to a variety of conditions such as, heart disease, high 
cholesterol, high blood pressure, obesity, and diabetes mellitus (Type 2) 
(Fillit et al., 2008).  
Many reports have examined the effects of these lifestyle and 
environmental factors on the risk of dementia (e.g., Anstey et al., 2007; 
Foley and White, 2006; Larson et al., 2006; Lautenschlager et al., 2008; 
Luchsinger et al., 2007; Rosendorff et al., 2007; Scarmeas et al., 2006).  
Table 2.1 summarizes some of the risk factors associated with mild cognitive 
impairment (MCI) and Alzheimer’s disease.   
 
Table 2.1 Risk factors for Mild Cognitive Impairment (MCI) and Alzheimer’s 
disease  
Epidemiologic Genetic Physiologic 
Age ApoE-e4 genotype Hypothyroidism 
Female sex SORL1 genotype Hypercholesterolemia 
History of head trauma Family hx of dementia or AD Diabetes Mellitus (Type 2) 
Hx of midlife hypertension  Hyperinsulinemia 
History of stroke 
Small head circumference 
 Elevated serum         
homocysteine levels 
Adapted from Cummings et al. (2007). 
 
2.3.1 Diet 
Observational data suggest that the low risk of dementia in some 
developing countries can be attributed to the type of diet (Lushinger et al., 
2007).  Diets rich in fruits, vegetables, and fibre improve human well-being 
and significantly reduce development of the pathological processes that are 
characteristic of neurodegenerative disorders (Martin et al., 2002).  
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The Mediterranean diet has been shown to reduce risk for 
cardiovascular disease, cancer, and increase longevity (Knoops et al., 2004).  
The Mediterranean diet consists of a high intake of fruits and vegetables, 
legumes, cereals, fish, monounsaturated fats (e.g., olive oil), small amounts 
of meat and poultry, dairy products (in the form of cheese and yogurt) and 
wine with meals.  A study by Scarmeas et al. (2006) examined the link 
between the Mediterranean diet and the risk of Alzheimer’s disease by 
following 2258 non-demented elderly subjects for an average of 4 years.  
These authors reported that subjects who most closely followed the 
Mediterranean diet had a 40% to 54% reduced risk for Alzheimer’s disease 
compared to those who were least likely to follow the diet.  
The low incidence of dementia despite increased longevity in 
Okinawa, an island south of Japan, is consistent with their traditional low 
caloric and low fat diet.  The diet primarily consists of lean meat, fish, tofu 
and vegetables, (especially dark green leafy vegetables and sweet potato).  
The significance of these dietary factors is reinforced by the finding that 
when the Okinawa’s migrate, they develop Western world diseases, such as 
heart disease, dementia and cancer (Yamada et al., 2002). 
Chinese studies suggest that regular tea drinking might be protective 
against Alzheimer’s disease (Wang et al., 2004b).  A recent study by 
Eskelinen et al. (2009) examined the association between coffee and tea 
consumption and the risk of dementia and Alzheimer’s disease later in life.  
This study followed 1409 individuals (aged from 65-79) for 21 years and 
found that the coffee drinkers amongst them had the lowest risk of dementia 
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and Alzheimer’s disease compared to those drinking little or no coffee.  A 
65% reduced risk was observed in those who drank three to five cups of 
coffee per day.  This study did not find tea to have a protective effect.  
 
2.3.2 Exercise 
 Recent studies have shown the beneficial effects to patients who 
exercise moderately (three times per week) in improving their cognitive 
function.  Lautenschlager et al. (2008) found that non-demented older 
subjects (>50years) who were assigned to a 6 month exercise program of 
moderate intensity (1/2 hr of exercise 3 times per week) showed an 
improvement of 1.3 points in cognitive functioning, as defined by the ADAS-
cog compared to the non-exercise group.  Notably, the benefits of exercise 
persisted for a further 12 months after the exercise intervention had 
stopped.  
Likewise, physical activity was associated with a reduced incidence of 
dementia in subjects aged > 65 years who exercised 3 or more times per 
week (relative risk, 0.68; CI 0.48 to 0.96) compared to those who exercised 
fewer than 3 times per week (Larson et al., 2006).  Additionally, exercise 
was further associated with the greatest risk reduction in subjects who had 
poor physical functioning at baseline.  
 
2.3.3 Smoking 
The relationship between smoking, cognitive function and dementia is 
not well established.  Studies have generally provided conflicting results 
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(Epping Jordan, 1998).  Observational data by Anstey et al. (2007) suggests 
a positive link between smoking and Alzheimer’s disease.  This study 
assessed cognitive decline and incidence of dementia in 26,374 subjects 
(mean age=74) and found that current smokers had an increased risk of 
Alzheimer’s disease (relative risk, 1.79; CI 1.43 to 2.23).  Those who were 
current smokers had a significantly greater decline in cognitive ability 
compared to those who had never smoked or those who were former 
smokers (relative risk, 1.70, CI 1.25 to 2.31).  However, this study did not 
take into account the influence of other health and lifestyle factors 
associated with smoking that may also explain these associations (e.g., poor 
nutrition and less physical activity). 
The association between smoking and Alzheimer’s disease is 
supported by Luchsinger et al. (2005) who demonstrated that current 
smoking was strongly related to a higher risk of Alzheimer’s disease both 
independently and in the context of other vascular risk factors. 
 
2.4 Education and the cognitive reserve hypothesis 
Illiteracy or low educational achievement has been reported to be a 
robust risk factor for dementia (Borenstein et al., 2006).  The cognitive 
reserve hypothesis assumes that favourable hereditary and environmental 
factors increase the brain reserve, which in turn, may delay the clinical onset 
of dementia (Allen et al., 2005; Fratiglioni and Wang, 2007).  It has been 
shown that higher levels of education lower the risk of Alzheimer’s disease, 
even in the presence of pathological changes, compared to those with less 
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education (Roe et al., 2008).  Cognitive changes would be less noticeable in 
highly educated persons because of higher pre-morbid functioning compared 
to those with less education.  However, one should keep in mind that lower 
rates of education may also be linked to poverty or lower socioeconomic 
status.  These have been associated with poorer health, less access to health 
care which may increase the risk of dementia (Prince et al., 2003). 
Moreover, studies have demonstrated that transgenic mouse models 
of Aβ deposition raised in an enriched environment (e.g., running wheels, 
coloured tunnels and toys) had less Alzheimer pathology (e.g., reduced Aβ 
levels and amyloid deposits in the brain) compared to mice raised in a 
“standard environment” (Lazarov et al., 2005).  This study suggests a gene 
environment interaction and that exercise and environmental enrichment 
may be protective against developing or delaying the onset of Alzheimer’s 
disease.   
 
2.5 Trauma 
The risk of Alzheimer’s disease is doubled for individuals with a history 
of head injury that led to a loss of consciousness or hospitalization (Mortimer 
et al., 1991).  Retired professional football players with a history of 
concussion showed greater cognitive impairment in later life than did retired 
players without a history of concussion (Guskiewicz et al. 2005).  Similarly, a 
condition can develop in ex-boxers with neurological sequelae known as 
“Punch Drunk Syndrome” (Roberts et al., 1990). 
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2.6 Medical conditions 
Cardiovascular risk factors 
It is well established that Alzheimer’s disease and cardiovascular 
disease share many common risk factors, such as hypertension, 
hypercholesterolemia, and Type 2 diabetes mellitus (de la Torre, 2008; 
Papademetriou, 2005).  
Vascular risk factors have been implicated in the pathogenesis of 
Alzheimer’s disease (Kloppenburg et al., 2008; Luchsinger et al., 2005).  In a 
review of studies, Kloppenburg et al. (2008) found Type 2 diabetes mellitus 
and obesity were consistently associated with an increased risk of dementia, 
increasing the risk for any dementia by 1.5 times.  
Luchsinger et al. (2005) followed 1138 non-demented subjects (mean 
age=76.2) for 5.5 years and found the risk of Alzheimer’s disease increased 
with the number of vascular risk factors present.  Type 2 diabetes mellitus 
and current smoking were the strongest independent risk factors.  Having 
three or more vascular risk factors increased the risk of developing 
Alzheimer’s disease three-fold. 
 
Diabetes Mellitus 
Type 2 diabetes mellitus is a well-known risk factor for cardiovascular 
disease (Arvanitakis et al., 2004; Schnaider et al., 2004).  Type 2 diabetes 
develops in the context of insulin resistance, frequently accompanied by 
other vascular risk factors such as hypertension, dyslipidaemia and obesity.  
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Each of these risk factors has been associated with cognitive decline and 
dementia (e.g., Fillit et al., 2008). 
Evidence for Type 2 diabetes mellitus as a risk factor for dementia is 
provided by Luchsinger et al., (2005) who demonstrated that Type 2 
diabetes mellitus was the strongest predictor of dementia beyond the age of 
65 years from among the vascular risk factors.  One recent study showed 
that individuals with both type 2 diabetes and the ApoE e-4 allele had a five 
times higher risk for developing Alzheimer’s disease compared to those with 
neither risk factor (Irie et al., 2008).  This shows that risk factors for 
Alzheimer’s disease can be additive. 
 
Hypertension and stroke 
There is strong evidence linking hypertension to dementia through its 
association with cerebrovascular disease.  Hypertension increases the risk of 
stroke, which, in turn increases the risk of Vascular Dementia and 
Alzheimer’s disease (Honig et al., 2003).  Patients with a history of stroke are 
between 3.5 and 6 times more likely to develop dementia than those without 
stroke (Lays et al., 2005).  Hypertension is a mid-life risk factor and by late 
life, usually before the dementia diagnosis is made, blood pressure drops.  
Kloppenburg et al. (2008) reported the risk of dementia was highest in 
subjects with midlife hypertension, accounting for 30% of cases of late life 
dementia. 
Luchsinger et al. (2005) reported that hypertension clustered with 
other cerebrovascular risk factors, such as Type 2 diabetes mellitus, heart 
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disease, and current smoking contributed to a higher risk of Alzheimer’s 
disease compared to hypertension alone.  This study suggests that 
hypertension may cause cognitive impairment and dementia through its 
association with other cerebrovascular risk factors.  Another report showed 
that non-demented subjects (n=918; aged > 65 years) with a history of 
hypertension have an increased risk of MCI by 1.5 times (Reitz et al., 2007).  
 
Obesity  
Obesity has been linked to a number of medical conditions, including 
hypertension, stroke, Type 2 diabetes mellitus, and cardiovascular disease 
and poor cognitive performance (Kopelman, 2000).  Midlife obesity has been 
associated with an increased risk of dementia and Alzheimer’s disease in 
later life (Kivipelto et al., 2005).  In turn all of these conditions have been 
linked to an increased risk of dementia via their association with vascular risk 
factors. 
There has been increased emphasis on central obesity (abdominal 
distribution of fat) which is considered to be a more potent risk factor for 
vascular disease than Body Mass Index (Luchsinger, 2008).  A recent study 
spanning 36 years reported an independent association of midlife central 
obesity with an increased risk of dementia by three times (Whitmer et al., 
2008). 
Parkinson’s disease with dementia 
Parkinson’s disease is a neurological condition characterized by motor 
slowing, tremor, rigidity along with executive dysfunction (set-shifting and 
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temporal sequencing difficulty) and impairment in memory retrieval.  
Parkinson’s disease typically begins with unilateral motor signs, such as 
tremor in one hand.  However, patients with Parkinson’s disease are six 
times more at risk of dementia compared to age-matched controls (McKeith, 
2007). 
Parkinson’s disease with dementia describes the dementia that occurs 
in the context of well established Parkinson’s disease.  This dementia can 
present in three forms: 1) as a prominent dysexecutive syndrome (common); 
2) as dementia with Lewy bodies with prominent fluctuations in cognition 
and hallucinations (common); or 3) as an amnestic “Alzheimer-like” 
syndrome (less common);  (McKeith, 2007).  This condition is slightly more 
prevalent in men and onset is between 40 and 70 years. 
 
2.7 Depression  
There is ongoing controversy as to whether major depression 
represents an actual risk factor or is a prodrome of dementia (Dal Forno et 
al., 2005; Kral and Emery, 1989).  Some studies indicate that major 
depression may be an independent risk factor for Alzheimer’s type dementia 
(Geerlings et al., 2008; Ownby et al., 2006; Wilson et al., 2008).  Geerlings 
et al. (2008) examined the link between a history of major depression 
(26.6% of sample) and Alzheimer’s disease in 503 non-demented subjects 
(age range 60 to 90).  Over a 6-year follow-up, 33 subjects developed 
Alzheimer’s disease.  Subjects with a history of late-onset major depression 
were 2.5 times more likely to develop Alzheimer’s disease than those without 
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a history.  The risk was even higher in subjects whose major depression 
occurred before 60 years of age.  They were four times more likely to 
develop Alzheimer’s disease compared to those without major depression. 
However, Bartolini et al. (2005) found an increase in depressive 
symptoms one year prior to diagnosis of Alzheimer’s disease in non-
demented subjects (mean age=69.2; SD=4.8) referred to a memory clinic 
after complaining of memory problems.  At baseline, of the 222 subjects, 
124 met the criteria DSM-III-R for major depression.  In 31 of the 124 
(25%), the increase occurred in motivation-related (concentration difficulties, 
loss of interest) rather than mood-related (dysphoria, feelings of guilt) 
symptoms of major depression.  This observation led the authors to conclude 
that motivational symptoms of depression are cognitively loaded as they 
were linked to the subject’s basic processing resources, such as the ability to 
focus attention on the task at hand, while closing out irrelevant information.  
This study suggests that certain aspects of major depression are a prodrome 
of dementia. 
However, it remains difficult to determine whether major depression 
contributes to the cognitive difficulties or if it is secondary to the memory 
problems.   In effect major depression may impair memory functioning. 
 
2.8 Genetics 
Early onset Alzheimer’s disease has a strong genetic component but 
only a small percentage of all AD cases are early-onset (before 65 years of 
age).  Of these, approximately 40% are sporadic.  The remaining 60% have 
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a familial dominantly inherited Alzheimer’s disease with mutations in any of 
three genes: APP on chromosome 21, presenilin 1 on chromosome 14 and 
presenilin 2 on chromosome 1 (Levy-Lahad et al., 1995; Sherrington et al., 
1995).  However, these three genes do not explain all cases of familial 
Alzheimer’s disease.  The majority of AD cases are late-onset (after the age 
of 65 years), of which approximately 75% are sporadic, probably caused by 
a genetic predisposition in combination with environmental factors.  The 
remaining 25% of late-onset cases have a family history of Alzheimer’s 
disease where several genes have been implicated (Bertram and Tanzi, 
2008).  To date, only the Apolipoprotein E gene (ApoE) remains accountable 
for more than 50% of the risk associated with late onset Alzheimer’s disease 
(Corder et al., 1993).  
First degree relatives of a person with Alzheimer’s disease have a 
greater risk of developing the disease than those without a family history.  
Twin studies have estimated heritability for Alzheimer’s disease to be as high 
as 79% (Gatz et al., 2006).  In addition, estimations of concordance have 
demonstrated that if one twin develops Alzheimer’s disease, the other twin 
will also develop the disease in 59% of the monozygotic twin pairs, whereas 
this only occurs in 32% of same-sex dizygotic twins and in 24% of opposite-
sex dizygotic twin pairs.  As twins are assumed to share not only genes but 
also the environment during a critical period for brain development, this 
demonstrates a high genetic component to Alzheimer’s disease (Gatz et al., 
2005). 
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2.9 The role of the ApoE 
The ApoE-ε4 allele on chromosome 19 was the first genetic risk factor 
to be identified for late-onset Alzheimer’s disease (Corder et al., 1993; 
Strittmatter et al., 1993).  Subsequent studies have confirmed the ApoE as 
the single most important susceptibility gene for sporadic and late-onset 
familial Alzheimer’s disease yet identified (National Institute on 
Ageing/Alzheimer’s Association Working Group, 1996; Raber et al., 2004).  
It has been suggested that the ApoE isoforms may affect amyloid 
deposition, tangle formation, cholinergic function or neuronal plasticity and 
repair (Mahley and Rall, 2000).  However, one should keep in mind that, 
ApoE is neither sufficient nor necessary for the development of Alzheimer’s 
disease, as not all Alzheimer’s patients have an ApoE-ε4 allele and not all 
individuals with an ApoE-ε4 allele will develop Alzheimer’s disease.  
Therefore, ApoE should not be used as a sole diagnostic test for Alzheimer’s 
disease (Liddell et al., 2001).  
Three different alleles, ε-2, ε-3 and ε-4, encode the isoforms of ApoE. 
These base pair substitutions result in changes in the relative affinity of the 
ApoE protein for receptors and lipoproteins.  In the brain, ApoE is 
synthesized by astrocytes and microglia, whereas ApoE in the periphery is 
mostly synthesized in the liver.  It is a lipid transporter in cerebrospinal fluid 
and plasma and the primary protein component of lipoproteins in the central 
nervous system.  Through the interaction with cell surface lipoprotein 
receptors it is involved in cholesterol homeostasis.  The ApoE4 is associated 
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with increased levels and ApoE2 with decreased levels of cholesterol in 
plasma, compared to ApoE3 (Davignon et al., 1988).  
The six possible ApoE genotypes (epsilon 2/2, 2/3, 2/4, 3/3, 3/4 and 
4/4) differ in their frequency of occurrence in the population.  ApoE epsilon-3 
is the most common allele occurring on more than 75% of chromosomes in 
Caucasian populations.  The average frequencies of ε-2 and ε-4 are 8% and 
15%, respectively.  
 
2.9.1 ApoE ε4 as a risk factor 
The ApoE 4 genotype represents an important biological risk factor for 
Alzheimer’s disease world-wide (Pericak-Vance et al., 2000).  A pioneering 
study by Farrer et al. (1997) found the ApoE epsilon 4 allele increased the 
relative risk of developing Alzheimer’s disease.  Carriers of the epsilon 4 
allele (ε2/4, ε3/4) had an odds ratio between 2.2 and 4.4 of developing 
Alzheimer’s disease compared to people with the epsilon ε3/3 genotype.  
The most common variant, ε3, is neutral for Alzheimer’s disease risk.  
Carriers of the epsilon 4 (ε4/4) have an odds ratio ranging from 5.1 to 34.3.  
The ε2 allele is the most unusual of the three and is considered 
somewhat protective for Alzheimer’s disease (Corder et al., 2004). Carriers of 
the ε2:ε2 genotype are under represented in Alzheimer’s disease and over 
represented in populations of healthy centenarians.  It has been associated 
with longevity, successful ageing and protection against Alzheimer’s disease 
(Panza et al., 2004; Talbot et al., 1994). 
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According to Farrer et al. (1997) women are more vulnerable to 
Alzheimer’s disease irrespective of their ApoE status, possibly due to 
independent factors such as estrogens.  Comparison of ApoE 4 heterozygous 
men and women showed that women had an increased risk of developing 
Alzheimer’s disease two-fold. 
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Figure 2.1. Age of onset and the risk of Alzheimer’s disease for different carriers of ApoE 
genotypes.  Adapted from Farrer et al. (1997). 
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2.9.2 ApoE and age of onset 
As shown in Figure 2.1, ApoE 4 genotype has a significant role in the 
age-of onset of Alzheimer’s disease (Bird, 2008, Farrer et al., 1997).  Each 
additional epsilon 4 allele shifts the age of onset to a younger age.  Corder 
et al. (2004) reported that in families with histories of late-onset Alzheimer’s 
disease, the risk of Alzheimer’s disease increased from approximately 20% to 
over 90% and mean-age-of-onset decreased from 84 to 68 years with 
increasing number of epsilon 4 alleles.  
 
2.9.3 ApoE and cognitive decline and dementia  
Whilst the role of the ApoE ε4 in Alzheimer’s disease is well 
established, its role in cognitive decline remains uncertain (Kleiman et al., 
2006; Fliesher et al., 2007). Many studies have attempted to model the 
effects of the ApoE ε4 to examine whether it provides independent 
information on risk of future cognitive decline.  The outcomes of these 
studies have varied widely.  Some studies indicate that the ApoE ε4 may 
accelerate decline in those with cognitive impairment or Alzheimer’s disease 
(Consentino et al., 2008; Fratiglioni et al., 2004).  Another study reported 
that the ApoE ε4 does not affect patients with preclinical Alzheimer’s disease 
(Estevez-Gonzalez et al., 2004).  The ApoE ε4 has also been shown to impair 
specific domains such as episodic memory (Kozauer et al., 2008).  One study 
indicated that the ApoE ε4 provides an independent contribution to the risk 
of cognitive decline, especially after the age of 50 (Caselli et al., 2004).  The 
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ApoE ε4 has also been related to a faster decline in non-demented samples 
(Small et al., 2004).   
 A recent study showed that the ApoE ε4 allele appears to accelerate 
cognitive decline in patients with early stage Alzheimer’s disease (Consentino 
et al., 2008; Fratiglioni et al., 2004).  To examine the effect of ε4 on the rate 
of cognitive decline in patients with Alzheimer’s disease, Consentino et al. 
(2008) recruited patients from two longitudinal cohort studies and one clinic-
based sample.  The 3 samples studied included: 199 (48%) incident 
Alzheimer’s disease; 215 (54%) prevalent Alzheimer’s disease, and 156 
(71%) patients diagnosed with Alzheimer’s disease.  Over a 4-year follow-up 
period, in the incident sample, the presence of the ε4 allele was associated 
with more rapid cognitive decline, even after demographic adjustments.  In 
contrast, ε4 was not associated with the rate of change in either of the other 
groups.  However, after adjustment for disease severity or exclusion of 
severely impaired subjects, a faster decline in e4 carriers was also apparent.  
This study shows that the ApoE ε4 influences cognitive decline in the earliest 
stages of disease with minimal effects or none in the moderate to severe 
stages. 
 In a large epidemiological study, Jorm et al. (2007) examined the 
effects of ApoE ε4 allele on cognitive functioning in 6,560 subjects and 
observed no association.  The subjects were aged 20-24, 40-44, and 60-64 
and all received cognitive testing.  Whilst, the cross-sectional analysis 
showed differences in cognitive performance across the age categories, 
these authors failed to find an effect of the ApoE ε4 genotype on cognitive 
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functioning across the age categories or an age by genotype interaction.  In 
this study, normal cognitive ageing between the ages of 20 and 60 years 
could not be attributed to the effects of the ApoE ε4 (Jorm et al., 2007). 
 In a subsequent study, these same authors Christensen et al. (2008) 
re-examined the effects of the ApoE ε4 allele on cognitive function in a 
sample of 2,021 subjects, aged between 65-69 years.  This is the age when 
the ApoE ε4 exerts its maximal effect (Blacker et al., 1997).  Over a follow-
up period of 4-years, MMSE scores were significantly lower for ε4 
homozygotes than heterozygotes or non-carriers.  The effects of the ApoE ε4 
on cognitive decline were found on the MMSE and Symbol-Digit Modalities 
test, after controlling for risk factors, such as previous head injury or low 
education.  Christensen et al. (2008) suggested that it is possible for ApoE ε4 
carriers to be more vulnerable to greater cognitive decline in the presence of 
other risk factors between the ages of 65-69 years. 
 In healthy ageing, the ApoE ε4 appears to have some influence in 
global cognitive function, however only in some specific domains.  A meta-
analysis of 38 studies (Small et al., 2004) reported that ApoE ε4 carriers 
scored modestly but significantly poorer in the areas of global cognitive 
function, episodic memory and executive functioning compared to ApoE 
ε3/ε3 carriers.  Notably, ApoE ε2 carriers performed better than the controls 
in global cognitive function.  This is consistent with the protective effect of 
the ApoE ε2 against Alzheimer’s disease. 
 In a retrospective analysis, using patients with established Alzheimer’s 
disease, Estevez-Gonzalez et al. (2004) used formal assessment to examine 
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the association between the ApoE ε4 allele and memory profile in 24 patients 
in the preclinical stage of Alzheimer’s disease who were either ApoE ε4 
carriers (n=13) or ApoE ε3 homozygotes. (N=11).  A one-way analysis of 
variance comparing ApoE ε4 carriers and patients with ApoE ε3 
homozygosity showed that 2 years prior to AD diagnosis both genotype 
groups had similar memory performance on a number of tasks, including 
working memory, declarative memory and non-declarative memory. 
 Similarly, Caselli et al. (2004) examined whether memory loss could 
be identified in subjects prior to the onset of MCI by recruiting 180 subjects 
from the community at increased risk for Alzheimer’s disease due to the 
presence of the ApoE ε4 allele.  A total of 180 subjects (mean age=60; SD: 
6.2) were classified as normal on the basis of their MMSE scores=29.6 + 0.7; 
45 were ApoE ε4/ε4 homozygotes, 42 ApoE ε3/ε4 heterzygotes, and 93 ApoE 
ε4 non-carriers.  Over the 33-month interval, carriers of the ApoE ε4 had 
poorer performance on multiple measures of verbal memory tests including 
(total score on Auditory Verbal Learning Test (AVLT); delayed recall; and 
Selective Reminding Test (SRT), free and cued recall) compared to non-ApoE 
ε4 carriers.  Additionally, these authors reported that carriers of the ApoE ε4 
aged between 50 to 59 showed greater declines on the AVLT delayed recall, 
SRT free and cued recall, and Complex Figure Test.  This study suggests that 
prior to the onset of MCI or dementia; ApoE ε4 carriers show a modest 
decline in memory skills commencing from the age of 50 onwards. 
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2.10 Summary  
 To summarise, Alzheimer’s disease is considered to be a multi-
factorial disease.  The risk for Alzheimer’s disease is not likely to be 
determined in any single time period but results from a complex interplay 
between genetic and environmental exposures throughout one’s life 
(Borenstein et al., 2006).  All of these factors are likely to have synergistic or 
additive effect on the risk of Alzheimer’s disease which increases with age.  
Also, the role of ApoE ε4 status in memory function remains controversial.  It 
is not clear whether ApoE has a direct effect on memory in the absence of 
disease or acts only through association with Alzheimer’s disease.  This may 
be attributed to the small effect size related to the ApoE and that very large 
samples (n>1000) may be required to find subtle associations or to 
determine the mechanism of action.  Nevertheless, several studies have 
reported a higher proportion of ApoE ε4 carriers in patients with advanced 
Alzheimer’s disease and thus remain an important risk factor for developing 
the disease.  The next chapter examines the risk of Alzheimer’s disease 
associated in individuals with subjective memory complaints or mild cognitive 
impairment. 
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Chapter 3: 
Normal ageing, 
memory complaints 
and Alzheimer’s disease 
 
3.1 Cognitive decline and normal ageing  
It is well known that old age is accompanied by a loss of memory 
(Collie et al., 2001; Geslani et al., 2005; Maruff et al., 2004).  However, 
along the cognitive continuum, a loss of memory can also indicate the onset 
of a dementia syndrome (McKhann et al., 1984; American Psychiatric 
Association, 2000) or be a predictor of future Alzheimer’s disease (Saxton et 
al., 2004).  Scientific evidence has shown that the cognitive domains known 
to be impaired in preclinical Alzheimer’s disease, such as episodic memory, 
executive function and perceptual speed have also been implicated in normal 
cognitive ageing (Bäckman et al., 2004a; Twamley et al., 2006; Bäckman 
and Small, 2007).  Thus, the boundary that separates normal ageing from 
pathological ageing is not entirely clear.  
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In normal ageing, memory problems tend to reflect a generalized 
decrease in the efficiency by which information is processed and retrieved.  
Memory functioning is generally well maintained up until the age of 60 years 
(Allen et al., 2005).  In non-demented elderly there are clear signs of age-
related cognitive decline, from the mid 70s onwards (De Ronchi et al., 2005).  
These changes have been reported to occur primarily on tasks of new 
learning, speed and flexible adjustments (cognitive flexibility) to new 
situational demands.  In contrast, tasks that draw on previously acquired 
knowledge have limited speed demands or are highly automatic show little 
or no age-related decline.  These are summarized below and discussed 
further in Chapters 5 and 6. 
 
Episodic Memory 
Increasing age is accompanied by a gradual decrease in episodic 
memory functioning.  This decrement in performance can also be observed 
in the oldest old.  Age-related impairments in free recall of stories and word 
lists are evident by age 50.  When cognitive support or structure is provided 
by the use of recognition testing, more study time, or cueing to facilitate 
episodic memory functioning, the age-related differences diminish.  This 
suggests that as we age there is a greater impairment of retrieval processes 
than of encoding or retention (Bäckman and Small, 1998; Bäckman et al., 
2004a).  In contrast, transferring information from a temporary storage to a 
more permanent memory store becomes increasingly difficult with advancing 
age (Bäckman et al., 2004a). 
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Working memory 
Working memory is typically well-preserved unless there is high 
demand placed on processing capacity.  Performance on Digits Forward (a 
task involving repeating sequence of numbers) is robust to age-related 
decline, because this task places few demands on working memory.  By 
contrast, performance on Digits Backward declines with increasing age, 
because this task places demands on working memory.  In this task the 
information needs to be manipulated in a relatively untransformed fashion, 
which is cognitively taxing. 
 
Information processing speed 
A prominent impairment that accompanies increasing age is a 
decrease in performance in information processing speed (Craik and 
Rabinowitz, 1984).  This slowing down can be observed on tests of cognitive 
speed, such as Trail A and Trail B tasks (Tombaugh, 2004).  Even in the very 
old, the age-related differences observed in Trail-Making have been isolated 
to the speed with which the task could be completed, and not to accuracy 
(Bäckman et al., 2004a).  Although, Trail B, places additional demands on 
executive function, the age-related slowing observed in Trail-Making has 
been reported to result from impairments in visuomotor tracking (Bäckman 
et al., 2004a). 
 
                                                                  Chapter 3- Memory complaints and Alzheimer’s disease 
__________________________________________________________________________ 
 51 
Semantic memory 
A moderate age-related decline has been observed on both letter and 
category fluency tasks, especially in the very old.  Thus, although different 
mechanisms assist with fluency tasks, (switching and clustering), both 
fluency tasks are affected equally in the old, and suggest that the underlying 
processes are similarly impaired (Bäckman et al., 2004a, Tulving, 2002).  
 
3.2 The concept of early detection 
There has been a recent shift to thinking about Alzheimer’s disease in 
pre-dementia terms (Ganguli, 2006; Petersen et al., 2007; Winblad et al., 
2004).  This is evident in the literature where patients presenting with 
cognitive impairment have been depicted by a variety of terms, such as mild 
cognitive impairment (MCI: Ganguli et al., 2004; Gauthier et al., 2006), 
subjective memory complaints/impairment (or subjective cognitive 
impairment) (SMC: Abdulrab and Heun, 2008; Geerlings et al., 1999; 
Jungwirth et al., 2004; Reisberg et al., 2008; Schofield et al., 1997), age-
associated cognitive decline (Schonknecht et al., 2005), as well as cognitive 
impairment no dementia (CIND: Palmer et al., 2002; 2003), questionable 
dementia (Lam et al., 2005a; 2005b) and isolated memory impairment 
(Bowen et al., 1997; Tierney et al., 1996).  Each of these terms has been 
used to identify a pre-dementia stage of cognitive impairment (e.g., aMCI), 
with variable prognosis. 
The use of the term ‘preclinical’ denotes a clinical condition with high 
progression to Alzheimer’s disease, whilst the use of the word ‘predementia’ 
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denotes a stage of cognitive impairment with variable prognosis.  It is 
important to emphasize that some persons might have a clinical presentation 
of cognitive impairment in the predementia state. 
The MCI criteria have undergone significant change over the last 10 
years.  In 1958 Kral introduced the term “benign senescent forgetfulness” or 
(mild memory loss) to describe a mild memory disorder in the elderly that 
accompanied old age but was not considered to be abnormal or become 
pathological.  Since this initial report, MCI has undergone a significant 
evolution over the past 10 years with a number of related concepts having 
emerged to describe memory impairment in old age.  Some of these include: 
‘Cognitive Impairment no Dementia’ (Jacova et al., 2008), ‘Age Associated 
Memory Impairment’ (Goldman and Morris, 2001).  All of these terms have 
different criteria to identify a type of memory impairment that inevitably 
leads to dementia and Alzheimer’s disease.  Hence MCI research findings 
that are often disparate are likely to be partly due to this. 
However, AD development is associated with objective cognitive 
decline prior to clinical diagnosis, it is vital to improve the diagnostic tools, 
such as brief screening tests able to detect the disease (Oksengard et al., 
2004).  This will facilitate the early detection.  Recently, there has been 
increased awareness that persons who complain about their memory should 
be taken seriously and be assessed for dementia (Dufoil et al., 2005; Coley 
et al., 2008).  In this setting, general practitioners are a critical point of early 
intervention (Brodaty et al., 2006; Ganguli et al., 2004)   
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In primary care, several brief screening tests have been proposed by 
Brodaty et al. (2006), including the GP Assessment of Cognition; the Mini-
Cog and the Memory Impairment Screen.  However none have been as 
universally accepted as the Mini-Mental State Examination (MMSE: Folstein 
et al., 1975) which continues to be used widely in clinical practice (Lavery et 
al., 2007).  The question is whether brief screening tests, such as the MMSE 
or Mini-Cog are able to detect early signs of Alzheimer’s disease, especially in 
high functioning individuals.  The next section provides a more detailed 
discussion of the limitations of brief screening tests and the need for formal 
assessment. 
 
3.2.1 Screening for early dementia   
It has been suggested that neuropsychological assessment will play a 
pivotal role in the new diagnostic challenges faced by all clinicians (Bondi et 
al., 2008; Cummings et al., 2007).  However, identifying subjects who are in 
the earliest phases and are likely to progress to Alzheimer’s disease is not 
straightforward.  
There are current concerns regarding the ability of brief screening 
tools such as the MMSE to identify impairment in cognitive domains other 
than memory.  With new evidence identifying impairments in semantic 
memory and executive function (Ahmed et al., 2008; Hodges et al., 2006; 
Rouch et al., 2008), the sole reliance on brief screening tools seems 
inappropriate.   
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The MMSE is thought to be an insensitive screening tool for 
identifying both MCI and dementia (Tariq et al., 2006), especially in pre-
morbidly high-functioning individuals with memory complaints (Geerlings et 
al., 1999; van Oijen et al., 2007).  This has been attributed to its ceiling 
effect and lack of delayed recall condition (Chen et al., 2000).  Also, 
impairments in those with MCI are mild and subtle (Gallassi et al., 2008) and 
not easily detected by simple global screening tasks.   
In addition, the cut-off score to define impairment in those with MCI 
may not be appropriate.  Solomon et al. (2002) reported that in a research 
clinic, an MMSE cut-off score of 24 and above, accurately identified 
Alzheimer’s disease in 98 of 110 (89%) patients (mean age= 71.6, SD=7.5) 
with very mild impairment (mean MMSE score on initial assessment = 25.7 + 
1.4).  This suggests that the MMSE is useful in identifying individuals in the 
later phases of the disease. 
There are alternative screening tests highly relevant in the study of 
dementia, such as the Seven Minute Screen (7MS).  The 7MS has been 
shown to reliably distinguish Alzheimer’s disease from normal ageing and 
other dementias (e.g., Meulen et al., 2004; Solomon et al., 1998).  However, 
it has not been examined in the study of subjective memory complaints 
(SMC).  The 7MS is highly sensitive and specific in the identification of 
Alzheimer’s disease (92.9%; 93.5%, respectively) and performance is not 
affected by age, sex or education (Solomon et al., 1998).  It includes several 
tests, selected because they examine areas typically compromised in early 
Alzheimer’s disease (orientation, memory, clock drawing and animal fluency).    
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 Similarly, the Dementia Rating Scale (DRS: Mattis et al., 1976) is 
highly sensitive in identifying cognitive impairment that is associated with 
dementia.  It also consists of several domains of cognitive functioning in 
addition to memory.  The sensitivity and specificity of the DRS is 74% and 
93%, respectively (Vangel and Lichenberg, 1995).  Unlike the MMSE, age, 
education and IQ do not affect performance on the DRS (Chan et al., 2001). 
The process of intervention begins with being able to identify deficits 
related to SMC by examining a wide range of cognitive functions.  
Neuropsychological assessment and more sensitive screening tests may help 
identify those with suspected cognitive compromise.  As mentioned in 
Chapter 1 (Section 1.7), the early identification of Alzheimer’s disease 
provides therapeutic opportunities for intervention at an earlier stage rather 
than waiting for significant decline to occur. 
 
3.3 Mild cognitive impairment (MCI)  
Mild Cognitive Impairment (MCI) is a research term proposed to 
denote a transitional stage between the cognitive changes of normal ageing 
and early dementia or Alzheimer’s disease (Winblad et al., 2004; Petersen, 
2004).  Mild cognitive impairment manifests by presenting as cognitive 
impairment which is abnormal for age with preserved activities in daily living, 
but does not meet the criteria for dementia (Gauthier et al., 2006; Petersen, 
2007).  The memory loss is subtle and formal psychometric testing is needed 
to measure the decline.  This occurs once the patient (or a reliable 
informant) has complained about their memory.  The concept of MCI has 
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recently emerged as an important clinical entity, which has been proposed 
for entry into the DSM-V (Petersen and O’Brien, 2006). 
Whilst many reports acknowledge MCI as a transitional stage between 
normal ageing and dementia (e.g., Allegri et al., 2008; Burns and Zaudig, 
2002; Mariani et al., 2007; Orgogozo, 2006), not all accept MCI as a risk 
factor for dementia.  Some reports indicate that MCI identifies subjects who 
already have the disease in the prodrome stage (Morris, 2006).  Other 
reports describe MCI as a predementia stage which inevitably leads to 
Alzheimer’s disease (e.g., Orgozozo, 2006).  
The prevalence of MCI varies considerably and has been reported to 
be as high as 65% per year (Busse et al., 2006) in different studies.  It has 
been estimated that patients with MCI progress to dementia at inconsistent 
rates, ranging anywhere from 10% to 15% per year (Luis et al., 2003) 
compared to healthy elderly who progress to dementia at a rate of 1 to 2% 
per annum (Petersen et al., 2001).  In a clinical setting, Gabryelewicz et al. 
(2007) reported an annual progression rate of 7.3%.  The variability in 
outcome has been attributed to many factors including, age of subjects, 
inconsistent application of the criteria, use of different tests to define 
impairment, different follow-up time periods, different entry levels and study 
setting.  All of these factors vary widely between studies (Bondi et al., 2008; 
Small et al., 2007).  
The working group of Winblad et al. (2004) revised the criteria for 
MCI to acknowledge non-amnestic presentations which may occur in the 
preclinical stage (Ribero et al., 2006; Ringman, 2005).  The clinical syndrome 
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of MCI was divided into two broad subtypes: amnestic MCI (aMCI) 
characterized by the presence of isolated memory impairment, and non-
amnestic MCI (naMCI) in which other cognitive functions rather than 
memory are mostly impaired (Winblad et al., 2004).  The general criteria for 
MCI are provided in Table 3.1.  
 
Table 3.1. General criteria for Mild Cognitive Impairment (MCI) 
a. Absence of dementia according to DSM-IV or ICD-10 
b. Self and/or informant reported cognitive decline 
c. Impairment on cognitive tasks, and 
d. preserved basic activities of daily living or minimal impairment in complex 
instrumental function 
Adapted from Winblad et al. (2004). 
 
Mild cognitive impairment (MCI) was divided further into three 
categories; i) single non memory domain MCI, with isolated impairment of a 
cognitive domain other than memory; ii) multiple domain amnestic MCI, 
characterised by a slight impairment of multiple cognitive domains including 
memory; and iii) multiple domains non amnestic MCI, with a slight 
impairment of multiple cognitive domains but without memory deficits 
(Petersen, 2007).  
In terms of risk factors for Alzheimer’s disease, there is consensus 
that aMCI represents the highest risk subtype and is described as the ‘AD 
prodrome’ (Gauthier et al., 2006; Lehrner et al., 2005).  This supports the 
hypothesis that isolated memory loss favours a diagnosis of Alzheimer’s 
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disease (Bowen et al., 1987; Petersen et al., 2001).  However, one report 
indicated that there was no distinction between the two and that amnestic 
MCI is really just early Alzheimer’s disease (Bruscoli and Lovestone, 2004).  
Likewise, some consider mdMCI to represent a more advanced stage of the 
AD prodrome (Alexopolous et al., 2006) and therefore greater risk.  By 
contrast, the cognitive prognosis of the multiple domains MCI and single 
domain non-amnestic MCI subtypes appear more varied.  These include; 
normal ageing, vascular dementia, frontotemporal dementia, dementia with 
Lewy body dementia, primary progressive aphasia or Alzheimer’s disease 
(Guarch et al., 2008; Levey et al., 2006; Small et al., 2007).  
Mild cognitive impairment is a highly debated concept that has been 
challenged on several grounds (e.g., Visser, 2007).  The primary issue 
relates to MCI as a risk factor for Alzheimer’s disease.  Mild cognitive 
impairment is perceived to have poor predictive validity for Alzheimer’s 
disease (e.g., Visser et al., 2006; Whitehouse et al., 2006).  Research on 
MCI has shown that none of the MCI subtypes necessarily progress to 
Alzheimer’s disease, but many remain stable or even improve their cognitive 
performance (e.g., Ganguli et al., 2004; Ganguli, 2006; Palmer et al., 2003; 
Perri et al., 2007; Visser et al., 2006). 
Furthermore, there is no universally accepted approach to the 
objective identification cognitive impairment or agreement on the degree of 
objective impairment necessary to constitute decline.  There is also 
confusion on how to define ‘minimal impairment’ or alterations in 
instrumental activities of daily living (Hodges, 2006).  All of these factors 
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influence outcome.  The inclusion of SMC in the criteria that define MCI is 
also disputed, and this is discussed in Section 3.4. 
Despite ongoing controversies, MCI represents a step towards early 
diagnosis of Alzheimer’s disease and the possibility of earlier therapeutic 
treatment of symptoms.  It provides some indication of the boundary 
between normal ageing and dementia.  Currently, MCI is hindered by the 
inconsistent application of the criteria, lack of consensus regarding the tests 
used to measure cognitive impairment and the role of SMC.  A consensus on 
these issues may improve sensitivity and therefore prediction.  Also, the 
issues surrounding memory complaints need to be resolved before MCI can 
be accepted into the DSM-V as a clinical syndrome.  Thus, the challenge 
which remains for MCI is to consistently identify high-risk individuals with 
MCI who will progress to a dementia of the Alzheimer’s type and other 
dementias from those who will not.  It is also important to achieve a 
consensus regarding the criteria included in the diagnosis of MCI (Levey et 
al., 2006; Touchon, 2006).   This will pave the way for the early diagnosis of 
Alzheimer’s disease and allow identification of subjects with high or ultra 
high risk.  This will enable the development of strategies for early 
intervention.  
 
3.4 The neuropsychology of Alzheimer’s disease 
As we progress towards early identification and treatment of 
Alzheimer’s disease, understanding the neuropsychological impairments in 
different pre-dementia states will become increasingly important.  This 
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section commences with a discussion of the typical language impairments 
observed in Alzheimer’s patients, and then proceeds to highlight the 
consistency of impairment observed on tasks of episodic memory, as 
measured by delayed recall.  To date, there is considerable agreement that 
episodic memory impairment remains one of the most defining 
neuropsychological observations during the preclinical phase of Alzheimer’s 
disease, and represents the hallmark of the syndrome of dementia of the 
Alzheimer’s type. 
 
3.4.1 Language impairment 
 Alzheimer’s disease is characterized by disorders in the semantic 
system affecting various aspects of language ability (Bayles and Tomoeda, 
1983; Gainotti, 1992; Hodges and Patterson, 1995; Vogel et al., 2005).  
Language deficits occur very early in the course of the disease and are 
evident on tasks including: the ‘Supermarket Task’ (Martin and Fedio, 1983), 
verbal fluency (Hodges et al., 1991), confrontation naming (Gainotti, 1992), 
object sorting (Martin et al., 1986), free-word association (Abeysinghe et al., 
1990), and naming of famous faces (Thompson et al., 2002).  These deficits 
contrast with speech, which remains fluent and articulate (Kertesz et al., 
1986) well into the later stages of the disease.  
 The most sensitive test to identify early Alzheimer’s disease is 
category fluency (Hodges et al., 2006; Salmon et al., 2002).  An early 
decline in category fluency performance has been reported to occur in the 
pre-dementia phase of Alzheimer’s disease (Raoux et al., 2008) and in the 
                                                                  Chapter 3- Memory complaints and Alzheimer’s disease 
__________________________________________________________________________ 
 61 
absence of other semantic deficits (Monsch et al., 1992).  It contrasts with 
letter fluency, which remains unimpaired.  The deficit in category fluency is 
demonstrated by the Supermarket Task, when asked to generate items 
found in a supermarket, patients with Alzheimer’s disease generate fewer 
examples from each category in addition to providing the category label to 
which an item belongs rather than the item (e.g., vegetable instead of 
carrot) (Martin and Fedio, 1983). 
 Confrontation naming impairment is also a prominent feature of early 
Alzheimer’s disease, which remains insensitive to the effects of normal 
ageing (Flicker et al., 1997).  It is thought that naming deficits tend to reflect 
a loss of detailed subordinate category level information (Rosch et al., 1976).  
The deficit in naming is apparent when patients with Alzheimer’s disease are 
asked to name an object, the same pattern of impairment observed on 
category fluency emerges, in addition to providing the name of another 
object from the same semantic category (e.g., naming a “banana” an 
“apple”) (Bayles and Tomoeda, 1983).  
However, the mechanisms underlying semantic deficits in Alzheimer’s 
disease are controversial.  Some reports argue that these deficits reflect 
difficulty accessing a semantic system, which is essentially intact (Hillis et al., 
1995; Nebes, 1989), whilst others argue that there has been a loss of 
semantic knowledge (Chertkow et al., 1992; Flicker et al., 1997; Garrard et 
al., 2005; Hodges et al., 1991; Martin and Fedio, 1983).  The evidence 
favours the latter account of a loss of semantic knowledge (e.g., Chertkow et 
al., 1992; Gainotti, 2006) as observed by item consistency in an animal 
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decision task.  The report by Chertkow et al. (1992) demonstrated a striking 
item-to-item correspondence, such that when a patient could not correctly 
identify an animal on an Animal Decision task, they could not answer probe 
questions about the animal.  
This argument was further extended to include the issue of category-
specificity within the semantic system and whether patients with Alzheimer’s 
disease are more impaired on living items (e.g., animals) than non-living 
items (e.g., baseball bat).  The issue of category specificity has been 
criticized as being experimentally induced by the test material used.  
Category-specific semantic impairments have been attributed to item 
familiarity, name frequency and visual complexity of the items (Parkin and 
Stewart, 1993).  Thus, better performance is expected on living items that 
are identified primarily by their visual properties, which provide preferential 
access to stored knowledge.  In contrast, non-living items are identified in 
terms of their functional properties, which make identification more difficult, 
because the person must draw on semantic knowledge (Chertkow et al., 
1992).  In spite of the ongoing controversy, evidence strongly favours 
categories of knowledge (Gainotti, 2006; Rosch et al., 1976). 
These findings are of interest because of their implications for the 
early diagnosis of Alzheimer’s disease.  These issues highlight the potentially 
confounding effects of test material and the deficits that will manifest as a 
consequence.  This is relevant for new concepts such as mild cognitive 
impairment (MCI), which relies on sensitive tests not influenced by the 
inherent properties of the test material.  Consideration of these issues may 
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help to clarify the importance of semantic memory deficits that have been 
increasingly recognized as impaired during the dementia prodrome (e.g., 
Amieva et al., 2005; Hodges et al., 2006; Saxton et al., 2004). 
 
3.4.2 Neuropsychological predictors of Alzheimer’s disease 
Alzheimer’s disease is characterised by a long preclinical stage of 
cognitive decline during which impairments have been demonstrated across 
a range of cognitive domains including, episodic and semantic memory, 
psychomotor speed, attention, verbal ability, visuospatial skill and global 
indicators of cognition, such as the MMSE (Amieva et al., 2005; Arnaiz and 
Almkvist, 2003; Bäckman et al., 2005; Bäckman and Small, 2007; Morris, 
2006; Orgogozo, 2006).  Despite the multiple nature of the impairments 
(Bäckman et al., 2004b; Twamley et al., 2006), there is agreement that 
deficits in episodic memory, especially if isolated to this domain, predict 
Alzheimer’s disease.  However, there is a lack of consensus regarding how 
early the deficit appears and the sequence of deficit acquisition leading to 
Alzheimer’s disease.  These deficits have been shown by many longitudinal 
studies examining cognitive decline over time using healthy older people and 
patients at increased risk of Alzheimer’s disease due to family history or MCI 
(De Jager et al., 2003; Fox et al., 1998; Ganguli et al., 2004; Guarch et al., 
2008; Howieson et al., 2008; Visser et al., 2006). 
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Episodic memory impairments 
There is no doubt that deficits in episodic memory represent the 
hallmark of Alzheimer’s disease and can be observed many years before 
clinical onset of the disease (Bäckman et al., 2005; Bondi et al., 2008).  Of 
the many cognitive tasks studied, deficits in episodic memory, especially in 
delayed recall, appear to be the most sensitive early clinical indicator of the 
dementia prodrome (Bondi et al., 1995; Butters et al., 1987; Chen et al., 
2001; Elias et al., 2000; Linn et al., 1995; Perri et al., 2007; Solomon et al., 
1998; Tierney et al., 1996; 2005).  The deficit typically manifests in terms of 
a poor ability to learn and remember new information after a short period of 
delay, such as in a word-list learning task (Andersson et al., 2006; Bäckman 
and Small, 1998; Gainotti et al., 1998; Guarch et al., 2008).  Recent 
evidence has identified accelerated forgetting rates and increased sensitivity 
to non-word lists during retrieval (Manes et al., 2008).  The impairment in 
episodic memory is consistent with the critical role of the medial temporal 
lobe and hippocampus in the formation of new memories (Tulving and 
Markowitsch, 1998), which is affected in the early stages of Alzheimer’s 
disease. 
 
The Rey Auditory Verbal Learning Test (RAVLT) 
The predictive value of the RAVLT (Rey, 1964) in determining which 
aspects of episodic memory are more impaired in preclinical Alzheimer’s 
disease is well established (Andersson et al., 2006; Bäckman et al., 2001; 
Estevez-Gonzalez et al., 2003; Gainotti and Mara, 1994; Gainotti et al., 1998; 
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Saxton et al., 2004; Woodard et al., 1999).  Patients who are likely to 
develop Alzheimer’s disease lose more information over a brief delay than 
other patients with amnesia or other dementing disorder (Gainotti et al., 
1998).  In particular, poor delayed recall combined with a failure to benefit 
from semantic cues to facilitate remembering may be an index of more rapid 
progression to Alzheimer’s disease (Andersson et al., 2006; Buschke et al., 
1999; Dubois and Albert, 2004; Estevez-Gonzalez et al., 2003; Grober et al., 
2000; Lehrner et al., 2005; Perri et al., 2007; Saxton et al., 2004; Sarazin et 
al., 2007).  Thus, tests of delayed recall are now frequently used to identify 
subjects at high risk of Alzheimer’s disease (e.g., Andersson et al., 2006; 
Cargin et al., 2007 and 2008; Estevez-Gonzalez et al., 2003; Lerhner et al., 
2005; Saxton et al., 2004). 
Based on evidence that the RAVLT is an early neuropsychological 
marker of Alzheimer’s disease, Estevez-Gonzalez et al. (2003) recruited 70 
subjects (mean age 67) from the community with SMC to examine if the 
RAVLT could identify which subjects with SMC would develop AD over the 
next 2 years.  Two years later, 27 (39%) patients with SMC were diagnosed 
with probable AD; 26 (37%) with MCI and 17 (24%) remained cognitively 
normal.  The authors reported the profile of impairment which characterised 
the 27 Alzheimer’s patients, consisted of a profound amnestic disorder as 
evidenced by lower baseline test scores and frequently recalling zero words 
in the delayed recall test (Trial 6) unadjusted for age or having a percentage 
of forgetting (difference between Trial 5 and Trial 6) of more than 75%. 
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3.5 Subjective memory complaints (SMC)  
Memory complaints are common among older adults and often 
considered an initial symptom of cognitive impairment; possibly heralding 
the onset of a dementia syndrome (Reisberg et al., 2008).  This is evidenced 
by their inclusion in the criteria that define MCI.  Subjective memory 
complaints (SMC) refers to reports of concern about memory performance in 
relation to everyday functioning, such as remembering names and recalling 
where one has placed things in response to a question on memory (Coley et 
al., 2008; Mitchell, 2008b).  
Self-reports of memory loss are generally perceived as problematic 
and have been criticised on several grounds (Ahmed et al., 2008; Jungwirth 
et al., 2004).  The techniques used to assess SMC vary widely across 
studies; some use a single question on everyday abilities or probe about 
changes in memory (Estevez-Gonzalez et al., 2003; Palmer et al., 2003; Kim 
et al., 2006), whilst others use questionnaires to define SMC (Perri et al., 
2007), such as the Memory Assessment Clinic-Questionnaire.  The clinical 
significance of each method remains to be determined, as not all 
measurement techniques are equal.  The lack of consensus on the criteria 
that define and quantify SMC has produced inconsistent reports regarding its 
clinical utility (Abdulrab and Heun, 2008; Mitchell, 2008a). 
Furthermore, the complaint is not always detected on psychometric 
testing or spontaneously disclosed when questioned directly (Lavery et al., 
2006), despite being consciously aware of a change in their memory (Lam et 
al., 2005b; Wong et al., 2006).  In this regard, subjects with a clinically 
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significant disorder can be excluded, underestimating the clinical utility of 
MCI and progression rates to dementia (Mitchell, 2008b).  Jungwirth et al. 
(2004) reported that a significant number of their subjects with objective 
memory impairment (94%) did not complain about their memory.  This issue 
is problematic for the concept of MCI and has led to calls for the removal or 
separation of SMC from MCI (Purser et al., 2006; Mitchell, 2008b). 
It has been demonstrated that patients with more severe cognitive 
impairment or with Alzheimer’s disease underestimate their memory 
difficulties compared to informant information (Farias et al., 2005).  A meta-
analysis examining the clinical significance of SMC reported that 60% of 
people with dementia do not complain of simple memory complaints even on 
specific questioning (Mitchell, 2008b).  It has been suggested that patients in 
the early to mild stages of Alzheimer’s disease have poor insight into their 
memory difficulties (Kim et al., 2006).  In this regard, recommendations 
specify this information can be provided by a relative or reliable informant, 
such as a general practitioner (Mackinnon et al., 2003; Winblad et al., 2004).  
However, whilst this is important in severely impaired subjects, the 
information provided by an informant may introduce bias.  Some subjects 
may be able to hide problems by the use of lists and other strategies.  Thus, 
only those with more severe impairment would be noticed by informants.  
It remains unclear, however, whether SMC are a useful clinical 
indicator.  Some studies of elderly subjects have reported an association 
between SMC and a subsequent diagnosis of dementia (Geerlings et al., 
1999; Jorm et al., 2005b; St John and Montgomery, 2002; Wang et al., 
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2004a; Wong et al., 2006).  Jorm et al. (2005b) reported older males who 
developed dementia had SMC at least 3 to 6 years earlier, often before 
objective deficits could be measured on tests of episodic memory, 
orientation and language.  Other studies have not supported the association 
(Cargin et al., 2008; Jessen et al., 2007; Minett et al., 2008) and have 
attributed it to older age (Park et al., 2007; Treves et al., 2005).  Further 
discussion of the relationship between memory complaints and objective 
memory impairment and dementia is provided in section 3.6. 
Subjective memory complaints are common across a range of clinical 
disorders, and are consistently reported to be associated with 
psychoaffective disorders, such as depression, anxiety (Jorm et al., 2001; 
Jungwirth et al., 2004; Lautenschlager et al., 2005; Minett et al., 2005; 
Minett et al., 2008; Wong et al., 2006), personality disorders and neuroticism 
(Dux et al., 2008).  A report by Lautenschlager et al. (2005) showed that 
SMC are more prevalent in subjects with depression and anxiety than with 
dementia.  Psychoaffective factors could lead to an overestimation of 
memory problems, especially in those with MCI (Kumar et al., 2006).  It is 
well known that subjects with depression overestimate their memory 
difficulties and complain more spontaneously (Steffens and Potter, 2008).  
However, not all studies support the link between depression and SMC (St. 
John and Montgomery, 2002).  
The connection between memory complaints and Alzheimer’s disease 
is rather complex and many factors have been implicated in the relationship.  
Some of these include; older age, psychological factors and different 
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measurement and techniques.  This makes the cognitive burden incurred by 
patients presenting with SMC difficult to objectively measure, especially in 
the early stages of disease when memory complaints are difficult to assess.  
All of these factors have made it difficult for SMC to consistently predict 
dementia. 
Nevertheless, SMC play an important role in the pathway to care for 
persons with cognitive disorders.  Whilst SMC may be non-specific to a 
number of disorders and their role in diagnostic criteria may require further 
refinement, they do seem to increase the likelihood that the individual will 
seek medical attention.  Thus, identifying a cohort that may better respond 
to the available treatment therapies. 
Collectively, these issues have led to uncertainty about the clinical 
significance of SMC, especially in defining MCI.  Disagreement remains with 
respect to the aetiology and clinical significance of SMC.  Reports are now 
calling for memory complaints to be separated from MCI (Allegri et al., 2008; 
Mitchell, 2008) and for a consensus to be reached on the criteria to define 
SMC that reliably predict progression to MCI (Reisberg et al., 2008).  The 
separation of SMC from MCI may help to clarify the role of SMC in cognitive 
function and possibly represent a step towards earlier diagnosis. 
 
3.6 The predictive role of subjective memory complaints  
Prompted by the recent availability of effective symptomatic treatment 
and the prospect of identifying a pre-dementia diagnosis of Alzheimer’s 
disease, clinical inquiry into the role of SMC in cognitive impairment and 
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dementia has significantly escalated in recent years (Abdulrab and Heun, 
2008; Ahmed et al., 2008; Coley et al., 2008; Mitchell, 2008; Reisberg et al., 
2008; Reisberg and Gauthier, 2008).  Subjective memory complaints by self-
report or an informant are part of the criteria for MCI.  Whilst, MCI is a 
clinical condition with an increased risk of developing dementia, the risk of 
developing dementia by people with SMC is much less clear. 
Numerous studies have considered the importance of memory 
complaints as a predictor for future cognitive decline and dementia with 
variable prognosis.  The parameters and brief outcome of these studies are 
listed in Table 3.3.  This section will provide a brief review of recent 
evidence exploring potential relationships between SMC and cognitive 
function drawing on findings from community-dwelling residents; longitudinal 
population-based studies, memory clinics, tertiary referrals, and primary care 
outpatients.  Also, despite the many terms used to describe memory 
complaints, for ease of reference the term SMC will be adopted to describe 
all memory complaints. 
 
3.6.1 Subjective memory complaints (SMC) and dementia  
Several recent cross-sectional studies examining the association 
between SMC and dementia have reported inconsistent findings (e.g., Archer 
et al., 2006; Clement et al., 2008; Jessen et al., 2007; Minett et al., 2008; 
Park et al., 2007; Rouch et al., 2008; Snitz et al., 2008).  For example, 
Jessen et al. (2007) examined the association between SMC, cognitive 
function and depression in 2389 non-demented subjects (mean age 80) from 
                                                                  Chapter 3- Memory complaints and Alzheimer’s disease 
__________________________________________________________________________ 
 71 
a population-based cohort and identified a relationship between SMC in tasks 
of daily living with depressive symptoms.  However, these authors also 
reported an association between SMC and lower scores on verbal delayed  
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Table 3.2 Longitudinal studies examining subjective memory complaints (SMC) as a predictor of cognitive decline or dementia 
Study  
Setting  
Screening 
Test Score; n 
Age; mean 
years (SD)  
Proportion with 
SMCs 
SMC quantified F/UP 
(years) 
Outcome 
Community       
Cargin et al. (2008) 32 normal  
68 memory declining 
69 (8) 60% normal  
75% declining 
Single question 
CFQ 
2.5 No association 
Estevez-Gonzalez et 
al. (2003) 
70 subjects with SMCs 67 (NR) 100% Single question 2 
 
AD (27; 39%); MCI (26; 37%); Normal (17; 
24%) 
Geerlings et al. 
(1999) 
2169 non-demented 65-84  11.5% Single question 3.2 Alzheimer’s disease (77; 4%) 
Jungwirth et al. 
(2008) 
382 normal; 
202 questionable 
impairment 
75-76 49% of normal gp 
58% impaired gp 
Four single questions 2.5 AD in 46 (12%) normal subjects; 
AD in 44 (22%) subjects with questionable 
impairment,; 
Association between verbal memory and AD in 
both normal and impaired groups 
Kim et al. (2006) 686 non demented;  
included 133 (19%)  with 
MMSE<21 
71.3 (5.2) 19.7% GMS 2.4 Dementia (57; 8.3%) 
3.4% per annum 
Purser et al. (2006) 
 
3673: 72% normal;  
25% MCI; 
3% severe impairment 
> 65  34% Self-rating 10 Cognitive decline; no association 
St. John et al. (2002) 1416 normal subjects 76 (NR) 21% Single question 5 Dementia in 22.6% of total sample; 
CIND in 18.8% of total sample 
Wang et al. (2004a) 
 
1,883 non-demented 74.6 (5.8) 4.6% SMRS 5.2 Cognitive decline and dementia in 21% of 
sample 
Memory Clinic       
Gallassi et al. (2008) 92 non-demented 
subjects with SMCs 
67.4 (10.4) 100% MAC-Q .75 MCI (49; 53%) 
 
Glodzik-Sobanska et 
al. (2007)1 
230 67.0 (8.4) 81% GDS 8.4 MCI or dementia (84; 37%); normal (111; 
48%); unstable (35; 15%) 
Huen et al. (2006) 757 non-demented > 55 50.6% Single question 4.7 AD (38; 5%) 
Lehrner et al. (2005)      6.5% 
Guarch et al. (2008)1 34 normal; 47 AD; 
43 with SMCs 
67 (NR) 35% Single question; 2 AD in 10 subjects with SMCs; associations low 
baseline global scores, esp. episodic and visual 
memory  
Treves et al. (2005) 
 
211 subjects with SMCs 67.4 (9.4) 100% Single question 3 Dementia (5%) 
Population-based       
Crowe et al. (2006) 
 
55 subjects with aMCI >65 N/A 6 item of the PIC; 
14 items of the MFQ; 
2 single qus. 
2 Cognitive decline on MMSE; no association 
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Dufoil et al. (2005) 733 MMSE 27.6+2.1; 
range 18-30 
59-71 NR CDS  4 and 6 Cognitive decline on MMSE , WAIS and Delayed 
Recall 
Jorm et al. (2005) 3734 CASI > 74 71-93 NR 4 single questions 6 Dementia in 52; associations with episodic 
memory   
Mol et al. (2006) 
 
557 55-85 26.6% Single question 6 Cognitive decline at baseline in some specific 
domains (Delayed recall, info processing speed); 
no association at follow-up 
Palmer et al. (2003) 
 
1435 dementia free 75-95 years 48% Single question 3 Alzheimer’s disease and dementia (18%) 
van Oijen et al. 
(2007). 
6927  69.5 (9.1) 19% Single question 9.1 Alzheimer’s disease (568; 8%) 
  NR=Not reported;  
  CFQ= Cognitive Failures Questionnaire 
  GMS=Geriatric Mental State Schedule;  
  SMRS=Subjective Memory Rating Scale 
  MAC-Q=Memory Assessment Clinic-Questionnaire 
  CDS=Cognitive Difficulties Scale;  
  IPC= Personality in Intellectual Aging Contexts 
  MFQ=Memory Functioning Questionnaire 
  CASI=Cognitive Abilities Screening Instrument
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recall in non-depressed subjects, which they interpreted as indicating the 
presence of early Alzheimer’s disease. 
Similarly, Minett et al. (2008) also examined the association between 
SMC, cognitive function and depression in 114 non-demented subjects (>50 
years) with and without SMC at baseline from a geriatric clinic.  These 
authors reported an association between SMC and depression as evidenced 
by the lack of difference in cognitive function in subjects with and without 
SMC.  A domain specific association in non-depressed subjects with SMC was 
apparent in animal fluency.  
In contrast, Snitz et al. (2008) examined the association between SMC 
and memory performance in 276 older primary care outpatients (mean 
age=73.2) with MMSE scores >19.  These authors found SMC were 
significantly associated with memory test performance, even after controlling 
for depressive symptoms and education.  A limitation of this study is that 
patients with dementia may have been included as evidenced by the low 
MMSE cut-off score.  
Likewise, a community study by Rouch et al. (2008), examined the 
association between memory complaints, cognitive and executive function 
and affective disorders in 937 non-demented community-dwelling subjects 
(mean age=65).  These authors reported an association between cognitive 
complaints with lower scores on verbal memory (Free and Cued Selective 
Reminding Test) and executive function (Digit Symbol Substitution Test, Trail 
Making B), independent of affective problems.  
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Whilst the above studies suggest a potential association between SMC 
and cognitive impairment, they highlight that additional information on the 
role of SMC can be obtained by using different neuropsychological tests 
other than brief screening instruments.  Although these cross-sectional 
studies provide some clinical information, they cannot examine cognitive 
changes associated with SMC over time.  Hypotheses relating to SMC and 
cognitive decline are more appropriately addressed by longitudinal studies 
(Jungwirth et al., 2008; Sinforiani et al., 2007).  
There are many studies that have examined the course of SMC on 
cognitive decline over varying time intervals (see Table 3.3).  Several studies 
have consistently reported associations in older subjects with SMC and 
normal baseline rather than impaired cognition, frequently measured by the 
MMSE.  Most of the studies reporting a positive relationship have used a 
single question to measure SMC.  These studies are in support of the 
hypothesis that SMC predict cognitive decline and Alzheimer’s disease.  
In an assessment of SMC, Geerlings et al. (1999) recruited 2169 
randomly selected elderly subjects (age range 65-84) from the community 
and categorized them as having either normal baseline cognition (MMSE= 
26-30; n= 1956) or impaired baseline cognition (MMSE <26; n=213).  After 
a mean interval of 3.2 years, SMC, measured by a single question were 
associated with a threefold increase in the risk of developing Alzheimer’s 
disease among young elderly subjects (aged 65-74) with high MMSE scores 
(>26).  A total of 77 patients developed Alzheimer’s disease.  Notably, no 
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association was found among those with low MMSE scores (<26), SMC and 
Alzheimer’s disease.  
In a similar study examining the association between SMC and 
Alzheimer’s, Jungwirth et al. (2008) recruited 584 non-demented community 
residents aged 75-76 years at baseline.  Subjects were categorized as either 
cognitively healthy (n=382), defined by a MMSE score of >28 (28-30) or as 
having questionable cognitive impairment (n=202), defined by a MMSE score 
ranging from 23-27.  Over a follow-up period of 2.5 years, a univariate 
analysis showed that SMC as quantified by four single questions predicted 
Alzheimer’s disease in 46 subjects with normal baseline cognition compared 
to none of the subjects with questionable cognitive impairment.  Additionally, 
a multivariate analysis showed that only impaired verbal memory and anxiety 
predicted Alzheimer’s disease in normal subjects, whilst memory 
performance independently predicted Alzheimer’s disease in 44 subjects with 
cognitive impairment.  Like the previous study, both studies concluded that 
SMC have merit in predicting dementia, despite the lack of supportive 
evidence from the MMSE. 
A study by van Oijen et al. (2007) examined education level on SMC 
and risk of Alzheimer’s disease in 6927 non-demented subjects recruited 
from a population-based cohort, mean age 69.5 (SD=9.1) years.  Over a 
follow-up period of 9.0 years, endorsement of a single question on SMC was 
associated with three times the risk of Alzheimer’s disease in subjects who 
were highly educated and without objective deficits (MMSE score >29) 
compared to subjects with low education and equally high MMSE score 
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(>29); their risk of Alzheimer’s disease was 1.5 times.  However, as 
performance on the MMSE deteriorated, the risk of Alzheimer’s disease 
associated in highly educated subjects was similar to that of persons with 
low education.  
Gallassi et al. (2008) examined the outcome of SMC as either NCI (No 
Cognitive Impairment; MMSE score >23.8) or MCI according to established 
criteria Winblad et al. (2004) by recruiting 92 non-demented outpatients 
(MMSE=28.1 + 2.0; mean age=67.4 + 10.4) with SMC from a tertiary 
setting.  Over a follow-up period of 9 months, self-reported SMC, measured 
with the Memory Assessment Clinic Questionnaire predicted MCI in 49 
subjects with SMC.  Notably, many of the MCI patients had mild impairment 
usually confined to a single cognitive domain.  Comparison of the two groups 
showed that the 43 NCI patients were on average younger (63.3+11.2 and 
71.1+8.1), had higher education (10.8 and 8.0 years) and higher MMSE 
scores (29.09 and 27.30) compared to the MCI patients who had more 
severe depression and irritability.  This study highlights the effects of age on 
memory complaints.  That is, there is a strong association with age in those 
identified as having MCI. 
However, not all studies have reported SMC as a prerequisite for 
cognitive decline and dementia (St. John and Montgomery, 2002; Wang et 
al., 2004a).  In an assessment of SMC on future dementia, Wang et al. 
(2004a) recruited 1, 883 non-demented community-based subjects (mean 
age of 74.6 + 5.8) from a population-based cohort with no baseline objective 
cognitive impairment on the basis of their score of >91 on the Cognitive 
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Ability Screening Instrument.  Over a 5-year follow-up interval, SMC was 
associated with cognitive decline and dementia in 15% of subjects with SMC 
and 6% without SMC.  Notably, the risk of dementia was 6 times greater in 
subjects reporting SMC at the age of 70 compared to a risk of 1.6 times at 
the age of 80.  
However, other studies examining the role of SMC have included 
subjects with questionable cognitive impairment as evidence by the low 
MMSE cut-off scores (<24) or have included subjects with baseline cognitive 
impairment, such as aMCI (e.g., Crowe et al., 2006; Dufouil et al., 2005; Kim 
et al., 2006; Lerhner et al., 2005; Palmer et al., 2003; Treves et al., 2005), 
adversely influencing cognitive decline.  In spite of using a population with 
lower baseline cognitive abilities, these studies also report positive 
associations between SMC and cognitive impairment.   
Dufouil et al. (2005) recruited 733 subjects (aged from 59-71) from a 
population-based longitudinal study to explore whether the number of 
cognitive complaints can be used to predict future cognitive decline.  Their 
mean baseline MMSE scores were (27.6 + 2.1, range 18-30).  After an 
interval of 4 years, those who endorsed a greater number of SMC, measured 
with the Cognitive Difficulties Scale were associated with greater prior 
cognitive decline as measured by the MMSE, WAIS, and Delayed Recall.  
Also, more SMC at 4-year follow-up were associated with greater cognitive 
decline in MMSE scores 2 years later, compared with subjects with no 
apparent cognitive decline in the 4-year period preceding the cognitive 
complaint assessment.  This study supports the use of SMC as a useful 
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indicator of measured cognitive decline and in predicting future decline, prior 
to observable detection by testing.  
In an assessment of SMC on cognitive decline, Crowe et al. (2006) 
recruited 55 subjects >65 years (mean age = 74 years) from a population-
based cohort who met the criteria for aMCI at baseline.  Inclusion into the 
study was based on obtaining a score >23 on the MMSE; the presence of 
SMC was not a compulsory inclusion criterion.  Multiple regression analysis 
showed that, over a two-year follow-up period, those with SMC at baseline 
predicted future decline in memory in subjects with aMCI.  Whilst this study 
suggests that patients with aMCI have some insight into their memory 
difficulties; a limitation of this study is the presence of baseline cognitive 
impairment. 
Likewise, Kim et al. (2006) examined the association between 
changes in self-reported memory complaints and dementia in 686 non-
demented subjects (mean age=71.3, SD=5.2) living within the community.  
Over a follow-up period of 2.4 years, SMC, measured using the Geriatric 
Mental State Schedule was associated with a higher rate of dementia in 
subjects with persistent SMC (present on both occasions) and transient SMC 
(present only at baseline) compared to the subjects without SMC at both 
points.  The incidence of dementia was 3.4% per annum.  Subjects with 
persistent SMC had 4.8 times greater risk of dementia, whilst subjects with 
transient SMC had a dementia risk of 2.3 times.  Notably, dementia was not 
associated with new complaints at follow-up.  However, when adjustment 
was made for baseline cognitive impairment (n=133, defined by MMSE < 
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21), the association between baseline SMC and dementia was weakened. 
However, not all studies have supported the role of SMC with 
cognitive impairment (e.g., Cargin et al., 2008; Dik et al., 2001; Jungwirth et 
al., 2004; Mol et al., 2006; Purser et al., 2006), irrespective of baseline 
functioning.  This may be partially attributed to methodological differences. 
Mol et al. (2006) assessed SMC on cognitive function by recruiting 557 
healthy subjects (mean age=67.7, SD) from the Maastricht Ageing Study 
who at baseline had MMSE scores >24.  At baseline, SMC, measured with a 
single question was associated with lower scores on both the information 
processing speed task and delayed recall task.  However, over a mean 
interval of six years, baseline SMC no longer predicted a change on any 
cognitive task in subjects with and without SMC.  These authors found that 
SMC had higher correlations with symptoms of depression and anxiety, 
compared to subjects with cognitive decline alone.  A limitation of this study 
concerns the exclusion of 78 subjects with SMC who were not worried or 
hindered by their forgetfulness.  It is possible that some of these SMC 
subjects may have developed demonstrable cognitive decline at follow-up. 
Cargin et al. (2008) examined SMC by recruiting high functioning non-
demented subjects residing in the community (mean age=69, SD=8) on the 
basis of scoring >28 on the MMSE or above the age appropriate limit on the 
Short Blessed Test.  Subjects were grouped according to their performance 
on a task of Delayed Recall identified as either normal controls (n=68) or 
memory declining (n=32).  Over a follow-up period of 2.5 years, SMC, as 
measured by the Cognitive Failures Questionnaire were unrelated to 
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objective cognitive functioning in both normal controls and those with 
objective memory decline.  These authors reported stronger associations 
between SMC and the subject’s level of depression, anxiety and general 
mental health. 
In a retrospective assessment of SMC on cognitive decline and 
dementia, Glodzik-Sobanska et al. (2008) examined the medical records of 
230 cognitively normal elderly subjects (mean age=67.0, SD=8.4 years) 
attending a memory clinic.  Nineteen percent had a Global Deterioration 
Scale rating of 1 and 81% had a rating of 2, where a rating of 1 indicated no 
SMC and a rating of 2 indicated awareness and complaint of memory change 
in the absence of objective evidence.  Over a period of 8.4 years, SMC, 
measured using the Memory Assessment Clinic Questionnaire, predicted both 
future decline to MCI or dementia, and an unstable diagnosis.  The outcome 
consisted of: cognitively normal (n=111), declining to MCI or dementia 
(n=84), and diagnostically unstable (n=35).  Compared to the unstable 
group, the declining group was older, had lower depression scores and 
greater deficits in delayed memory.  The presence of more severe 
complaints did not further increase the risk of cognitive decline in this group.  
In contrast, the risk of an unstable diagnosis was associated with a higher 
level of anxiety, more severe memory complaints, and younger age.  Despite 
the retrospective nature, this study gives some support to SMC predicting 
cognitive decline (MCI) and dementia in these cognitively normal subjects 
attending a memory clinic.  
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3.7 Summary and conclusions  
In this review of the literature, the clinical utility of SMC to identify 
subjects who are likely to have cognitive impairment or develop dementia 
remains unclear.  The studies reviewed have varied widely in the depth and 
type of assessment of SMC and cognitive function and the populations being 
examined.  The differing methodologies are likely to have contributed to the 
variable cognitive prognosis associated with SMC.  These being: retaining 
normal cognitive function, a fluctuating course to developing a dementia 
syndrome.  In addition to cognitive function, SMC have also been linked to 
different clinical conditions, such as depression.  
A large extent of the data examining the relationship between SMC 
and cognitive function has been obtained from studies using older 
populations.  The average age of the subjects has been > 70 years (see 
Table 3.3).  As the prevalence of SMC increases with age, deficits in older 
subjects might be reflective of normal ageing.  Much less is known about the 
role of SMC in middle-aged subjects and whether they can be used to predict 
cognitive impairment or dementia.   
It is interesting that the majority of the studies have employed a very 
limited assessment of cognitive ability.  Namely, much of the current 
knowledge on SMC is provided by studies that have employed simple 
measures of global cognitive functioning (e.g., MMSE).  This is relevant 
because the initial deficits are often subtle (Clement et al., 2008) and can be 
missed by the use of these tasks.  Many studies have neglected to consider a 
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wider array of cognitive tasks which limits the available evidence regarding 
the clinical utility of SMC.   
This review has shown that very few studies have examined the role 
of SMC in predicting cognitive impairment in subjects below the age of 70 
years, especially for community samples.  Far fewer studies have used 
formal cognitive assessments to examine SMC and other risk factors to 
examine their importance in identifying younger subjects who develop 
dementia later in life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                  Chapter 4 – Aims and hypotheses 
__________________________________________________________________________ 
 84 
Chapter 4: 
Aims and Hypotheses 
 
4.1 Rationale for study 
As shown in this review of the literature, the clinical utility of SMC to 
identify subjects who develop dementia is unclear.  SMC have been related 
to many different cognitive outcomes.  These include retaining normal 
cognitive function, a fluctuating cognitive performance and the development 
of a full dementia syndrome of the Alzheimer’s type (Gallassi et al., 2008; 
Glodzik-Sobanska et al., 2008; Jungwirth et al., 2008; van Oijen et al., 
2007). 
Much of what is currently known about SMC has been obtained from 
studies that have predominantly used older subjects, brief screening 
instruments or a limited range of tests (Geerlings et al., 1999; Palmer et al., 
2003).  Also, a majority of these studies have recruited subjects from 
ongoing studies on healthy ageing, such as the Maastricht Ageing Study by 
Mol et al. (2006) or the Iowa 65 + Rural Health Study by Purser et al. 
(2006).  These studies have not employed fully comprehensive cognitive 
assessments.  It remains unclear whether the use of SMC can predict the 
subsequent development of cognitive impairment in subjects under the age 
of 70 years. 
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The studies reviewed have differed in their methodology, which may 
also account for the observed discrepancies regarding the role of SMC in 
cognitive impairment. 
Firstly, many studies have examined memory complaints in older 
subjects over the age of 70 (e.g., Palmer et al., 2003; Jungwirth et al., 
2008).  Since the prevalence of SMC increases with age, some of these 
findings may reflect normal ageing rather than the effects of memory 
complaints on cognition.  Much less is known about the role of SMC in 
younger subjects under the age of 70 years.  Current available evidence 
examining younger subjects is scarce (Cargin et al., 2008; Dufoil et al., 
2005; Jorm et al., 2004; Rouch et al., 2008)   It is not known whether 
memory complaints are useful in predicting dementia in younger subjects. 
In addition, many of the studies reviewed have used simple measures 
of global cognitive functioning (e.g., MMSE).  The MMSE is considered to be 
insensitive for identifying both MCI and dementia (Tariq et al., 2006).  This is 
relevant because the initial deficits are often subtle (Clement et al., 2008) 
and can be missed by the use of these tests.  Based on earlier evidence 
provided by Solomon et al. (2002) the MMSE may be more appropriate for 
identifying individuals in the later phases of the disease.  Many studies do 
not consider a wider array of cognitive tasks.  This limits the available 
evidence regarding the role of SMC in cognitive function.  The few studies 
that have used several neuropsychological tests to examine other cognitive 
domains frequently report domain specific associations, even when no 
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impairment on the MMSE is apparent (Jessen et al., 2007; Minett et al., 
2008; Mol et al., 2006; Rouch et al., 2008).  
Finally, a methodological issue relates to the techniques used to 
quantify SMC.  These have varied widely across studies.  Some use a single 
question; others employ questions about everyday abilities, or memory 
questionnaires.  This has rendered comparisons between studies difficult.  Of 
the studies reviewed, the use of questionnaires has to lead to the exclusion 
of subjects who did not meet the threshold for having SMC, despite reporting 
a memory complaint (e.g., Mol et al., 2006; Wang et al., 2004a).  
The current study was specifically designed to address these issues.  
The main aim of the present study was to identify subjects who are at 
greater risk of developing Alzheimer’s disease at an earlier age, based on 
their risk profile and neuropsychological assessment.  Therefore, this study 
examines the role of SMC as well as established risk factors (i.e. age, family 
history) on cognitive function using a comprehensive neuropsychological test 
battery.  These tests assessed cognitive processes thought most likely to be 
impaired in the early phases of a dementia of the Alzheimer’s type. 
To identify subjects at greater risk of developing Alzheimer’s disease 
at an earlier age, community-dwelling subjects (aged from 50-79) were 
recruited.  GP referrals, or those under the care of a specialist in a memory 
clinic, are likely to have a more advanced stage of cognitive impairment or 
dementia and were deemed to be unsuitable candidates for this study. 
As SMC has been linked with an increased risk of cognitive decline 
and dementia (Jungwirth et al., 2008; Gallassi et al., 2008; Geerlings et al., 
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1999), this study recruited subjects from the community with SMC.  
However, as SMC has also been linked to different psychoaffective states, a 
well-validated episodic memory task was used to further classify the subjects 
into three groups (discussed below).  This occurred after the initial analysis 
of both subjects with SMC and without SMC. 
As reviewed in Chapter 2, there are many risk factors which 
contribute to an increased risk of Alzheimer’s disease.  Therefore, this study 
applied exclusion criteria to minimise the possibility that SMC were due to 
other psychiatric (e.g., depression) medical conditions (e.g., stroke), drug or 
alcohol problems and head trauma.  However, subjects with mild (non-
major) depression were not excluded because we were also interested in 
examining the relationship between SMC and mild depression. 
To maximise the possibility of identifying subjects with an increased 
risk of Alzheimer’s disease, subjects were screened to identify their ApoE 
genotype.  The present study was also interested in examining whether the 
ApoE ε4 affects cognitive function over time in subjects with SMC.  Previous 
research indicated that over a 33 month interval, ApoE ε4 carriers aged 
between 50 and 59, showed a modest decline in memory skills from the age 
of 50 onwards (Caselli et al., 2004).  There have been few studies that have 
examined the effect of the ApoE ε4 and its association with cognitive decline 
using younger subjects (Caselli et al., 2004; Christensen et al., 2008; Jorm et 
al., 2007), especially in subjects with SMC (Cargin et al., 2008). 
As discussed in Chapter 3, deficits in episodic memory, especially in 
delayed recall, appear to be sensitive early clinical indicators of the 
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Alzheimer’s dementia prodrome (Andersson et al., 2006; Howieson et al., 
2008; Guarch et al., 2008).  Therefore, performance on the delayed recall 
task was used to classify subjects as having normal memory, SMC or aMCI.  
It is important to emphasize that in the present study subjects with 
aMCI were not defined using the strict criteria of Winblad et al. (2004).  To 
maximise subject numbers, those with impairment in other cognitive 
domains were not excluded.  All subjects were classified according to their 
performance on delayed recall and response to a single question on memory 
difficulties.  A more detailed discussion of group classification is provided in 
Chapter 5 (Methods). 
 
4.2 Aims and Hypotheses 
The aims are as follows: 
1. To determine whether age and/or other factors such as mild depression 
influence the relationship between SMC and objective measures of cognitive 
function;  
2. To ascertain whether the DRS or 7MS are sensitive screening tools to 
identify MCI; 
3. To examine whether the presence of SMC affects the 3-year cognitive 
outcome of subjects 
4. To examine whether the ApoE ε4 affects cognitive function over time in 
subjects with SMC. 
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Hypotheses 
The hypotheses related to these aims are as follows:  
1. Subjects with SMC will demonstrate significant cognitive impairment on 
formal neuropsychological assessment compared to those without SMC; 
2. There is in existence screening tests that are both sensitive and relatively 
easy to administer and can be used to potentially identify subjects with MCI; 
3. Subjects with SMC will demonstrate evidence of worsening cognitive 
function over a 3-year interval; 
4. Subjects with SMC and the ApoE e4 allele will show evidence of worsening 
cognitive function over time; 
 
The next chapter describes in detail the neurocognitive test battery 
used for the formal clinical assessment of cognitive function and discusses 
the different aspects of memory and cognition measured by each test.  It 
also lays the foundation of the pattern analysis for assessing deficits to 
single and multiple cognitive domains. 
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Chapter 5: 
Neuropsychological 
assessment of memory 
 
5.1 Cognitive domains and neuropsychological tests of memory  
Formal neuropsychological testing is essential to “identify cognitive 
impairments in a maximally objective manner” (Lindeboom and Weinstein, 
2004, p. 83).  It is invaluable for quantifying the degree of cognitive 
impairment (Arnaiz and Almkvist, 2003), assists in differential diagnosis and 
may complement clinical judgement.  Thus, when these strengths are 
combined, neuropsychological assessment can play a pivotal role in the early 
detection of Alzheimer’s disease. 
In this section, a description of the tests used in the 
neuropsychological evaluation of all individuals in the present study is 
provided.  A brief summary of the test battery categorized by cognitive 
domain is presented in Table 5.1 and is attached to the Appendix.  The 
psychometric properties of these tests are provided in Chapter 6 (Methods), 
which discusses the unique and overlapping components of each test and 
the influence of confounding variables; such as the age and education.  This 
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background information will lay the foundation for understanding the 
different types of neuropsychological impairments reported in Alzheimer’s 
disease. 
Additionally, the similarities subtest (from the WAIS-R, Wechsler, 
1981) was also administered to the subjects even though it was not included 
in the evaluation of global functioning. 
Many neuropsychological tests share common underlying cognitive 
components.  Thus, impairment on a single test cannot exclusively be 
attributed to one cognitive domain, primarily because of the inter-
relationships between tests.  There are many studies that use the same 
neuropsychological test for different purposes.  For example, category 
fluency, a test of semantic memory has also been used as a test of executive 
function (e.g., Bäckman et al., 2004a).  Similarly, digit span has been used 
as a test of attention and also working memory.  The interpretation of test 
results requires consideration of the common underlying cognitive 
mechanisms of the test. 
The categorisation of neuropsychological tests into composite 
cognitive scores to reflect common cognitive domains is a useful way to 
conceptualise performance and overcome some of the difficulties associated 
with the use of a single test.  This method facilitates comparisons between 
studies and has recently been used in a study on memory complaints in 
patients with MCI (Clement et al., 2008). 
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Table 5.1 Brief description of neuropsychological tests used in this study, 
grouped by cognitive domain 
 
Cognitive domain and test 
 
Source and task 
 
 
1. Current intellectual functioning (IQ) 
     Full scale IQ 
 
NART: National Adult Reading Test 
Pronouncing 50 irregular words 
 
 
2. Working memory (WM)  
     Digit span (forward) 
     Digit span (backward) 
     Serial 7’s (score 2 if correct, 1 or 0 if incorrect) 
 
WAIS-R: given series of numbers to repeat 
forward and backward 
 
WMS: Counting backwards from 100 by 7 
 
 
3. Verbal learning/acquisition (VL) 
 
     RAVLT: trials 1-5 (total) 
 
 
 
RAVLT: Rey Auditory Verbal Learning 
Test 
Learning a list of 15 words over 5 trials, and 
repeating the list back to the examiner after 
each trial 
 
 
4. Verbal recall (VR) 
     RAVLT: immediate recall 
 
     RAVLT: delayed recall (20 min) 
 
      
     Recognition A (maximum 15) 
 
RAVLT 
Recalling words from the list in trials 1 to 5, 
without a subsequent presentation Recalling 
words from the list in trials 1 to 5 
(immediately) and after a 20 min delay 
Correctly identifying the words from the list 
in trials 1 to 5 from amongst foils 
 
5. Verbal ability (language skills) (VA) 
    F A S (total number of words) 
 
    Category fluency (total number of words) 
    Boston Naming Test 
 
Naming words starting with letters F, A and 
S, in one minute for each 
Naming as many animals in one minute 
Correctly naming 60 pictures of line 
drawings     
     
6. Visual recall (VsR) 
    Rey Complex Figure Test (recall) 
 
ROCFT: Rey-Osterrieth Complex Figure Test 
Drawing a complex visual picture from 
memory 
 
7. Visuospatial ability (VsA) 
    Rey Complex Figure Test (copy) 
 
    Praxis (maximum 60 points) 
 
ROCFT 
Copying a complex visual figure from a 
diagram 
Ability to initiate action commands 
 
8. Visuomotor speed (VsS) 
    Trail Making-A (seconds) 
 
Trail A 
Time to complete a simple paper pencil task 
connecting digits (1, 2, ... 25) 
 
9. Cognitive flexibility/Executive function (EF) 
    Trail Making-B (seconds) (max 300 sec) 
 
 
Trail B 
Time to complete a more complex task 
alternating digits and letters (1-A, 2-B, etc 
to 12-L) 
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5.2 Domain 1: Intellectual functioning  
The National Adult Reading Test (NART: Nelson and Willison, 1991) 
The National Adult Reading (NART) is an oral, single word reading 
test, and was chosen because it can reliably estimate pre-morbid cognitive 
functioning in subjects suspected of having brain damage.  In this test, 
subjects read aloud fifty irregularly spelled words that violate the traditional 
rules of grapheme to phoneme correspondence (e.g., naïve, chord) and are 
listed in order of increasing difficulty of pronunciation (e.g., deny, puerperal).  
Performance is expressed in terms of the number of errors, with high scores 
reflecting poor performance.  Thus, the subject’s predicted IQ and optimum 
level of intellectual ability is based on an estimate derived from the number 
of pronunciation errors (Nelson and Willison, 1991).  This may be further 
adjusted for age and education. 
NART is impervious to the presence of mental disease, such as early 
Alzheimer’s disease, where reading ability is generally well maintained 
(Hodges, 1994).  Performance on NART declines in the later stages of the 
disease.  This has been attributed to impairment within the semantic system 
(Patterson et al., 1994). 
 
5.3 Domain 2: Working memory 
Digit Span subtest (WAIS-R: Wechsler, 1981) 
The digit span subtest from the WAIS-R (Wechsler, 1981) is 
commonly used to measure both attention and short-term working memory 
capacity, which are closely related to the integrity of executive function.  
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Testing included both the digits forward and the digits backward 
components.  In both conditions, a string of digits was read aloud to the 
subjects at the rate of 1 digit per second.  Subjects were asked to repeat the 
digits back to the candidate.  The number of digits in both conditions 
progressively increased upon successful repetition on 2 trials of the same 
string of digits.  If the subject scored a zero on both trials of an item, the 
test was discontinued. 
Digit span forward is sensitive to immediate memory (short-term 
memory storage capacity).  Backward digit span is sensitive to working 
memory in which the information held in the short-term memory store is 
manipulated mentally.  According to Baddeley (1986), backward digit span 
requires temporal reorganization of digits, and thus poses demands on 
working memory (Baddeley, 1986).  There is disagreement regarding what 
this test measures.  Some consider this to be the classical test of attention 
(van Zomeren and Brouwer, 1994), whereas others consider it a test of 
working memory (Baddeley, 1986).  In this study, digit span was used as a 
test of short-term working memory.   
 
Serial Sevens Subtraction (WMS: Wechsler, 1945) 
Serial Sevens Subtraction is a test of mental control and calculating 
ability.  In this test, the subjects were asked to subtract 7 from 100, and to 
continue subtracting 7 from their answer until they were told to stop.  The 
time limit was 76 seconds.  One point was deducted for each error.  An error 
free performance within the time limit was given a score of 2, which was the 
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maximum score.  Some consider this test to measure attention and mental 
control (Tierney et al., 1996).  In this study it was used as a test of working 
memory.  Deficits in mental control have been reported to occur in preclinical 
Alzheimer’s disease and in subjects with memory complaints (Tierney et al., 
1996).  The scores of all three tests were averaged to assess working 
memory. 
 
5.4 Domains 3 and 4: Verbal learning and verbal recall 
Rey Auditory Verbal Learning Test (Rey, 1964; Schmidt, 1996) 
The Rey Auditory Verbal Learning Test (RAVLT) is a verbal serial 
learning test consisting of two lists of 15-high frequency, semantically 
unrelated words.  It measures the ability to encode, consolidate, store and 
retrieve verbal information (Schmidt, 1996).  It is critically dependent on 
episodic memory and provides a measure of immediate recall, evaluates 
learning over consecutive trials, and assesses confabulation and 
susceptibility to interference (Gainotti and Marra, 1994).  The RAVLT is 
sensitive to identification of impairment in the medial temporal lobe.  It was 
chosen because it engages the memory systems maximally.   
In this test, the candidate read aloud the 15 words (List A; see page 
A20) with a 1-s interval between each word for five consecutive trials (Trials 
1 to 5).  Each trial was followed by a free-recall test.  Subjects were advised 
to listen carefully to a list of 15 words because they would be asked to 
repeat back as many of the words that they could recall.  The order of 
presentation of the words remained fixed across the trials.  Instructions were 
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repeated before each trial to minimize forgetting.  After Trial 5, an 
interference list (List B) was read aloud by the candidate and each subject 
was asked to freely recall words from this list.  Following this recollection, 
each subject was asked to recall as many words from the original list (List A) 
used in Trials 1 to 5, without a further presentation of that list.   
After a 20-minute period of delay that was filled with other 
psychometric tasks, subjects were again asked to recall the words from List 
A.  This formed Trial 6 (Delayed Recall).  Subjects were also asked to 
recognize as many of the target words (Lists A and B) from amongst a list of 
50 words, which included the 30 targets and 20 foils mixed randomly.  This 
became the delayed recognition score for the list of words presented in 
Trials 1-5. 
The following indices were computed according to previously 
described and commonly reported indices in the literature (Estevez–Gonzales 
et al., 2003; Gainotti and Marra, 1994).   
1. number of correct responses given in each Trial (1 to 5); 
2. immediate recall score: the sum of all correct responses given in the 
five consecutive Trials (maximum score=75); 
3. delayed recall: the number of words recalled from List A after a 20 
minute delay (Trial 6, maximum=15); 
 
The RAVLT is considered to be one of the most sensitive tests for 
identification of preclinical Alzheimer’s disease, especially the Delayed Recall 
subtest.  Profound impairment in delayed recall has been reported to 
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consistently predict progression to Alzheimer’s disease, ranging anywhere 
from two to nine years (in non-demented subjects) prior to disease onset 
(e.g., Amieva et al., 2005; Estevez-Gonzalez et al., 2003; Saxton et al., 
2004).  A useful diagnostic measure for identifying preclinical Alzheimer’s 
disease is to compare immediate and delayed recall performance on word list 
learning tasks.  A discrepancy between the two is thought to be indicative of 
a dementia syndrome of the Alzheimer’s type (Gainotti et al., 1998). 
Additionally, RAVLT is sensitive to memory deficits in different patient 
groups and can thus be used to distinguish between Alzheimer’s disease and 
other causes of cognitive impairment.  Woodard et al. (1999) reported that 
normal ageing was characterised by learning deficits rather than 
consolidation deficits on RAVLT.  In contrast, both learning and consolidation 
deficits are more apparent in patients with Alzheimer’s disease (Woodard et 
al., 1999).  Similarly, Gainotti and Marra (1994) reported that Alzheimer’s 
patients could be characterized by the presence of many intrusions errors on 
delayed recall. 
 
5.5 Domain 5: Verbal ability 
Word Fluency ‘FAS’ (Benton et al., 1983) 
Verbal fluency was measured using the ‘FAS’ task (Benton et al., 
1983) and the animal naming task (Borbowski et al., 1967).  Word fluency 
critically depends on the integrity of semantic memory as well as the ability 
to initiate systematic search and retrieval strategies (Fabrigoule et al., 1998).  
In category fluency, multiple cognitive mechanisms are involved in successful 
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retrieval and recall of words.  Identifying which aspect of category fluency is 
impaired is not always straightforward.  The cognitive mechanisms 
implicated in category fluency are presented in Table 5.2. 
In the present study, word fluency was assessed using both the initial 
letter and category fluency tasks (part of 7 Minute Screen).  Although both 
tasks evaluate word fluency, they differ in terms of difficulty in the strategies 
that are required for successful performance.  The former relies on switching 
and the latter relies on clustering.  Successful performance on a category 
fluency task depends on the ability to organize output in terms of clusters 
(i.e., producing words within a given semantic category) of meaningfully 
related words (Estes, 1974).  In contrast, successful performance on a letter 
fluency task depends on switching (i.e., finding new semantic categories) 
(Bäckman et al., 2004a).  Theoretically, clustering is thought to be an 
automatic process that depends upon the availability of memory storage for 
words.  In contrast, switching is an effortful process that requires speed as 
well as cognitive flexibility and is thought to be dependent on the 
effectiveness of the subject’s search processes (Troyer et al., 1997).   
In the initial letter fluency task, subjects were asked to generate as 
many words as they could think of beginning with the letters F, A and S, 
respectively.  A one-minute time limit was given for each letter.  Subjects 
were instructed not to give proper names, numbers, or words as well as 
repetitions of words with different suffixes (e.g., rain, rained, and raining).  
The total score was the sum of the number of words generated for all three 
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Table 5.2 Cognitive mechanisms underlying verbal retrieval and recall 
________________________________________________________________ 
Auditory attention; 
Ability to initiate and maintain word production set; 
Cognitive flexibility (in rapidly shifting from one word to the next within a selected  
     category); 
Response inhibition capacity; 
Speed of mental processing; 
Response speed; 
Long-term vocabulary storage and executive functions; 
Short-term memory of keeping track of the words that have already been said; 
Adapted from Mitrushina et al. (2005). Handbook of Normative Data for Neuropsychological 
Assessment, 2nd edition. Oxford University Press: New York 
 
 
letters.  The lowest acceptable total for elderly subjects of low educational 
attainment is around 25 words (Hodges, 1994).   
Category fluency is a useful test to identify Alzheimer’s disease, 
because it is highly sensitive to frontal ‘executive’ dysfunction and subtle 
degrees of semantic memory impairment.  It is also one of the best 
indicators of the spread of pathology beyond the medial temporal lobe 
(Hodges, 1994).  Patients with early Alzheimer’s disease are frequently more 
impaired on category fluency than letter fluency (Butters et al., 1987).  It is 
thought that category fluency is more affected by deterioration in the 
structure of semantic knowledge in Alzheimer’s disease (Martin and Fedio, 
1983; Monsch et al., 1992).  Depending on bias, some reports conceptualize 
category fluency as a test of executive functioning.  In this study it was used 
as a test of semantic memory (verbal ability and language skills). 
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Boston Naming Test (BNT: Kaplan et al., 1983) 
The Boston Naming Test (BNT) is a visual confrontation naming test 
that was initially designed to examine aphasic patients.  This is 
demonstrated by the design of the test in which the items to be named 
decrease in their frequency of occurrence within the English language.  The 
BNT is frequently used in the assessment of Alzheimer’s disease, notably for 
identifying impairment and documenting severity.  Naming is critically 
dependent on the integrity of semantic memory, which is compromised in 
the early stages of Alzheimer’s disease (Bayles and Tomoeda, 1983; Gainotti, 
1992).  As such the BNT was chosen for this reason.  
In this test, subjects were required to name line pictures (60 line 
drawings), which ranged from simple, high frequency items (“tree”) to less 
common items (“abacus”) (see page A24).  As the test progresses, the 
pictured items become increasingly less familiar and difficult to name.  
Subjects were allowed up to 20 seconds to name each object and 
were given various prompting cues, depending on the nature of their error.  
If an error was spontaneously self-corrected, full credit was given.  If the 
subject did not produce the name spontaneously, various prompting cues 
were provided.  If the subject did not know the answer or gave a response 
that indicated a misperception of the object (e.g., “spear” instead of 
asparagus for item 49), a stimulus cue was given that provided some 
conceptual information about the picture (e.g., “it is something to eat”).  If a 
general or vague response was given about the object (e.g., “animal” for 
camel for item 17), the subject was asked to provide a more specific 
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response (e.g., “could you be more specific?” or “could you tell me what 
type of animal?”).  If the subject responded correctly to this question, this 
was recorded as a stimulus-cued response rather than as a spontaneous 
response. 
A phonemic cue (the sound produced by the first few letters of the 
object) was given (a) after a stimulus cue did not result in the correct 
answer, or (b) when an incorrect response was given and a stimulus cue was 
not appropriate (“horse” rather than unicorn for item 57).  The appropriate 
phonemic cue would be, “it’s not a horse, and it’s a uni…”.  If a subject gave 
the correct response after being informed that their answer was incorrect, 
but before the phonemic cue, the answer was scored as a stimulus cue.  The 
maximum score is 60.  This is comprised of both the number of 
spontaneously correct responses and the number of correct responses 
following a stimulus cue. 
 
5.6 Domains 6 and 7: Visual recall and visuospatial ability 
Rey-Osterrieth Complex Figure Test (ROCFT: Rey, 1964) 
The Rey-Osterrieth Complex Figure Test (ROCFT) is a test of 
visuospatial constructional ability (copy trial) and visual memory (delayed 
recall copy trial).  Initially, subjects were asked to copy the figure without a 
time restriction.  After a delay of 30 minutes and without prior warning, 
subjects were asked to redraw the figure “from memory” (see page A8 for 
copy figure).  The accuracy of the copied and recalled versions were scored 
using a standardized scoring system, which assigned a maximum of two 
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points to each of the 18 elements within the figure, depending on the level 
of accuracy achieved.  The two ROCFT measures used were the copy score 
and the recall score.  
This test is extremely sensitive to detecting visual neglect in patients 
with lesions.  By definition, unilateral (or hemi-spatial) neglect refers to a 
lack of attention to events and actions in one-half of space (Humphreys and 
Riddoch, 1984).  Unilateral visual neglect may be observed by failure to copy 
one-half of the diagram.  By observing the method that the individual uses 
when performing the task and, noting which details are omitted from the 
figure, the presence or absence of neglect can be determined as can the 
presence of a possible lesion. 
 
Praxis (WMS-R: Wechsler, 1981) 
Praxis consists of 20 items which require the subject to make 
purposeful movements in response to a command.  The body movements 
were further divided into 4 categories, which included: the upper limb; facial; 
instrumental and complex.  The commands ranged in difficulty from “make a 
fist” to “pretend to play the piano”.  A score of 3 points was given for good 
performance; 2 points for an approximate performance or good performance 
on imitation only; and a score of 1 point for an approximate performance on 
imitation.  The total score was summed over items with a maximum score of 
60.  Slight impairments in instrumental and complex functions may be 
evident early in the course of a dementia syndrome as highlighted by their 
inclusion in the criteria for MCI (Winblad et al., 2004; Petersen, 2007). 
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5.7 Domains 8 and 9: Visuomotor speed and executive functioning 
Trail-Making Test (Reitan, 1958) 
Trail Making is a test of attention, speed and mental flexibility 
(Strauss et al., 2006).  This test requires the subject to draw upon multiple 
cognitive skills for successful performance.  This test was administered in 
two parts (A and B).  Part A consisted of 25-circled numbers randomly 
arranged on a page (see page A14).  Subjects were asked to draw a line 
connecting the numbers in sequential order from 1 to 25, in as short a time 
as possible.  Part A is regarded as a classical visual test of selective attention 
that primarily draws on attentional skills and psychomotor speed (van 
Zomeren and Brouwer, 1994).  These skills are also necessary for successful 
performance in Part B.  
Part B is a more cognitively complex because of the increased 
demand in speed of processing and the executive functions of working 
memory and set-shifting.  Part B consists of both circled numbers and letters 
randomly arranged on a page (see page A15).  Subjects were asked to draw 
a line connecting the numbers and letters in a sequential and alternating 
order (1-A, 2-B, 3-C up to 12-L-13) as quickly as possible.  In Part B, the 
demands on working memory are increased because subjects must hold 
information both of the alphabet and of calculation, whilst manipulating this 
information in an orderly fashion.  It is extremely easy to become confused 
on this task due to the increase in visually interfering stimuli (Gaudino et al., 
1995).  Part B is considered to be a test of divided attention (van Zomeren 
and Brouwer, 1994).  Errors were pointed out to the subject, as they 
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occurred, to allow for correction.  The subject was timed on both parts of the 
test and scored as the number of seconds taken to complete the task.  If the 
time taken to complete the task was greater than 5 minutes, a maximum 
score of 300 was recorded.  Both tasks are sensitive to the early cognitive 
changes associated with progression to Alzheimer’s disease (e.g., Chen et 
al., 2001). 
 
5.8 Tests not assigned to a domain 
Similarities subtest (WAIS-R: Wechsler, 1981) 
Similarities are a test of abstract reasoning ability and semantic 
knowledge.  In this task, the candidate read aloud word pairs in reference to 
either an object or situation.  The subject was asked to explain what each 
pair of seemingly unrelated words had in common.  The word pairs ranged in 
the level of abstraction required (and hence difficulty), from ‘orange-banana’ 
to ‘work-play’.  To keep the overall assessment time to a minimum, a subset 
of 7 word pairs was used in this study (see page A22).  They were items 1, 
2, 3, 4, 7, 9 and 12.  Therefore, a total maximum score of 14 was possible.  
The scoring system was hierarchical in nature (Rosch et al., 1976), in that 
categorisations that identified the super-ordinate category (general 
properties in common with other objects, e.g., fruits, animals) were given a 
score of two.  Naming one or more common properties or functions was 
given a score of one.  A score of zero was given when the response was only 
relevant for one member of the pair, or if they indicated a difference existed 
between the pair, or if the demonstrated only a generalised understanding of 
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the word pair e.g. “You can eat them both”. 
The use of this test was theoretically motivated by reports that 
patients with early Alzheimer’s disease have difficulty understanding the 
conceptual relationship between objects (Chertkow et al., 1992; Fabrigoule 
et al., 1996).  For example, when patients with Alzheimer’s disease are 
asked to say in what way an orange and a banana are alike or similar, they 
often respond that they are not alike, thus demonstrating impairment in 
forming abstract relations between objects. 
 
5.9 Summary 
This chapter provided a detailed discussion of the tests (as grouped 
by cognitive domain) used for the clinical assessment of all test subjects in 
this study.  The next chapter will discuss the Methods and study procedures.  
It will also detail the psychometric properties of each of the 
neuropsychological tests used in the test battery. 
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Chapter 6: 
Methods 
 
6.1 Subjects and recruitment 
Community-dwelling subjects aged between 50 to 79 years, living in 
the catchment area of Central Sydney Area Health Service, were recruited 
into the study.  The subjects were recruited via advertisement in local 
newspapers and flyers placed on community and hospital bulletin boards.  
The notices invited individuals with or without memory difficulties or a family 
history of Alzheimer’s disease to participate in a research study on ageing 
and Alzheimer’s disease (see page A25 for Flyer).  
All subjects underwent a screening procedure prior to inclusion.  
Subjects were required to be free of any relevant underlying medical, 
neurological, or psychiatric illness, by self-report; and be willing to 
participate in the study procedures.  In addition, to minimise the likelihood of 
including into the study, those who may develop vascular dementia at a later 
date, subjects with a history of major vascular disease (e.g., atrial fibrillation 
or cerebral infarcts) were excluded.  Subjects with a history of diabetes 
mellitus (Types 1 and 2) and those taking medication capable of producing 
sedation or reduced mental alertness were also excluded. 
 
                                                                                                    Chapter 6 – Methods 
__________________________________________________________________________ 
 107 
The present study was initially designed to investigate fMRI changes 
in patients with preclinical Alzheimer’s disease.  However, during the course 
of the study, the principal supervisor left the organisation to pursue other 
career interests.  This prompted a change in supervision.  Also due to the 
departure of the principal supervisor, funding for the fMRI scans was no 
longer available which prompted a slight modification in the study design.  
An increased focus was placed on the role of subjective memory complaints 
(SMC) and neuropsychological testing.  Although the separation of SMC 
subjects into groups with and without objective impairment was not part of 
the original design, these subjects were nevertheless separated due to the 
availability of information on SMC.   
Consequently, the change in study design prompted a change in the 
use of the depression scale was made in order to more reliably measure 
symptoms of depression in subjects under the age of 65 years.  The reasons 
for this are discussed in section 6.5.3 as is the method of aligning scores on 
the two scales.  The minor adjustments to the protocol did not affect the 
study outcome.  A copy of the initial advertisement recruiting subjects for 
neuropsychological testing and fMRI is attached in the Appendix (see page 
A26).  
All subjects were either cognitively normal or demonstrated mild 
impaired cognitive deficits.  All subjects spoke fluent English, had adequate 
vision and hearing and were able to understand task instructions.  The 
subjects lived at home with no assistance and many were not working or 
retired (77%). 
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Prior to the initial assessment, a brief telephone screening interview 
was conducted with all potential subjects to determine suitability for 
participation.  The subjects answered questions in relation to concerns about 
their memory, family history of Alzheimer’s disease, psychiatric and medical 
history, involvement in a major car accident and drug and alcohol problems. 
 
6.1.1 Ethical approval 
This study was approved by the Human Research Ethical Committees 
of the Royal Prince Alfred Hospital (X99-0116, X02-0324); Concord Hospital 
(CH62/612002-108) and The University of Sydney (6705).  These 
committees are governed by guidelines set out by the National Health and 
Medical Research Council (NH&MRC).  All subjects provided written informed 
consent prior to the initial interview.  Subjects were given information on the 
study (page A27) and were provided with the results of their cognitive 
testing.  The candidate further explained the procedure involved with 
venepuncture.  The ethical issues involved in testing for ApoE were 
addressed both verbally and within the handout (see page A30).  
 
6.2 Study design and procedure  
6.2.1. Initial assessment 
This study was divided into two stages: initial assessment and follow-
up assessment.  After initial screening, all subjects underwent a cognitive 
assessment using a standard neuropsychological test battery (see Section 
6.6).  In addition, two other tests were included to examine their potential as 
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tools for early detection of subjects that might have dementia (Dementia 
Rating Scale and 7 Minute Screen).  Subjects were also screened for stroke 
and depressive symptoms (Psychogeriatric Assessment Scale and Geriatric 
Depression Scale), as well as a question examining subjective memory.  
Relevant demographic information was also obtained. 
Between 1999 and 2003, subjects were assessed at the Royal Prince 
Alfred Hospital.  Between 2004 and 2005 subjects were primarily assessed at 
Concord Repatriation General Hospital.  The candidate was flexible regarding 
the place of assessment.  Most of the assessments were conducted on 
weekdays early in the morning when subjects were more likely to be alert 
and feeling refreshed.  On both campuses the room was well lit, comfortable 
and quiet.  During the process of testing, noise and visual distractions were 
kept to a minimum level.  There was no clock in the room, since providing an 
estimation of time was part of the assessment.  
 
6.2.2 Follow-up assessment 
The candidate wrote to all the subjects inviting them back for a re-
assessment of their memory.  The letter asked subjects to indicate their 
interest in a second memory test by placing a tick in one of the appropriate 
boxes.  The options available on the letter were: ‘Yes, I wish to be 
contacted’; ‘No, I do not wish to be contacted’ and ‘the above mentioned 
person does not live here anymore, please give forwarding address if 
known’.  Non-responses were followed-up with a phone-call after a period of 
2 weeks.  Although, it would have been desirable to have a 100% follow-up 
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rate, the first wave of subjects were not expecting to be followed up as they 
were initially assessed for an fMRI scan.  Notwithstanding this, 42 (49%) 
subjects from the first wave returned for a second interview. 
The follow-up assessment was conducted after an average period of 
three years to allow sufficient time to assess changes in cognitive function.  
A longitudinal approach is invaluable as it provides further information 
regarding the stability of any relationship between SMC and cognitive 
function observed in cross-sectional studies.  It has been suggested that in 
subjects with memory complaints, a period of 5 years is desirable for 
cognitive impairment to manifest (Wang et al., 2004a).  Some reports 
consider SMC to be a stage that occurs prior to MCI in the evolution of 
Alzheimer’s disease and lasts for approximately 15 years (Prichep et al., 
2006; Reisberg et al., 2008; Reisberg and Gauthier, 2008).  In the present 
study, three years was deemed to be an acceptable minimum time interval 
to allow deficits to occur and did not extend beyond the period of 
candidature.  Many studies that have employed similar time frames report a 
significant relationship between SMC and cognitive decline (Geerlings et al., 
1999; St John and Montgomery, 1992). 
The same research battery of neuropsychological tests used in the 
initial assessment was used in the follow-up assessment.  Subjects who 
consented to be re-tested underwent the same screening procedure that was 
employed in the initial assessment.  
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6.3 Measurement of memory complaints 
In the literature, memory complaints have been referred to by a 
variety of terms including, subjective memory complaints, subjective memory 
impairment, subjective cognitive impairment, and subjective cognitive 
complaints (Cargin et al., 2008; Mitchell, 2008a; Petersen and O’Brien, 2006; 
Reisberg and Gauthier, 2008).  The present study used the term subjective 
memory complaint to refer to complaints of memory by self-report.  
Subjective memory complaints were quantified using a single question 
administered at initial assessment (“Do you have a problem with your 
memory”).  Previous research indicates this is sufficient to demonstrate a 
significant correlation between memory complaints and test performance 
(Geerlings et al., 1999; Jorm et al., 2005b; Lam et al., 2005b; Minett et al., 
2008; Palmer et al., 2003; Snitz et al., 2008; van Oijen et al., 2007).  
Responses were coded “Yes” or “No”.  This question was simple and 
straightforward and made no suggestions about memory loss.  This question 
made no direct reference to a specific time frame for the perceived memory 
loss.  Therefore it allowed for a subjective opinion of memory encompassing 
elements of the remote past, present and future.  Information from an 
informant was not collected, because the study focused on the subject’s 
perception of their own memory difficulties.  This will be taken up later in the 
discussion.  
The subjects reported recurrent episodes of memory loss, which 
caused them sufficient concern.  The defining feature of the memory 
complaint was based on their own self awareness that their memory had 
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changed.  They presented with subjective feelings of memory loss for simple 
everyday activities which did not have a negative effect on their everyday 
lives.  Some examples of the types of memory complaints reported by the 
subjects included: misplacing objects, forgetting the names of familiar 
people, unable to recall recent events and forgetting familiar telephone 
numbers.  
 
6.4 Classification of memory status 
The subjects were classified according to two criteria; (1) their 
response to the question “Do you have a problem with your memory?” and 
(2) performance on initial assessment on a task of word list delayed recall 
(RAVLT, Rey, 1964).  They were then classified as having normal memory 
(normal controls; no SMC and a recall score > 4 words on the RAVLT), SMC 
(the presence of a SMC and a recall score > 4 words on the RAVLT) or aMCI 
(the presence of a SMC and a recall score < 4 words on RAVLT).  The 
process of determining the appropriate cut-off on the RAVLT is discussed in 
section 7.5 (page 147).   
          The classification occurred after the initial assessment when 
comparisons were made between subjects with and without SMC.  As this 
study was partially designed to be exploratory in nature rather than 
diagnostic, subjects were not informed of their group.  The implication of 
this is addressed in Feedback to subjects (page 132).  The three groups 
were formed based on their risk of developing dementia at a later date.   
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6.4.1 Normal control group 
Subjects who answered “No” to the question “Do you have a problem 
with your memory?” and had a delayed recall score on the RAVLT of >4 (i.e. 
no objective evidence of memory impairment) were considered to have 
normal memory functioning and formed the normal control group.  
Individuals aged between 50 and 79, fulfilling these criteria had various 
education levels, normal orientation and social functioning within the 
community.  They may or may not have had a family history of Alzheimer’s 
disease.  Notwithstanding ApoE status, it was hypothesized these subjects 
would have the lowest risk of developing Alzheimer’s disease in the future 
based on this risk factor profile. 
 
6.4.2 Subjective memory complaint (SMC) group 
Subjects who answered “Yes” to the question: “Do you have a 
problem with your memory?” were grouped as having SMC.  For some of the 
analyses, the subjects were further grouped according to their performance 
with delayed recall on the RAVLT.  That is, subjects with SMC who scored >4 
on the RAVLT (i.e. no objective evidence of memory impairment) were 
considered to have SMC.  Subjects with SMC fulfilled the following criteria: 
1. a memory complaint by self-report; 
2. a recall score >4 on the delayed word recall test of the RAVLT; 
3. normal orientation and apparent adequate social functioning within 
the community; 
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6.4.3 Amnestic mild cognitive impairment (aMCI) group 
Subjects who answered “Yes” to the question “Do you have a problem 
with your memory?” and had a delayed recall score on the RAVLT of <4 
(objective evidence of memory impairment) were considered to have 
amnestic Mild Cognitive Impairment (aMCI: Peterson, 2007; Winblad et al., 
2004).  Based on initial findings, these subjects scored 2.0 standard 
deviations (SDs) below the mean for the normal controls.  This cut-off score 
is consistent with previous studies (Guarch et al., 2004; 2008) that reported 
subjects with SMC who developed Alzheimer’s disease within 18 months, 
were defined by a deficit of 2.0 SDs below the mean on an episodic memory 
tasks that was unadjusted for age (delayed verbal memory).  The deficit in 
delayed verbal memory predicted 80.5% of cases (Guarch et al., 2008). 
This allowed the candidate to include into this group subjects with 
typical aMCI as defined by Winblad et al. (2004).  To maximise subject 
numbers, those with impairments in others domains were not excluded.  
Thus, in the present study, aMCI is not used in the strict sense as defined by 
Windbald et al. (2004).  The Winblad criteria allow also for the patient to not 
self-complain as long as someone else who knows them well complains.  
Subjects with aMCI fulfilled the following criteria: 
1. a memory complaint by self-report; 
2. normal orientation and apparent adequate social functioning within 
the community; 
3. a recall score < 4 on the delayed word recall test of the RAVLT; 
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There were no subjects without a SMC and recall score of < 4, hence 
there was no need for further categorisation.  The criteria for MCI are 
discussed in Chapter 3, Section 3.3. 
 
6.5 Screening tests 
The screening tests included the 7 Minute Screen (Solomon et al., 
1998); the Mattis Dementia Rating Scale (Mattis, 1976); the Geriatric 
Depression Scale, Short Form (Sheikh and Yesavage, 1986) and two scales 
within the Psychogeriatric Assessment Scale (Jorm and MacKinnon, 1995; 
Jorm et al., 1995) (i.e. the Stroke Scale and Depression Scale).  The details 
of these tests are provided below and were part of the overall assessment 
procedure. 
 
6.5.1 The 7 Minute Screen (7MS: Solomon et al., 1998) 
The Seven-Minute Screen Neurocognitive battery is a brief screening 
test for cognitive impairment aimed at early identification of dementia 
(Solomon et al., 1998).  It consists of four tests (temporal orientation, short- 
and long-term memory, naming, visuospatial organisation, semantic 
processing and storage), selected because they examine cognitive domains 
typically impaired in Alzheimer’s disease (see pages A9-A12).  Abnormalities 
in these domains are considered highly sensitive in identifying early stage 
Alzheimer’s disease (Solomon et al., 1998).  The 7MS has excellent 
predictive validity and can reliably distinguish Alzheimer’s disease from 
normal ageing and other dementias, such as fronto-temporal dementia (e.g., 
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Drake et al., 2003; Meulen et al., 2004).  
Solomon et al. (1998) validated the test in a community sample of 60 
patients with Alzheimer’s disease and 30 healthy controls.  He reported an 
overall test/retest reliability in the range of 0.83 to 0.92 and an inter-rater 
reliability of 0.93.  The 7MS classified 92% of patients with Alzheimer’s 
disease correctly and 96% of control subjects correctly.  Unlike the MMSE, 
scores on the 7MS are not influenced by age, sex or education. 
The 7MS has been widely accepted as a screening test for identifying 
early Alzheimer’s disease due to its good diagnostic power and reliability 
(e.g., Del Ser et al., 2006; Drake et al., 2003; Meulen et al., 2004; Skjerve et 
al., 2007; Tsolaki et al., 2002).  Meulen et al. (2004) reported a high level of 
sensitivity of 92.9% for Alzheimer’s disease and 89.4% for other types of 
dementias, and equally high specificity in both populations (93.5%).  
However, in Meulen’s et al. (2004) study, performance was influenced by 
age, sex and education. 
Compared to the MMSE, Meulen et al. (2004) reported the 7MS is 
more sensitive in identifying Alzheimer’s disease.  Others have indicated the 
7MS is a useful brief screening tool for deciding who would benefit from 
further neuropsychological assessment (Henderson, 2004; Solomon et al., 
1998). 
6.5.1.1 7MS subscales 
The 7MS consists of the following 4 subscales: 
1. Benton Temporal Orientation (BTO):  In this test, orientation to time is 
measured and quantified by the degree of error.  The subject is asked the 
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date (day-month-year) and time.  The fewer errors made, the more likely 
the full score is given.  For example, 10 points are subtracted for each year 
off the target year, 5 points for each month off the target month, 1 point for 
each date and day of the week off the target date and day, and 1 point for 
each 30 minutes off the correct time.  However, when a question is met with 
a non-response or a response of “I don’t know”, the subject is asked to 
guess.  If they refuse to guess, no points are deducted.  The maximum total 
error score is 113, which indicates the worst possible performance.  The best 
score is 0.  For the purpose of analysis, only errors are recorded as high 
scores indicate poor performance. 
2. Memory (Enhanced cued recall: ECR):  Enhanced cued recall is a memory 
test that induces semantic processing and encoding, and is sensitive to early 
Alzheimer’s disease (Grober et al., 1988).  Patients with Alzheimer’s disease 
are typically unable to benefit from semantic cues to facilitate remembering.  
This test consists of 16 pictures, which are presented four at a time on four 
individual cards.  During the learning trial of each pictured item, the subject 
is given a semantic cue to assist with learning the to-be-remembered item.  
For example, “There’s an insect on this page; what is it?”  Immediately after 
presentation of all items, the subject is asked to free recall as many of the 
pictures as possible.  After a short interval, during which a distracter task is 
presented, the subject is asked to free recall all pictures.  The appropriate 
semantic cue is provided for unnamed pictures.  For example, “I showed you 
a picture of a musical instrument; what was it?”  Scores range between 16 
(maximum) and zero. 
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3. Clock Drawing (CD): Clock Drawing measures visuo-spatial memory and 
visuo-constructional ability, which are usually impaired in mild and moderate 
Alzheimer’s disease (Brodaty and Moore, 1997; Esteban-Santillan et al., 
1998).  In this test, the subject is asked to draw the face of a clock and 
place the hands at a fixed time “twenty-to-four”.  Points are deducted for 
different types of errors.  These include missing numbers, incorrect order 
and position of numbers.  Points are also deducted if both hands are not 
present, the hour or minute number is not indicated and if the hands are 
proportionally incorrect.  The best score is 7, which is the maximum total 
score; the lowest is zero. 
4. Category fluency (CF): Category fluency measures the integrity and ability 
to access semantic memory and is a sensitive marker of Alzheimer’s disease 
(Monsch et al., 1992).  In this test, the subject is asked to generate as many 
words as possible from the semantic category animals and is given a 60-
second time limit.  The total number of animals named is the score recorded.  
The best score is 45.  If no animals are named, a score of zero is assigned.  
 
6.5.1.2 Calculating the 7MS total score 
To determine the degree to which the 7MS discriminated between 
control subjects and patients with Alzheimer’s disease, Solomon et al. (1998) 
estimated a logistic regression model using the raw scores of the four 
subtests as predictor variables: 
Ln [P/(1-P)] = 35.59 – 1.303*ECR – 1.378 * CF + 3.298 * 
        BTO - 0.838 * CD 
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P indicates the probability of having Alzheimer’s disease, and ECR, VF, 
BTO, and CD are the scores for the Enhanced Cued Recall, Category Fluency, 
Benton Temporal Orientation, and Clock Drawing tests, respectively.  The 
natural logarithm (Ln) of P/(1-P) is equal to the total 7MS score of the above 
logistic regression formula.  The probability of having dementia decreases 
with a lower total score.  For example if the total score is -24.6, the 
probability of having dementia is less than 1%.  If the total score is 0, the 
probability of dementia is 50%.  Finally, when the total score is more than 7 
the risk is more than 99.9% (Solomon et al., 1998). 
In Solomon et al’s. (1998) initial study, total scores from the 7MS that 
fell between the normal control threshold (probabilities less than 0.3) and 
dementia (p>0.7) were not categorised (diagnosis deferred) and it was 
recommended to re-test these subjects 3-6 months later.  This indicated that 
the subject’s performance did not fit neatly into either category. 
 
6.5.2 The Dementia Rating Scale (DRS: Mattis et al., 1976) 
The DRS is a reliable screening test for dementia and is capable of 
measuring the progression of cognitive decline in older persons well into the 
later stages of dementia (Mattis, 1976; Salmon et al., 1990).  The DRS was 
used to provide an estimate of global cognitive function within the study 
population (see Appendix A16 for a list of questions).  The DRS total score is 
derived from five sub-scales of specific cognitive functioning.  These are: 1) 
attention (e.g., digit span), 2) initiation and performance (e.g., category 
fluency), 3) construction (e.g., copying designs), 4) conceptualisation (e.g., 
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similarities), and 5) verbal and non-verbal short-term memory (e.g., 
sentence recall and design recognition).  The total summary score has good 
concurrent and predictive validity (Strauss et al., 2006). 
Scores using all the DRS questions range from 0-144.  A score of 123 
(lower 95% confidence interval of norms) is commonly used to identify 
subjects with dementia (Mattis, 1976).  According to Strauss et al., (2006) 
the simple cut-off score of (<123) is inappropriate because it is based on a 
small well-educated sample size.  In the present study, two items in the 
memory subscale (orientation) were not used as they were more relevant to 
USA populations.  These two items were questions about the ‘city mayor’ 
(which may be confused with city of Sydney or local shire mayor) and the 
‘governor’ (which may be confused with the state Premier who actually 
‘governs’ the state, not the Governor General or the NSW Governor).  Thus, 
the DRS maximum in the current study was 142.  Moreover, the cut-off 
criteria for dementia was lowered from 123 to 121”.   
The DRS is highly sensitive to identifying cognitive impairment 
associated with dementia.  Vangel and Lichenberg (1995) successfully 
classified 87% of their healthy sample from amongst a group of 105 
cognitively impaired elderly subjects using a cut-off score of 120.  The 
sensitivity and specificity was reported to be 74% and 93%, respectively.  
Age, education and IQ have been documented to affect performance on the 
DRS (Chan et al., 2001; Schmidt et al., 1994b).  In this regard, the norms 
provided by Schmidt et al. (1994b) are highly sensitive because they are 
adjusted for age and education. 
                                                                                                    Chapter 6 – Methods 
__________________________________________________________________________ 
 121 
Further reliability data are provided by Mattis (1988) who reviewed 
evidence from several reports, which indicated that the total score had a one 
week test re-test reliability of (0.97), a split-half reliability of (0.90) and 
internal consistency estimates (Cronbach alpha) between (0.75 to 0.95) for 
each of the subtests.  However, Schmidt et al. (1994a) reported different 
degrees of internal consistency for the individual subtests, with Construction, 
Conceptualization, Memory and Total Score having the highest (0.70), and 
Initiation and Perseveration, (0.45), having the lowest. 
 
6.5.3 Screening for major depressive disorder 
All subjects were screened for past and present major depressive 
symptoms.  It has been documented that depression amongst the elderly is 
grossly underestimated (Snowdon and Lane, 2001) and may be concealed by 
an increase in somatic symptoms, such as fatigue and sleep problems.  
Whilst depression is common in the early stages of Alzheimer’s disease (van 
Oijen et al., 2007) it may also be a prodrome to dementia of the Alzheimer’s 
type (Wilson et al., 2008).  Thus, clinical judgement is required in 
combination with the use of scales when screening for major depression and 
identifying other underlying causes. 
During the course of the study, two self-report scales were used to 
screen for depression.  Initially, when the focus of the study was based on 
clinical referrals, the Depression Scale from the Psychogeriatric Assessment 
Scales (Jorm and Mackinnon, 1995; Jorm et al., 1995) was used.  However, 
when the study was modified in 2001 (and subjects under the age of 65 
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years were included), the GDS-15 (Sheikh and Yesavage, 1986) was 
subsequently used to screen for depression.  
To align the scoring systems of both screening scales, the cut-off 
scores from both scales; Depression Scale (PAS) and GDS were used to 
categorize subjects as 0, (no depression), to indicate the absence of clinically 
significant depressive symptoms (i.e., the subject scored within the normal 
range); 1, to indicate mild depressive symptoms (i.e., the subject scored 
between 5-7 on the PAS or 8-9 on the GDS), and 2 to indicate clinical signs 
of depression  (i.e., the subject scored >10).  This allowed for both groups 
to be rated for depression on the same scoring system, despite the use of 
two different scales.  The cut-off scores on the GDS-15 are similar to those 
employed by Freidman et al. (2005).  Friedman et al. (2005) looked at 
depression in subjects over the age of 65 (mean age=80) and used a similar 
cut-offs to the present study to determine the severity of depression.  That 
is, Friedman et al. used a score from 6-10 to classify subjects as having mild 
depression and a score from 11-15 to classify subjects as having severe 
depression.    
Subjects were excluded if they scored within the depression range on 
either assessment.  In the present study, subject number 75 was rated as 
having clinical signs of depression.  This subject spoke about stress and 
anxiety in her life and felt overburdened caring for her grandchildren.  This 
subject was advised to see her GP for treatment and was excluded from the 
analysis.  Eight subjects who were rated as having mild depressive 
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symptoms were not excluded from the analysis, but were used to assess the 
influence of increased depressive symptomatology on memory complaints. 
 
6.5.3.1 The Psychogeriatric Assessment Scale (PAS) (Jorm and 
MacKinnon, 1995) 
The Stroke Scale 
The Stroke Scale is part of the Psychogeriatric Assessment Scale 
(Jorm and MacKinnon, 1995).  This scale evaluates six symptoms of 
cerebrovascular disease.  It provides an indication of whether cognitive 
impairment might be due to vascular dementia or non-vascular types of 
dementia (mainly Alzheimer’s disease) (see page A3).  Subjects with vascular 
dementia obtain higher than average scores on this scale.  The validity of the 
Stroke Scale is demonstrated by its correlation with the Hachinski Ischemic 
Score; 0.71 and 0.65 (Jorm et al., 1995).  Approximately, 80% of vascular 
dementia cases obtain a score of one or more (Jorm and MacKinnon, 1995).  
The scores range from 0 to 6 with scores of 2 or more indicating the 
possibility of vascular dementia.  None of the subjects in the present study 
reported a history of stroke or transient ischaemic attacks (T.I.A). 
The Depression Scale  
The Depression scale evaluates 12 symptoms of depression over the 
previous two weeks (see page A4).  For example, “Have you had trouble 
sleeping over the past two weeks?”  The scale focuses on the physical and 
cognitive symptoms of depression.  The reference population used for 
determining the psychometric properties of the scale consisted of 134 
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geriatric and psychogeriatric patients from Sydney and Geneva, over the age 
of 70 years.  Reports indicate that the Depression Scale performs well as a 
screening test for major depression (Jorm et al., 1995).  Test-retest reliability 
for the Depression Scale is high and the validity of the scale is supported by 
its correlation with the Goldberg depression and anxiety scales, 0.67 and 
0.60 respectively.  Approximately 80% of major depression cases obtain a 
score of four or more (Jorm and MacKinnon, 1995). 
 
6.5.3.2 The Geriatric Depression Scale (Sheikh and Yesavage, 1986) 
The Geriatric Depression Scale (GDS) is a reliable and valid screening 
tool to detect the presence of a major depressive disorder amongst older 
persons in different settings (Sheikh and Yesavage, 1986).  It is used 
extensively in geriatric populations (Almeida and Almeida, 1999; D’Ath et al., 
1994; Friedman et al., 2005; Jongenelis et al., 2007) and is favoured 
because it excludes somatic symptoms of depression known to occur in the 
elderly that frequently are related to causes other than depression.  In the 
present study, subjects were administered the GDS-15 Short Form which has 
been validated for a diagnosis of major depressive episode according to the 
ICD-10 and DSM-IV criteria, for research and clinical purposes (Almeida and 
Almeida, 1999).  The GDS-15 consists of 15 questions enquiring about 
different aspects of depression in relation to mood and activity, e.g., ‘Do you 
think it is wonderful to be alive now?’  Subjects either responded with a ‘yes’ 
or ‘no’ answer to each question (see page A7).  The responses to the 15 
questions were summed to give a total score from 0 to 15, with higher 
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scores indicating more depressive symptoms.  A cut-off score of 5 or more 
indicates probable depression, but not necessarily major depression (D’Ath et 
al., 1994).  
Reliability data supports the clinical utility of the GDS-15 for 
measuring depression.  D’Ath et al. (1994) screened elderly subjects over 75 
years for depression using a cut-off score of 4/5, and reported high 
sensitivity (91%) and specificity (72%).  The internal consistency for the 
GDS-15 is also high (Cronbach’s alpha = 0.80) and all of the 15 items are 
significantly associated with the total score and hence ‘caseness’ (D’Ath et 
al., 1994).  However, internal consistency declines with increasing severity of 
dementia.  The GDS-15 has high test-retest reliability (0.84 to 0.85) for short 
intervals (less than 2 weeks).  This test correlates well with other measures 
of depression, (e.g., Beck Depression Inventory (r=0.84) and the Zung Self-
Rating Depression Scale (r=0.68) which are used for assessing depression in 
younger age groups.  
 
6.6 Clinical assessment of memory 
All subjects were evaluated with a standard neuropsychological 
battery consisting of 15 tests (see Chapter 5).  This included (a) one test of 
pre-morbid IQ (Nelson and Willison, 1991); (b) three tests of working 
memory; Digit span Forward and Backward (Wechsler, 1981), the Serial 7’s 
subtest from the Wechsler Memory Scale (Wechsler, 1945); (c) three 
memory tests (verbal learning and recall), the Rey Auditory Verbal Learning 
Test (Rey, 1964), Rey-Osterrieth Complex Figure Test (delayed recall of 30 
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min; Rey, 1964); (d) three language tests; Verbal Fluency for letters “FAS” 
and for categories “Animals’ (Benton et al., 1983) and the Boston Naming 
Test (Kaplan et al., 1983); (e) two tests of visuo-spatial ability; Rey Complex 
Figure Test; copy (Rey, 1964) and the subtest Praxis from the Wechsler 
Memory Scale-Revised (Wechsler, 1981); (f) one test of visuomotor speed; 
Trail Making Test-Part A (Reitan, 1958); and (g) one test of executive 
function (EF); Trail Making Test-Part B (Reitan, 1958).  Similarities 
(Wechsler, 1981) were administered as a test for abstract reasoning ability 
and semantic knowledge.  Each test is described below and the entire list of 
questions and items are provided in the Appendix.  
All of these tests have been empirically demonstrated to be useful, 
valid and reliable for the study of different cognitive functions (Lezak, 1995; 
Strauss et al., 2006).  The individual tests were further organized into eight 
categories of cognitive ability on the basis of the typical association between 
tests and ability domains seen in the neuropsychological literature (Lezak, 
1995; Mitrushina et al., 2005; Strauss et al., 2006).  
NART was used only for the purpose of providing an estimate of the 
subjects’ intelligence and was not incorporated in some of the analyses. 
 
The National Adult Reading Test (NART: Nelson and Willison, 1991) 
NART was used to estimate pre-morbid intelligence in the study 
population because performance on NART relies heavily on previous 
knowledge and not on current cognitive abilities (Nelson and Willison, 1991; 
Crawford et al., 2001).  In a review of studies, Strauss et al. (2006) reported 
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NART to be among the most reliable tests in clinical practice.  NART has high 
levels of internal consistency (alpha=0.90), test-retest reliability (0.98), and 
inter-rater reliability (κ>0.88).  
NART is unrelated to some demographic variables, such as age, 
gender and ethnicity.  These have little effect on the subject’s performance 
in this test (Anstey et al., 2000).  However, performance is correlated with 
education level and social class.  NART errors systematically decrease with 
increasing full score.  In terms of construct validity, NART correlates highly 
with measures of intelligence (especially verbal IQ and full-scale IQ) on the 
WAIS-R (r=0.85).  Among verbal subtests, NART errors correlate the highest 
with Vocabulary and Information. 
The reliability of NART was demonstrated by Crawford et al. (2001) 
who administered an IQ test to 177 individuals at age 11 and again at age 
77.  The NART scores obtained at age 77 were highly correlated (r=0.73; 
p<0.001) with the individual’s IQ scores obtained at age 11.  In the 
Crawford et al. (2001) study, NART accounted for more than 50% of the 
variance in the intelligence of the subjects, measured at age 11.  In these 
individuals, NART was impervious to the effects of age, education and 
general socio-economic influences encountered after 11 years of age. 
 
The Wechsler Adult Intelligence Test - Revised (WAIS-R Wechsler, 
1981) 
There is strong evidence to support the validity of the WAIS-R as a 
measure of global intelligence.  The psychometric properties of the three 
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individual subtests from WAIS-R (Digit Span, Similarities and Mental Control) 
are discussed under its parent test the WAIS-R (Wechsler, 1981).  The 
WAIS-R has been well standardized and is considered to be a reliable and 
valid instrument, which correlates highly with other IQ tests (Strauss et al., 
2006).  The reliability coefficients (internal consistency) for performance IQ, 
verbal IQ and full IQ range between 0.93 and 0.97.  The split-half reliability 
of the WAIS-R is also very high (0.95). 
 
The Rey Auditory Verbal Learning Test (RAVLT: Rey, 1964) 
The RAVLT is a sensitive measure of verbal learning and memory that 
correlates moderately well with other measures of learning and memory 
such as, the WMS-R Logical Memory and Visual Reproduction subtests, and 
the California Verbal Learning Test (Strauss et al., 2006).  The RAVLT is also 
sensitive to verbal memory deficits in different patient groups (Strauss et al., 
2006).  The RAVLT has been reported to distinguish patients with pseudo-
dementia from those with Alzheimer’s disease (Gainotti and Marra, 1994). 
According to Strauss et al. (2006), the most reliable measures are the 
total score, the delayed recall score, and Trial 5 score.  The internal reliability 
(Cronbach alpha) of the total score is high (0.90).  Over a one-year period, 
more adequate retest reliability has been reported for trial 5 and delayed-
recall trials (0.60 to 0.70).  The delayed-recall score correlates highly with 
the total score (r>0.75), adding to the concurrent validity of RAVLT. 
Performance on RAVLT is affected by age, education and intelligence 
(Strauss et al., 2006).  Age becomes increasingly important, (especially after 
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the age of 60) for the number of words recalled on immediate and delayed 
recall trials.  This is because forgetting is reported to increase with 
advancing age (Salthouse, 1996). 
 
Word Fluency (Benton et al., 1983) 
Word fluency is a measure of language ability. The internal 
consistency (Cronbach alpha) for each letter ‘FAS’ is high (0.83).  The test-
retest reliability for both the letter and semantic fluency tasks is consistently 
high (0.70) for both short and long intervals.  Word fluency correlates well 
with other language tests such as the Visual Naming Test (r=0.76 to 0.86). 
Increasing age is accompanied by a decrease in verbal fluency and 
category fluency (Bäckman et al., 2004a).  Benton et al. (1981) reported a 
decline in verbal fluency after the age of 80 based on a sample of 65-84 year 
olds.  Education level significantly influences scores on both fluency tasks, 
and higher levels of education have been associated with better performance 
(Bäckman et al., 2004a).  Tombaugh et al. (1999) reported FAS is more 
sensitive to the effects of education, whilst animal naming is more sensitive 
to the effects of age.  
 
Boston Naming Test (BNT: Kaplan et al., 1983) 
The BNT is a reliable measure of visual confrontation naming.  The 
internal consistency for the 60-item form ranges from 0.78 to 0.96.  The 
test-retest reliability of the BNT is consistently higher over shorter intervals 
(0.91) of 1 to 2 weeks than over longer intervals.  For example, over a, one-
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year period, the test re-test reliability has been reported to range from 0.62 
to 0.89.  The BNT correlates well with other language tests such as the 
Visual Naming Test (r=0.76 to 0.86) from the Multilingual Aphasia 
Examination and to measures of intelligence (Strauss et al., 2006). 
The BNT is sensitive to the effects of age.  Scores on the BNT 
decrease with age, with the greatest decrease occurring after the age of 70 
(Mitrushina et al., 2005).  However, increasing age is accompanied by 
increasing variability in the standard deviation, suggesting that some older 
groups maintain their performance, whilst others decline.  This may also 
represent the inter-individual differences that accompany increasing age 
(Christensen, 2001). 
Performance on the BNT is also affected by verbal intelligence, full-
scale IQ and educational achievement.  There is less of an age effect in 
more highly educated individuals (Welch et al., 1996).  The effects of 
education and intelligence can be seen by the high correlation that BNT 
scores have with Verbal IQ and vocabulary subtests of the WAIS-R 
(Thompson and Heaton, 1989).  Thus, it is important to consider premorbid 
ability when interpreting BNT performance. 
 
Rey-Osterrieth Complex Figure Test (ROCFT: Rey, 1964) 
The ROCFT is a valid measure of a number of cognitive processes, 
including constructional ability (copy) and memory (recall and recognition).  
Memory and visuo-motor ability contribute significantly to performance.  This 
is demonstrated by the significant correlation that the copy and recall 
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conditions have with tasks that require memory and constructional ability 
(e.g., RAVLT Trial 5 and Trail-Making B).  Also, ROCFT measures correlate 
more strongly with performance subtests (e.g., Perceptual Organisation from 
WAIS-R) than with verbal subtests (e.g., Verbal Comprehension from WAIS-
R). 
ROCFT scores correlate well with measures of general intellectual 
ability (Strauss et al., 2006).  ROCFT has high split-half reliability and 
Cronbach alpha (>0.60) for the copy condition and (>0.80) for the recall 
condition, suggesting the tests tap into a single factor (Strauss et al., 2006).  
Test-retest reliability is high for delayed recall (r=0.89) and recognition 
(r=0.87).  No data are available for copy because most normal subjects 
perform close to full score and this reduces the test-retest correlation 
coefficient. 
Increasing age is accompanied by a robust age-related decline in copy 
and recall scores as well as an increase in variability (Mitrushina et al., 2005; 
Strauss et al., 2006).  A consistent discrepancy has been reported in recall 
performance between older subjects (60-80 years) and younger subjects 
(20-59 years).  Older subjects score much lower than younger subjects 
(Strauss et al., 2006).  This has been attributed to the less efficient encoding 
and retrieval strategies, which accompany increasing age (Bäckman et al., 
2004a).  
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Trail-Making Test (Reitan, 1958) 
The Trail-Making Test is a measure of attention, speed, and mental 
flexibility and is highly sensitive to cognitive impairment.  In a review of 
studies, Strauss et al. (2006) reported that test-retest reliability is low for 
Part A (r=0.46) and high for Part B (r=0.89).  The inter-rater reliability has 
been reported to be high for both Part A (κ=0.94) and Part B (κ=0.90). 
Both parts of the Trail-Making Test correlate moderately with each 
other (r=0.31), suggesting a common underlying component, despite 
measuring different functions.  Part B places greater demands on motor 
speed and visual-perceptual processes (Strauss et al., 2006).  Part B also 
correlates well with other tests of executive function and frontal lobe 
dysfunction (Strauss et al., 2006). 
Performance on Trails A and B is strongly affected by age and has 
been shown to decline with increasing age (Bäckman et al., 2004a).  It is 
thought that age-related differences are related to the speed with which 
both tasks are completed.  Age is unrelated to the accuracy in performing 
the tasks (Bäckman et al., 2004a).  Although lower education and low IQ are 
associated with poor test scores, education may have a greater effect on 
Trail B for subjects over the age of 54 years (Tombaugh, 2004). 
After the cognitive testing, the raw scores of the control group were 
compared with published norms matched for age and education on each of 
the cognitive tasks.  This occurred prior to performing the z transformations 
on each of the nine cognitive domains.  The purpose of this was to 
determine whether a bias was present in the data because there was a 
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higher proportion of subjects with a family history of Alzheimer’s disease 
compared to the general population.  This was due to the initial 
advertisement which requested first degree family members in order to 
maximise the chance of finding subjects carrying the ApoE ε4 allele. 
 
6.7 Apolipoprotein E (ApoE) genotyping 
Following the cognitive assessments, subjects were asked to provide a 
blood sample to allow for the identification of their ApoE genotype.  This 
occurred on site at either the Royal Prince Alfred Hospital or Concord 
Repatriation Hospital. 
Blood samples (5ml) from each subject were collected in EDTA tubes.  
The genotype of each DNA sample at the ApoE locus was extracted by using 
standard methods in which DNA was amplified by the polymerase chain 
reaction (PCR: Poirier et al., 1993).  In this method a DNA solution is 
prepared from the whole blood using the Dynabeads DNA Direct Kit.  The 
DNA is bound to super-paramagnetic polymer particles and washed free 
from matrix and inhibitors using a magnetic particle concentrator.  After 
elution into buffer, the isolated DNA is then amplified using the PCR initiated 
by the enzyme Taq polymerase.  The DNA product is subsequently cut using 
a restriction enzyme (Cfo 1).  Electrophoresis on polyacrylamide gel identifies 
patterns of base pair fragments, which can be related to the ApoE gene 
structure.  Genotypes were determined by Biochemists whom were blind to 
subject status. 
Funding for ApoE genotyping was acquired in March 2003.  As a 
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result, not all subjects in this study were able to undergo ApoE genotyping.  
However, some subjects assessed before 2003 had a follow-up assessment 
and were then genotyped.  Two blood samples were lost due to 
administrative errors and were unavailable for analysis. 
 
6.8 Role of candidate 
The candidate played the primary role in all aspects of subject 
recruitment, data collection, management and interpretation.  This included: 
Study design 
The design of the study was performed in collaboration with and 
under the guidance of the primary supervisor. The candidate was solely 
responsible for researching and reviewing the literature and creating study 
information, in addition to selecting a neuropsychological test battery for 
testing the hypotheses of interest. 
The neuropsychological test battery examined nine domains of 
cognitive function.  The cognitive interview took an average of two to three 
hours to complete.  Subjects who had mild cognitive difficulties took longer 
to complete the test.  It is well documented that cognitive impairment 
increases the testing time of the individual (e.g., Meulen et al., 2004; 
Solomon et al., 1998).  Due to the extensive nature of the testing, most of 
the subjects were given short breaks to assist with feeling refreshed. 
Recruitment and data collection 
The candidate was solely responsible for recruiting all subjects, which 
included placing advertisements, arranging the interviews and blood tests.  
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The candidate performed all of the face-to-face initial and follow-up 
neuropsychological assessments and entered all of the data into the SPSS 
program prior to data analysis. 
Blood collection  
The candidate played a supportive role in the process of blood 
collection.  After testing, the candidate accompanied the subject to the 
Pathology Department within one of the two hospital settings.  Here a 
registered nurse extracted 5ml of blood from a vein in one of the subject’s 
arms.  The candidate then ensured that the blood was forwarded to the 
Biochemistry Department at the Royal Prince Alfred Hospital for ApoE 
genotyping.  The candidate communicated directly with the Biochemistry 
department regarding the dissemination of blood test results. 
Statistical design and analysis  
The candidate, under the supervision and guidance of the primary 
supervisor, performed the design, planning and execution of the statistical 
analysis. The candidate was responsible for collecting, entering and 
management of the data along with the interpretation of statistical analyses.  
Feedback to subjects 
The candidate provided each subject with a short report of their 
cognitive performance.  Subjects were not given a diagnosis.  Subjects who 
demonstrated cognitive impairment or remained concerned about their 
memory were advised to see their GP for follow-up support or referral to a 
specialist.  The subject did not receive feedback regarding their ApoE status.  
Research indicates that although the ApoE e4 allele is overrepresented in 
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patients with Alzheimer’s disease in comparison with the general population 
(Saunders et al., 1993) and is recognized as a risk factor for Alzheimer’s 
disease, evidence for a direct causation is lacking.  Thus, this information 
was not disclosed to the subjects unless they requested it.  However, a total 
of 11 subjects requested their ApoE status.  The candidate advised these 
subjects on the relationship between the ApoE e4 allele and Alzheimer’s 
disease. 
 
6.9 Statistical analysis  
To investigate cognitive differences between the groups, comparisons 
using one-way analysis of variance were conducted for each of the cognitive 
tests completed at both assessment intervals.  Demographic factors and 
clinical variables were examined between the groups using one-way analysis 
of variance for continuous data.  Categorical data were presented as 
percentage frequencies and were compared between groups using chi-
square analysis, with the Pearson chi-square value reported. 
To statistically control for the effects of potentially confounding 
variables such as age and years of education, analysis of covariance 
(ANCOVA) was used.  If a significant main effect for group emerged and 
there were more than two groups, post-hoc tests were conducted using the 
Tukeys’ B method.  Bivariate Pearsons’ coefficient of correlation was used to 
evaluate interrelationships between continuous variables, such as age and 
scores on formal tests (RAVLT, Trail making etc).  Where appropriate, 
Bonferroni corrections were used to correct for family wise error. 
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To obtain an overview on the pattern of performance across the 
spectrum of cognitive domains, data from raw test scores were transformed 
into normally distributed z-scores based on the mean values and standard 
deviations from the normal control group on initial and follow-up testing.  
The use of z-scores allows the direct comparison of performance in different 
cognitive domains.  The measures chosen for each composite cognitive 
domain were those deemed to load most heavily upon the cognitive function 
reported to be measured by the test (see Chapter 5). 
Three of the tests (non-list errors, Trail Making-A and B) were reverse 
scored so that higher z-scores indicated better functioning on each of the 
cognitive domains.  Domain z-scores were calculated by averaging tests 
within each domain.  Individual scores below 1 SD from the mean were 
summed over eight of the domains for each subject to reflect overall 
cognitive function. 
To determine whether change in cognitive function had occurred over 
time, and whether the pattern of performance differed between the three 
groups on all of the composite cognitive domains, a repeated measures 
multivariate analysis of variance (MANOVA) was conducted.  To further 
investigate the interrelationships between independent and dependent 
variables, multiple regression analysis was conducted.  The model identified 
demographic factors, which contributed significantly to composite z scores 
(average z scores of domains 2-9).  In this model, a simultaneous multiple 
regression analysis was chosen, due to the exploratory nature of this 
analysis.  In this method, all independent variables are entered together in 
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the model as one block (Tabecknick and Fidell, 2003). 
All tests used were two-tailed and the statistical significance level for 
comparisons was set at 0.05.  Data were analyzed using Statistical Package 
for Social Sciences (SPSS) for Windows, Version 13 (SPSS Inc. 2005) and 
SYSTAT, Version 8. 
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Chapter 7: 
Results, 
Initial assessment 
 
7.1 Introduction  
 This chapter reports on the initial assessments of 86 subjects 
recruited from the community.  The subjects were screened prior to 
assessment to exclude those with a current or past relevant medical, 
psychiatric, or neurological illness.  Subjects taking medication that may 
compromise their cognitive function (e.g., antidepressant medication, 
corticosteroids) were also excluded.  Demographic, clinical and 
neuropsychological data are presented for all subjects.   
The chapter commences by analyzing risk factors for cognitive 
impairment, such as age, education years, subjective memory complaint 
(SMC), family history of dementia of the Alzheimer’s disease, and depression.  
Information on the assessment of aMCI is provided.  The clinical utility of 
other screening tests that can be used as alternatives to the 7MS, DRS and 
delayed recall to identify cognitive deficits was also examined.   
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Comparisons were then made between subjects with (n=54) and 
without (n=32) SMC on each of the cognitive tasks.  It was noted that 12 of 
the 54 individuals with SMC also fulfilled the criteria for aMCI.  Therefore, 
two sets of analyses are presented; one with two groups and one with three 
groups to test specific hypotheses on how they relate to cognitive deficits.  
The next section examines the inter-correlations between age and cognitive 
domains for the three groups.  A multiple regression analysis was then 
carried out to examine the influence of age, education years, SMC, family 
history of Alzheimer’s disease, and depression using the global z-score for 
domains 2-8.  The results of the follow-up assessment will be presented in 
Chapter 8.  
 
7.2 Demographic background  
Between April 1999 and November 2003 a total of 108 potential 
subjects who responded to the community advertisement were screened 
over the phone.  Twenty-two subjects were excluded as they did not meet 
the inclusion criteria.  Seven subjects reported they had a medical or 
psychiatric illness.  Three of these subjects had a history of vascular disease, 
two had diabetes and two were treated for a major depressive disorder.  A 
further 15 subjects were excluded due to their age falling outside the 
designated age range of 50 to 79 years.  This resulted in a total sample size 
of 86 subjects, consisting of 53 females and 33 males who consented to a 
neuropsychological interview (Table 7.1).  Most of the subjects were born in 
Australia (70%) and were of Caucasian origin (93%).   
                                                                           Chapter 7 - Results-Initial assessment 
__________________________________________________________________________ 
 141 
Table 7.1 Demographic data for males and females on initial assessment 
(mean±SD) 
 
Characteristics 
Males 
(n=33) 
Females 
(n=53) 
Total  
(n=86) 
 
P value 
Age 64.2 ± 7.8 62.5 ± 8.7 63.1 ± 8.4 .368 
   (range) (51 to 79) (50 to 79) (50 to 79)  
Years of education 14.3 ± 4.6 13.4 ± 3.7 13.8 ± 4.1 .308 
Born in Australia 23 (70%) 37 (70%) 60 (70%) .991  
Race: Caucasian 31 (94%) 49 (93%) 80 (93%) .792 
Family history +AD 17 (52%) 24 (45%) 41 (48%) .574 
Subjective Memory 
Complaint (SMC) 
23 (70%) 31 (59%) 54 (63%) .296 
Depression      
   PAS total (n=43) 1.2 (1.7) 1.5 (1.8) 1.3 (1.7) .593 
   GDS total (n=43) 1.2 (1.3) 2.6 (2.4) 2.1 (2.2) .038* 
(rated as mildly 
depressed) 
1 (3%) 7 (13%) 8 (9%) .114 
Stroke score >1  2 (6%) 0 2 (2%) .070 
DRS total 133.6 (6.2) 132.8 (6.3) 133.1 (6.2) .606 
   (range) (118 to 141) (109 to 142) (109 to 142)  
Abnormal DRS (<121) 3 (9%) 4 (8%) 7 (8%) .800 
7 Minute Screen (7MS) 
total 
-11.7 ± 14.3 -14.7 ± 8.7 -13.5 ± 11.2 .234 
   (range) (-39 to 32) (-38 to 4) (-39 to 32)  
Abnormal 7MS (>1) 4 (12%) 2 (4%) 6 (7%) .139 
aMCI(Delayed Recall<4)  8 (24%) 4 (8%) 12 (14%) .087 
    *Statistically significant at p<.05 
 
Subjects had a median age of 63 years and an average of 13.8 years 
of education.  The majority of the sample was under the age of 70 (73%). 
There were no differences between the genders for any of the demographic 
items or for the majority of the clinical variables excluding depression. 
On the Geriatric Depression Scale (GDS), females had significantly 
higher scores, F(1,41)=4.61, p=.038 compared to males.  No gender 
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differences were apparent on the depression section of the Psychogeriatric 
Assessment Scale (PAS).   
On the GDS, subjects frequently endorsed questions in relation to life 
satisfaction (26%), dropping many activities (23%), fear that a bad event 
would befall them (21%), having more memory problems in relation to peers 
(21%), and feeling full of energy (35%).  On the PAS depression scale, 
subjects frequently endorsed items in relation to feeling depressed and sad 
(23%), trouble sleeping (16%), feeling worn out or little energy (21%) and 
trouble concentrating (19%).  Overall, more females (13%) had scores  
indicative of mild depression compared to males (3%), but this did not reach 
statistical significance (P = .114).   
Three (9%) men and four (8%) women had abnormally low DRS 
scores in the dementia range.  Four (12%) men and two (4%) women 
scored above the abnormal threshold on the 7MS.  More males (24%) 
fulfilled the aMCI criteria compared to females (8%), but this was not 
statistically significant (p=.087). 
 
Stroke history 
Two male (6%) subjects scored greater than one on the Stroke Scale 
(PAS: Jorm et al., 1995).  This scale asks subjects if they have ever had a 
stroke or mini-stroke in the past and to elaborate upon symptoms suggestive 
of a stroke.  None of the subjects responded “Yes” to two critical questions 
about a history of stroke, which were; “Have you ever had or been told that 
you had a stroke?” and “Have you ever experienced or been told that you 
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had a mini-stroke such as collapsing for no apparent reason or becoming 
disorientated?”   
Both subjects who scored greater than one had other physical 
ailments, which may have encouraged them to respond ‘yes’ to other 
questions on this scale.  These conditions included: arthritis (hence one of 
these subjects responded ‘yes’ to the question, “Have you ever had a sudden 
weakness on one side which got better?”), rheumatism and cataracts. 
Both subjects responded ‘yes’ to the question on memory difficulties, 
“Have you ever had or been told that you had a sudden severe difficulty with 
your memory?”  The answer to the question can be misconstrued by the 
researcher as a sign of a stroke, although the subject may have responded 
to this question in terms of their general difficulties and concerns with their 
memory, rather than a memory deficit that could be attributed to a stroke.  
It was concluded that a history of stroke was unlikely for either 
subject, especially as both had responded negatively to the question “have 
you ever had a stroke?” during the initial telephone screening interview.  
Thus, neither subject was excluded from the study.  
 
7.3 Risk factors for Alzheimer’s disease  
This section examines the role of established risk factors and their 
association with cognitive function, such as family history and age.  It also 
examines the role of education and SMC on cognitive function.   
To investigate the role of family history, the sample was dichotomised 
by the presence or absence of a family history of Alzheimer’s disease.   
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7.3.1 Family history  
In the present study, 48% of subjects had a first degree family history 
of Alzheimer’s disease.  The majority of the affected family members were 
parents (95%).  Eleven of these were part of a combination with other family 
members such as parents and/or siblings, aunty/uncle or grandparents.  A 
total of 5% had siblings with a history of Alzheimer’s disease.  Of those who 
were family history positive, 73% had one family member and 27% had two 
known family members. 
Table 7.2 Subjects with and without a first degree family history of Dementia of 
the Alzheimer’s Type (mean ± SD)  
 
 
Risk factors 
No family 
history 
(n=45) 
Family 
history 
(n=41) 
 
 
P value 
Age 64.4 ± 9.3 61.7 ± 7.1 .137 
Gender    
   Males 16 (36%) 17 (42%) .574 
   Females 29 (64%) 24 (59%)  
Education 13.4 ± 3.9 14.2 ± 4.3 .376 
Subjective memory complaint 27 (60%) 27 (66%) .575 
ApoE-ε4 positive* 8 (28%) 10 (37%) .449 
Dementia Rating Scale (total) 132.8 ± 6.5 133.5 ± 5.9 .587 
   (range) (109-142) (119-142)  
Abnormal DRS (<121) 4 (9%) 3 (7%) .790 
7 Minute Screen (7MS) total -12.2 ± 13.1 -15.1 ± 8.4  .231 
   (range) (-39 to 32) (-38 to 2)  
Abnormal 7MS (>1) 5 (11%) 1 (2%) .115 
            *Not all subjects were tested for ApoE-ε4 
            *Total number of subjects tested for ApoE-ε4; n=56, which consists of No Family History n=29;  
              Family History n=27 
 
Table 7.2 presents data on different risk factors for subjects with and 
without a first degree family history of Alzheimer’s disease.  There were no 
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differences between the two groups for any of the demographic variables.  
Both groups had a similarly high percentage of subjects who complained 
about their memory, 60% and 66%.  No differences were apparent for 
carriers of the ApoE-ε4 on both dementia screening tests.   
 
7.3.2 Age  
 To investigate the role of age in relation to cognitive function, the 
sample was categorised by age (decades) and analyses were performed on 
different demographic variables. 
Table 7.3 provides demographic data for subjects across three age 
categories.  There were no differences between the groups for any of the 
demographic variables.  There were also no differences in cognitive 
functioning in the two younger age groups (50-59, 60-69), whereas cognitive 
differences were apparent in the older age group (70-79 years).  
On the DRS, the older group (70-79) had a significantly lower DRS 
total score, F(2,83)=6.3, p=.003, including lower scores on initiation 
(p=.014) compared to the younger age groups (59-59, 60-69) and lower 
scores on memory (p=.002) compared to the 50-59 year age group.  The 
older group (70-79 years) also had a higher percentage of subjects with 
abnormally low DRS scores in the dementia range (26%) compared to 
subjects aged 50-59 years (3%). 
 On the 7MS, the older group (70-79) had significantly lower 7MS total 
scores, F(2,83)=6.9, p=.002 and animal fluency scores, F(2,83)=3.7, p=.028 
compared to the younger groups (50-59, 60-69).  Moreover, the older group 
(70-79 years) had a significantly higher percentage of subjects who scored 
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 Table 7.3 Demographic data categorized by age (decades) on initial assessment 
(mean ± SD) 
 
Characteristics 
50-59 
(n=35) 
60-69  
(n=28) 
70-79  
(n=23) 
 
P value 
Males 10 (29%) 15 (54%) 8 (35%) .118 
Females 25 (71%) 13 (46%) 15 (65%)  
Years of education 14.7 ± 3.9 13.7 ± 4.0 12.4 ± 4.1 .104 
Family history positive 19 (54%) 15 (54%) 7 (30%) .154 
Subj. memory complaint 21 (60%) 19 (68%) 14 (61%) .794 
Dementia Rating Scale     
   a) attention 17.7 (.60) 17.9 (.45) 17.7 (.63) .353 
   b) initiation 34.0 (3.8) 34.1 (3.9) 31.1 (5.1) a,b .014* 
   c) construction 6.0 (0) 6.0 (0) 6.0 (0) - 
   d) conceptualisation 35.6 (2.0) 35.3 (2.3) 34.3 (3.3) .125 
   e) memory 41.5 (.74) 40.9 (1.4) 40.3 (1.6)a .002* 
DRS total 134.8 (4.9) 134.0 (4.6) 129.4 (8.1)a,b .003* 
   (range) (122 to 141) (124 to 142) (109 to 142)  
Abnormal DRS (<121) 1 (3%) 0 6 (26%) .001* 
7 Minute Screen (7MS)     
   Orientation (error) .03 (.17) .57 (1.0) 1.4 (3.7)a .033* 
   Enhanced cued recall 15.6 (.69) 15.7 (.77) 15.7 (.54) .833 
   Clock drawing 7.0 (.17) 6.9 (.31) 6.6 (.89)a .028* 
   Animal fluency 19.1 (5.8) 19.0 (6.0) 15.3 (5.3)a,b .028* 
7MS total -16.9 (8.0) -14.9 (9.3) -6.8 (14.4)a,b .002*  
(range) (-38 to -4) (-39 to 2) (-28 to 32)  
Abnormal 7MS (>1) 0 1 (4%) 5 (22%) .004* 
aMCI(Delayed Recall<4) 1 (3%) 4 (14%) 7 (30%) .039* 
    * Statistically significant at p<.05 
    a Statistically significant at p<.05 compared to the 50-59 year age group (post hoc test) 
    b Statistically significant at p<.05 compared to the 60-69 year age group (post hoc test) 
        
above the abnormal threshold on the 7MS (22%) compared to the 60-69 
year age group (4%).  The older group (70-79) also had lower scores on 
temporal orientation (p=.033) and clock drawing (p=.028) compared to the 
50-59 year age group.  A significantly higher percentage of the older group 
(70-79 years) (30%) fulfilled the aMCI criteria compared to the younger 
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groups (50-59, 60-69) (17%).  The effects of age are further examined in 
section 7.5.2 and 7.9 examining correlations with dementia screening tests 
and cognitive domains.  
 
7.3.3 Education  
To assess the role of education on cognitive function, the sample was 
dichotomised by total years of education (<12 years or >12 years).  This 
cut-off was chosen because it fits the typical Australian education system 
which consists of 6 years of primary school and 6 years of high school.  
Table 7.4 indicates there were no differences between the groups for 
any of the demographic variables.  Subjects with <12 years of education 
reported slightly more memory complaints (73%) compared to subjects with 
>12 years of education (58%), but this was not statistically significant 
(p=.194).  On the DRS, subjects with <12 years of education had 
significantly lower DRS total scores compared to subjects with >12 years of 
education, F(1,84)=11.9, p=.001.  A significantly higher percentage of 
subjects with <12 years of education had an abnormal 7MS score (15%) 
compared to subjects with >12 years of education (3%), (χ2 = 4.06; df=1; 
p=.044; however two cells had low expected counts).  Education is further 
assessed in section 7.11 on global function in the multiple regression 
analysis. 
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Table 7.4 Demographic data for the sample based on years of education 
(mean±SD) 
 
Risk factors 
< 12 years 
(n=26) 
> 12 years 
(n=60) 
 
P value 
Age 65.4 ± 8.4 62.1 ± 8.1 .101 
Gender    
   Males 9 (35%) 24 (40%) .637 
   Females 17 (65%) 36 (60%)  
Subjective memory complaint 19 (73%) 35 (58%) .194 
Family history positive 11 (42%) 30 (50%) .512 
Dementia Rating Scale (total) 129.8 ± 7.0 134.5 ± 5.3 .001* 
   (range) (109 to 142)  (119 to 142)  
Abnormal DRS (<121) 3 (12%) 4 (7%) .448 
7 Minute Screen (7MS) total -10.5 ± 10.5 -14.9 ± 11.3  .093 
   (range) (-26 to 23) (-39 to 32)  
Abnormal 7MS (>1) 4 (15%) 2 (3%) .044* 
             *Statistically significant at p<.05 
 
7.3.4 Subjective memory complaint (SMC) 
To address the role of SMC in cognitive function, the sample was 
dichotomised by the presence or absence of SMC and analyses were 
performed on different demographic and cognitive variables.  Table 7.5 
provides demographic data for subjects with (n=32) and without (n=54) 
SMC.  The high percentage of subjects (63%) reporting a memory complaint 
was expected as the advertisement had requested subjects with memory 
difficulties.  The two groups did not differ on any of the demographic 
variables.  Subjects with SMC had significantly lower scores on the DRS total 
score, F(1,84)=11.5, p=.001.   
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Table 7.5 Demographic data for subjects with and without subjective memory 
complaint (SMC) on initial assessment (mean ± SD) 
 
Characteristics 
No SMC  
(n = 32) 
SMC 
(n = 54) 
 
P value 
Age 62.4 ± 8.9 63.5 ± 8.1 .565 
Gender    
   Male 10 (31%) 23 (43%) .296 
   Female 22 (69%) 31 (57%)  
Years of education 14.6 ± 3.4 13.2 ± 4.3 .117 
Family history 14 (44%) 27 (50%) .575 
Depression    
   PAS total (n=43) .94 (1.6) 1.6 (1.7) .208 
   GDS total (n=43) 2.4 (2.5) 2.0 (2.1) .554 
(mildly depressed) 4 (13%) 4 (7%) .432 
Stroke history  1 (3%) 1 (2%) .705           
Dementia Rating Scale    
   a) attention 17.9 ± .39 17.6 ± .62 .026* 
   b) initiation 35.2 ± 2.1 32.1 ± 4.8 .001* 
   c) construction 6.0 ± 0 6.0 ± 0 - 
   d) conceptualisation 35.5 ± 2.0 35.0 ± 2.8 .375 
   e) memory 41.3 ± .98 40.9 ± 1.5 .186 
DRS total 135.8 ± 3.3 131.5 ± 6.9 .001* 
   (range) (127-142) (109-142)  
   (rated < 121) 0 7 (13%) .034* 
7 minute screen (7MS)    
   Temporal orientation      
   (error) 
.19 ± .59 .81 ± 2.5 .167 
   Enhanced cued recall   
   (ECR) 
15.8 ± .56 15.6 ± .74 .262 
   Clock drawing 6.9 ± .34 6.8 ± .61 .722 
   Animal fluency 20.0 ± 4.8 16.9 ± 6.3 .020* 
7MS total -17.6 ± 6.4 -11.1 ± 12.7 .008** 
   (range) (-38 to –7) (-39 to 32)  
   Abnormal 7MS (>1) 0 6 (11%) .051 
          *Statistically significant at p<.05, **p < .01 
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On the DRS, subjects with SMC had lower scores on attention 
(p=.026) and initiation (p=.001).  Seven (13%) subjects with SMC had 
abnormally low DRS total scores in the dementia range (<121, note: 2 items 
were not used in the present study as these related to USA-related topics) 
compared to none of the subjects without SMC, (χ2=4.52; df=1; p=.034; 
however two cells had low expected counts).   
Table 7.5 further shows subjects with SMC had lower 7MS total 
scores compared to subjects without SMC, F(1,84)=7.36, p=.008.  Subjects 
with SMC had lower scores on animal fluency, F(1,84)=5.58, p=.020, which 
contributed significantly to this difference.  Six subjects in the SMC group 
scored above the abnormal threshold on the 7MS (>1) indicating the 
presence of probable dementia.  None of the subjects in the group without 
SMC had abnormal 7MS scores.  Thus, SMC had good specificity on both 
dementia screening tests (100%), but unacceptably low sensitivity (<15%).  
It should be emphasized that a subgroup of those with SMC do have 
MCI (n=12).  This information is presented in detail in section 7.5 (page 
151).   
 
7.4 The Rey Auditory Verbal Learning Test (RAVLT) 
 One of the aims of the study was to identify subjects with a high risk 
of developing Alzheimer’s disease.  This section examines performance on 
the Delayed Recall subtest from the RAVLT.  Table 7.6 shows the 
performance of subjects with and without SMC on the RAVLT, which has 
been analysed on the basis of its individual subtests: immediate memory, 
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new learning, and delayed recall. 
 Subjects with SMC had significantly lower scores on delayed recall 
compared to subjects without SMC, F(1,84)=5.4, p=.022.  It is noteworthy 
that the two memory complaint groups did not significantly differ in their 
 
Table 7.6 Data on the Rey Auditory Verbal Learning Test for subjects with and 
without SMC (mean ± SD) 
 
 
RAVLT 
No SMC 
(n=32) 
SMC 
(n=54) 
 
P value 
Verbal learning: 
  Trial 1 (max 15) 
 
5.9 ± 1.8 
 
5.2 ± 2.0 
 
.131 
  Trial 2 (max 15) 7.3 ± 1.9 7.3 ± 2.4 .924 
  Trial 3 (max 15) 9.3 ± 1.8 8.7 ± 2.6 .200 
  Trial 4 (max 15) 10.5 ± 2.5 9.5 ± 3.1 .135 
  Trial 5 (max 15) 10.9 ± 2.5 10.2 ± 3.1 .252 
Sum of Trials 1-5 (max 75) 
 44.0 ± 8.6 40.9 ± 11.5 .189 
Delayed recall score:    
  Trial 6 after 20 min delay  
  (max 15) 
9.2 ± 2.7 7.4 ± 3.8 .022* 
Delayed recall score:     
   Score = 0 0 2 (4%) .271  
   Score < 4 0 12 (22%) .004*  
   Score < 6 3 (9%) 16 (30%) .029*  
                *Statistically significant at p<.05 
                    
                   
performance on all five learning trials (trials 1-5) and were able to learn a 
similar number of total words (sum of trials 1-5).  Further analyses are 
conducted below to identify subjects in the SMC group with pronounced 
deficits on delayed recall. 
 
7.5 Classification of amnestic mild cognitive impairment (aMCI) 
 In this section, the delayed recall subtest of the RAVLT was used as a 
screening test to identify objective cognitive impairment and classify subjects 
as having aMCI.  To aid classification, a range of cut-off scores for 
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impairment were considered (0, <4, and 6) and applied to subjects with and 
without SMC.  Table 7.6 shows if a cut-off score of zero was applied to the 
current data, two (4%) subjects in the SMC group would be classified as 
having impairment compared to none in the No SMC group.  By applying a 
cut-off score of <6, a total of 16 (30%) subjects in the SMC group would be 
classified as having impairment compared to three (9%) in the No SMC 
group. 
However, if a cut-off score <4 on delayed recall was applied to the 
data, 12 (22%) of the subjects in the SMC group would be classified as 
having impairment compared to none of the subjects in the No SMC group.  
A cut-off score of <4 seemed realistic and demonstrated good separation 
between the groups.  This score is also about 2 SD below the mean for the 
SMC group.  This score was chosen to define impairment because it 
produced the best sensitivity and specificity balance and was similar to 
thresholds used by others (Guarch et al., 2008) to classify subjects as having 
aMCI.  The present study did not use cut-off scores adjusted for age.  This 
would have been preferable, however due to the small sample size this 
would have resulted in skewed information. 
  
7.5.1 Demographics   
  This section provides demographic and cognitive data to help examine 
differences between the three groups: controls, SMC and aMCI. 
As shown in Table 7.7, the aMCI group was slightly older, 
F(2,83)=5.44, p=.006 and had fewer years of formal education, 
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F(2,83)=3.88, p=.025 compared to the control and SMC groups.  All three 
groups had a high proportion (44-50%) of subjects with a first degree family 
history of Alzheimer’s disease.  There were no significant differences 
between the groups for depressive symptom scores.  Four (13%) subjects in 
the control and four (13%) in the SMC groups were rated as having mild 
depression.  None of the subjects in the aMCI group had scores in the mild 
depression range. 
 
Table 7.7 Demographic data for the three groups after screening for cognitive 
impairment (mean ± SD)  
 
 
Characteristics 
Normal 
Controls 
(n = 32) 
SMC 
(n = 42) 
aMCI 
(n =12) 
 
 
P value 
Age 62.4 ± 8.9  61.6 ± 7.3  70.1 ± 7.2a,b  .006* 
   (range) (50-79) (50-78) (57-79)  
Gender     
   Male 10 (31%) 15 (36%) 8 (67%) .087 
   Female 22 (69%) 27 (64%) 4 (33%)  
Years of education 14.6 ± 3.4 13.9 ± 4.1  11.0 ± 4.6a,b  .025* 
Born in Australia 21 (66%) 31 (74%) 8 (67%) .726 
Race: Caucasian 28 (88%)  41 (98%) 11 (92%) .234 
Family history 14 (44%) 21 (50%) 6 (50%) .854 
ApoE-ε4 positive** 8 (42%) 6 (20%) 4 (57%) .086 
Depression     
   PAS total (n=43) .9 (1.7) 1.9 (1.8) 1.0 (1.4) .237 
   GDS total (n=43) 2.4 (2.5) 2.0 (2.2) 2.0 (1.2) .841 
(rated as mildly depressed) 4 (13%) 4 (10%) 0 .445 
Stroke history 1 (3%) 0 1 (8%) .223 
  *Statistically significant at p<.05 
  a Statistically significant at p<.05 compared to the control group  
   b Statistically significant at p<.05 compared to the SMC group  
  ** Not all subjects were tested for ApoE-ε4 
  ** Total number of subjects tested for ApoE-ε4; n=56, which consists of Controls n=19; SMC n=30; aMCI n=7 
 
                                                                           Chapter 7 - Results-Initial assessment 
__________________________________________________________________________ 
 154 
7.5.2 Cognitive function 
Table 7.8 shows the aMCI group had lower DRS total scores 
compared to the control and SMC groups, F(2,83)=9.66, p=.001, including 
significantly lower scores on conceptualization (p=.012) and memory 
(p=.001).  On the initiation subscale, the aMCI group had lower scores 
compared to the control group (p=.004).  Four (10%) subjects in the SMC 
and three (25%) in the aMCI groups had abnormally low DRS scores in the 
dementia range (<121) compared to none of the subjects in the control 
group (χ2=7.50; df=2; p=.023; however three cells had low expected 
counts).   
On the 7MS, the aMCI group had lower scores compared to the 
control group, F(2,83)=4.30, p=.017, including significantly lower scores on 
clock drawing (p=.006) and animal fluency (p=.048).  On the enhanced cued 
recall task, the aMCI group had lower scores compared to both the control 
and SMC groups (p=.017).  Three (7%) subjects in the SMC and three 
(25%) subjects in the aMCI groups had an abnormal 7MS score (>1) 
indicating the presence of probable dementia, compared to none of the 
subjects in the control group (χ2=8.41; df=2; p=.015; however three cells 
had low expected counts).   
A Pearson Chi-square test was used to analyse whether performance 
on the 7MS and DRS was independent of age for the three groups.  This is 
illustrated in Figures 7.1 and 7.2.  Both screening instruments were 
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Table 7.8 Clinical data for the three groups on initial assessment (mean ± SD) 
 
 
Characteristics 
Normal 
Controls 
 (n=32) 
SMC 
 (n=42) 
aMCI 
(n=12) 
 
P 
value 
Dementia Rating Scale     
   a) attention 17.9 ± .39 17.6 ± .62 17.6 ± .67  .082 
   b) initiation 35.2 ± 2.1 32.3 ± 4.8 a 31.5 ± 4.7 a .004* 
   c) construction 6.0 ± 0 6.0 ± 0      6.0 ± 0 - 
   d) conceptualisation 35.5 ± 2.0 35.5 ± 2.4 33.2 ± 3.5 a,b .012* 
   e) memory 41.3 ± 1.0 41.3 ± .94 39.3 ± 2.1 a,b .000* 
DRS total 135.8 ± 3.3 132.6 ± 6.1 127.6 ± 8.5a,b .000* 
   (range) (129-142) (119-137) (109-136)  
   (rated +, score < 121) 0 4 (10%) 3 (25%) .023* 
7 minute screen (7MS)     
   Orientation (error) 0.19 ± 0.59 0.79 ± 2.6 0.92 ± 2.3 .379 
   Enhanced cued recall (ECR) 15.8 ± .55 15.7 ± .59 15.2 ± 1.0 a,b .017* 
   Clock drawing 6.9 ± .34 7.0 ± .22 6.4 ± 1.2 a,b .006* 
   Animal fluency 20.0 ± 4.8 17.3 ± 6.5 15.7 ± 5.3 a .048* 
   7MS total -17.6 ± 6.4 -12.0 ± 12.5 -8.1 ± 13.1 a .017* 
   (range) (-38 to –7) (-39 to 32) (-27 to 23)  
   Abnormal 7MS 0 3 (7%) 3 (25%) .015* 
  a Statistically significant at p<.05 compared to the control group (post-hoc test). 
  b Statistically significant at p<.05 compared to the SMC group (post-hoc test). 
 
moderately correlated with the subject’s age (r=0.28; n=86; p=0.008 for the 
7MS and r=-0.30; n=86; p=0.005 for the DRS).  Age was significantly 
correlated with higher scores on the 7MS for subjects with aMCI (r=.63; 
n=12 p<.05), but not for the control and SMC groups (r=-.16; n=32 p>.05 
and r=-.18; n=42; p>.05), respectively.  Moreover, there was no significant 
correlation between age and scores on the DRS for any of the three groups, 
indicating that age was not associated with performance on the DRS.  The 
lack of correlation between the two scales and the groups are likely due to 
small sample sizes of individual groups and smaller range in scores. 
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Figure 7.1 (above) Graph showing the relationship between age and 7MS scores for the 
three groups. 
Figure 7.2 (below ) Graph showing relationship between age and DRS scores for the three 
groups 
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A Pearson bivariate correlation was used to examine the 
interrelationship between the 7MS and DRS (see Figure 7.3).  There was a 
strong negative linear correlation between the 7MS and the DRS (r=-.65; 
n=86; p=.001).  Thus, higher scores on the 7MS were associated with lower 
scores on the DRS.  Threshold scores for the two tests are indicated by 
dotted lines showing there was strong disagreement between the two 
instruments for two SMC subjects with normal DRS scores (~135) and 7MS 
scores >10 (see filled circles, quadrant 2).  It should also be noted that two 
subjects in the aMCI group had abnormal scores on both tests (see filled 
stars, quadrant 1). 
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Figure 7.3 Graph showing the correspondence between the 7 Minute Screen and Dementia 
Rating Scale in identifying cognitive impairment in the three groups.  
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7.6 Other screening tests for dementia  
 This section briefly describes the clinical utility of other screening 
measures that have been used to screen for cognitive impairment.  Table 
7.9 lists five tasks that are either part of the 7MS (Clock drawing and animal 
naming) or others that are quick and easy to use, such as verbal fluency 
(FAS words), similarities and the Trail Making-B task.  The percentage of 
subjects with abnormal scores using published thresholds indicates the task 
with the best sensitivity and specificity was animal naming.  None of the 
control and SMC groups had abnormal scores on the Clock Drawing task, but 
it was less sensitive than animal naming which identified deficits in 36% of 
subjects with SMC.  Verbal fluency identified deficits in 21% of subjects with 
SMC, whilst Trail-B identified deficits in 14% of subjects with SMC.  Scores 
on Similarities did not differentiate between the groups. 
 
Table 7.9 Alternative screening tests using standard thresholds to detect 
dementia 
 
Task (threshold) 
Controls 
(n=32) 
% abnormal 
SMC 
(n=42) 
% abnormal 
aMCI 
(n=12) 
% abnormal 
χ2 value  
(df=2) 
 
Clock drawing (<5) 
 
0 
 
0 
 
1 (8%) 
 
6.24* 
Animal naming (<14) 2 15 (36%) 6 (50%) 11.90** 
Verbal fluency–FAS total (<27) 3 (9%) 9 (21%) 7 (58%) 12.18** 
Trail-B (> 120 sec) 4 (13%) 6 (14%) 6 (50%) 9.12** 
Similarities (< 6) 5 (16%) 9 (21%) 3 (25%) NS 
Threshold values were sourced from Solomon et al. (1998) for Clock Drawing; Monsch et al. (1992) for Animal 
naming and Verbal Fluency and Tombaugh, 2004 for Trail b test. Note age and education levels were not taken into 
consideration for determination of abnormality.  
*p<.05, **p=.001 
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7.7 Normative data on healthy ageing 
In this section, the raw scores for the present study of the controls 
(n=32) are compared to published norms on healthy ageing for each of the 
tests grouped by cognitive domain.  The purpose of this was to demonstrate 
the similarity in cognitive functioning between the control data in the present 
study with published norms prior to transforming the raw data to z-scores.  
A further aim was to examine the influence of age and/or education on each 
of the cognitive tests.   
  
7.7.1 Intelligent quotient (IQ) 
The National Adult Reading Test (NART) 
The intelligent quotient of the sample was assessed using NART.  
Table 7.10 shows the raw NART scores for this study using only the 
controls (n=32) compared to healthy subjects from Australian published 
norms (n=244; Collie et al., 1999).  Subjects in the published norms were 
over the age of 44 (mean age 63.1), and were recruited through media or 
contact with the research institute.  They scored > 28 on the MMSE, and 
were free of mental and psychiatric illness.  The majority of these subjects 
were well educated and of above average intelligence. 
Performance on NART for both studies was comparable across the 
age categories.  There were some small differences on NART for subjects in 
the present study with less than 12 years of education compared to the 
same subset in the published norms.  There was a trend for higher NART 
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Table 7.10 Comparison of performance on the National Adult Reading Test 
(NART) between the present study control values with Australian published 
norms by age and educational level  
 Present study Collie et al. 1999 
Education 
Level (years) 
50-64 years 
 
65-79 years  50-69 years 
 
70+ years 
 
<12 years      
N 3 4  77 31 
Mean 115.7 118.3  126.9 119.2 
SD 2.1 5.2  5.8 4.7 
> 12 years      
N 14 11  111 25 
Mean 116.6 119.5  121.4 121.8 
SD 5.9 5.3  4.1 4.3 
      
Source: Collie et al. (1999) Norms and the effects of demographic variables on a neuropsychological battery for use 
in healthy ageing Australian populations.  Australian and New Zealand Journal of Psychiatry: 33: 568-575. 
scores in subjects with greater than 12 years of education.  This was evident 
in both studies and reflects the influence of education on NART (Strauss et 
al. et al., 2006).  Age had little effect on performance.  A two-way ANOVA 
using age and education as factors indicated that NART was not affected by 
age, F(1,28)=1.4, p=.245 or education F(1,28)=0.22, p=.642.  The NART 
scores should be interpreted with caution, given the low subject numbers in 
the present study. 
To avoid duplication of normative data, published data on healthy 
subjects for subtests from the WAIS-R (digit span, similarities and mental 
control) are not presented.  The WAIS-R highly correlates with NART 
(Crawford et al., 2001; Strauss et al., 2006) and performance on WAIS-R 
can be predicted by performance on NART (Nelson and Willison, 1991). 
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7.7.2 Episodic memory  
The Rey Auditory Verbal Learning Test (RAVLT) 
 The RAVLT assessed verbal episodic memory and was classified as a 
test of verbal learning and recall.  Table 7.11 shows the raw RAVLT scores 
for the present study using only the control group (n=32) compared to 
healthy subjects from Australian published norms (n=62; Geffen et al., 
1990).  Subjects in the published norms were physically healthy and free of 
neurological symptoms by self-report.  They had an average education of 
11.2 (2.2) years, with a range of 7-22 years.  Their average estimated IQ 
(derived from error scores on the NART) was 116 (7.3), with a range of 94-
127.  
 
Table 7.11 Comparison of performance on the Rey Auditory Verbal Learning Test 
(RAVLT) between the present study control values with Australian published 
norms by age (mean, SD) 
 
 Present study (norms) by age Published norms by age 
RAVLT items 50-59 
(n=14) 
60-69 
(n=9) 
70-79 
(n=9) 
50-59 
(n= 20) 
60-69 
(n=22) 
70-86 
(n=20) 
trials 1-5 
  (New learning) 
45.2 
(5.9) 
48.1 
(8.2) 
37.9  
(9.8) 
47.6 
(8.1) 
42.9 
(7.8) 
37.1 
(7.5) 
Recall after 
  interference 
9.1 
(2.9) 
10.8 
(2.0) 
7.6  
(3.0) 
9.8 
(2.9) 
8.5 
(2.2) 
7.1 
(1.8) 
Recall after 20 
  min delay 
9.6 
(2.9) 
10.2 
(1.3) 
7.3 
(2.6) 
10.1 
(2.7) 
8.7 
(3.1) 
7.0 
(2.4) 
Recognition of 
  List A 
14.1 
(1.2) 
14.2 
(.83) 
12.8 
(2.2) 
13.8 
(1) 
13.1 
(2.0) 
12.6 
(2.3) 
Source: Geffen, Moar, O’Hanlon et al., 1990: Data for healthy Australian adults stratified by age group 
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 As shown in Table 7.11 the scores of individual subtests on the 
RAVLT in the present study were comparable to the Australian published 
norms of Geffen et al. (1990).  In both studies there was a trend for a 
steady decline in performance with increasing age on the total amount of 
words recalled after an interference list.  This declining trend was also 
observed for the 20-minute delayed recall component.  In the present study, 
subjects aged 60-69 years had slightly higher scores.  However, the data 
remained comparable because the means for this age group fell within the 
SD of the published norms.  Both data sets highlight that increasing age is 
accompanied by a decline in performance on episodic memory tasks, 
especially those which tax the memory system.   
As previously discussed, since recall of Trial 1 is considered a measure 
of short-term memory, and approximates Digit Span (WAIS-R) to within one 
or two points (Hodges, 1994), the control values in the present study will 
therefore approximate published norms on Digit Span.  This is supported by 
the similar performance on RAVLT between the control values in the present 
study with published Australian norms. 
 
Rey-Osterrieth Complex Figure Test (ROCFT) 
The ROCFT test assessed visual episodic memory and was classified 
as a test of visual recall and visuo-spatial ability.  Table 7.12 shows the raw 
ROCFT scores for the present study using only the control group (n=32) 
compared to published control values (n=698; Strauss et al., 2006).  
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Subjects in the published norms were well educated (mean=14 years), 
physically healthy and free of neurological symptoms. 
 
Table 7.12 Comparison of performance on the Rey-Osterrieth Complex Figure 
Test (ROCFT) between the present study control values with published norms by 
age (mean, SD) 
 
 Present study (norms) by age Published norms by age 
ROCFT 50-59 
(n=14) 
60-69 
(n=9) 
70-79 
(n=9) 
50-59 
(n=144) 
60-69 
(n=220) 
70+ 
(n=334) 
Copy 35.1 35.7 35.9 31.2 30.8 29.6 
SD (1.7) (0.71) (0.33) (3.7) (4.2) (3.4) 
Recall 14.0 16.8 13.7 14.9 14.2 11.7 
SD (4.4) (6.6) (7.0) (7.0) (7.5) (6.1) 
       Source: Strauss et al. (2006) 
 
Table 7.12 shows the copy scores on the ROCFT in the present study 
were slightly higher than the published norms for different age categories 
(Strauss et al., 2006).  The recall scores in both data sets were comparable 
(means are within 1 SD of each other) and showed the classical discrepancy 
in performance between copy and recall, which is greater for the 70+ age 
group than for the younger age groups.   
 
7.7.3 Semantic Memory  
Word Fluency 
Word fluency assessed semantic memory and was classified as a test 
of verbal ability.  Table 7.13 shows the word fluency scores for the present 
study using only the control group (n=32) compared to healthy subjects 
recruited from Canadian published norms (n=698; Tombaugh et al., 1999).  
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The Canadian subjects were healthy volunteers recruited from different 
sources within the community (e.g., shopping centres).  They were free of 
psychiatric and neurological illness and spoke English as a first language. 
 
Table 7.13 Comparison of performance on word fluency between the present 
study control values with published norms by age (mean, SD) 
 
 Present study (norms) by age Published norms by age 
Word 
Fluency 
50-59 
(n=14) 
60-69 
(n=9) 
70-79 
(n=9) 
50-59 
(n=144)  
60-69 
(n=220) 
70+ 
(n=334) 
Animals 20.4 
(5.7) 
19.4 
(4.7) 
20.0 
(3.9) 
20.1 
(4.9) 
17.6 
(4.7) 
16.1 
(4.0) 
FAS 
total 
45.1 
(11.5) 
39.1 
(13.1) 
36.0 
(11.1) 
42.1 
(11.1) 
38.5 
(13.7) 
34.8 
(12.8) 
Source for word fluency: Tombaugh et al., 1999: Data for the FAS and animal naming for a sample of healthy 
adults stratified by demographic groups.  
 As shown in Table 7.13, performance on word fluency for animals 
and letters was similar in both studies for subjects aged 50-59 and 60-69.  
This is shown by the similar means and SDs.  In the present study, animal 
fluency scores were slightly higher (20) than in the published norms (16) for 
subjects aged 70-79.  However, the data remained comparable because the 
SDs overlapped each other.  Both data sets further show a decline in 
performance on category fluency and verbal fluency with increasing age. 
The Boston Naming Test (BNT) 
The BNT assessed semantic memory and was also classified as a test 
of verbal ability.  Table 7.14 shows the raw BNT scores for the present 
study using only the control group (n=32) compared to healthy subjects 
from Australian published norms (n=136; Worrall et al., 1995).  Subjects in 
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the published norms consisted of independently living older persons, 
recruited through advertisements.  All subjects were free of neurological 
disease and spoke English as a first language.  The mean age for the sample 
was 70.4 (SD=7.8) years. 
 
Table 7.14 Comparison of performance on the Boston Naming Test (BNT) 
between the present study control values with Australian published norms by 
age (mean, SD) 
         The present study (norms) Worrall et al. (1995) 
BNT 50-64 
(n=17) 
65-79 
(n=15) 
55-64 
(n=36) 
65-74 
(n=66) 
75+ 
(n=34) 
Mean 54.8 53.8 53.1 53.2 48.0 
SD (5.7) (6.3) (4.4) (5.4) (7.2) 
           Source: Worrall et al., 1995 Data for a sample of healthy older Australians 
As shown in Table 7.14 comparison of the raw naming scores for the 
controls in the present study with the Australian published norms of Worrall 
et al. (1995) shows a similar pattern of performance for both studies across 
the age categories.  This is supported by the SDs within the present study 
which overlapped with published data.  
 
7.7.4 Visuomotor speed and executive functioning 
Trail-Making A and B 
The Trail-Making test A and B assessed visuo-motor speed and 
executive functioning, respectively (see Methods).  Table 7.15 shows the 
raw Trail-Making test scores for the present study using only the control 
group (n=32) compared to healthy subjects from Canadian published norms 
(n=287; Tombaugh, 2004).  Subjects from the published norms were 
                                                                           Chapter 7 - Results-Initial assessment 
__________________________________________________________________________ 
 166 
recruited from the community (e.g., shopping centres) and were free of 
neurological, psychiatric and medical symptoms by self-report.  Their mean 
age and years of education were 58 (21.7) and 12.6 (2.6), respectively.  All 
subjects had MMSE scores >23.   
Table 7.15 shows there was generally good agreement between the 
Trail Making A and B scores with the healthy control data in the present 
study and published norms (Tombaugh, 2004).  Both studies showed a trend 
for increased task time with increased task complexity, especially in subjects 
aged 70-79 years with lower levels of education.  The differences in the 
standard deviations in the present study reflect low subject numbers for 
some of the data cells. 
Table 7.15 Comparison of performance on the Trail-Making Test between the 
controls in the present study with published norms (mean seconds, SD) 
 Present study (norms) by age Published norms by age 
Education 
Level, yrs 
50-59 
(n=14) 
60-69 
(n=9) 
70-79 
(n=9) 
55-59 
(n=95) 
60-64 
(n=86) 
70-74 
(n=106) 
<12        
Trail A 22.7 43.4 30.7 35.10 33.22 42.47 
(SD) (.84) (29.8) (2.1) (10.94) (9.10) (15.15) 
12 +       
Trail A 28.4 26.9 39.7 31.72 31.32 40.13 
(SD) (6.8) (6.7) (8.7) (10.14) (6.96) (14.48) 
<12        
Trail B 188.0 78.3 81.0 78.84 74.55 109.95 
(SD) (158.4) (36.3) (23.0) (19.09) (19.55) (35.15) 
12 +       
Trail B 79.6 91.1 97.0 68.74 64.58 86.27 
(SD) (25.3) (52.7) (35.0) (21.02) (18.59) (24.07) 
Means and SDs are expressed in seconds. Lower scores indicate better performance. The time limit for Trail B is 
300 seconds.  A score of 300 is recorded if the task is not completed within this period.  
Source: Tombaugh, 2004. Data for a sample of healthy Canadian adults stratified by Age and Education 
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In summary, the controls in the present study were comparable to 
healthy aged-matched norms on all the neuropsychological tests reviewed.  
The mean scores were found to be either very close or within 1 SD of 
published norms.  Thus, the controls in the present study were considered to 
represent a group of subjects with normal cognitive functioning between the 
age of 50 and 79. 
The z-scores derived from the control group data were therefore used 
to compare the performance of subjects using a neuropsychological test 
battery.  The z-scores were calculated for each of the cognitive tests and 
then aggregated, if necessary, for each of the cognitive domains.  The next 
section provides a discussion on z-scores. 
 
7.8 Profile of neuropsychological functioning 
This section summarises the profile of neuropsychological functioning 
for two groups (subjects with and without SMC) and for three groups 
(controls, SMC and aMCI) on initial assessment.  Performance across the 
individual tests and their composite cognitive domains were expressed as a 
z-score. 
 
7.8.1 Computing and understanding z-scores 
The z-score represents, in standard deviation units, the amount a 
score deviates from the mean of the control group, which is represented by 
the zero line with a theoretical standard deviation of one.  The rationale for 
transforming raw data to z-scores is to more easily compare individual and 
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group data for the various domains that otherwise would have different units 
of measurement and variance.  
The following is an example of how to calculate the z-score of a 
subject using raw test scores and evaluate the subject’s performance in 
relation to a control reference group. For example, from the aMCI group, 
subject number 78 was able to generate a total of 53 words on Verbal 
Fluency using the letters ‘FAS’; scored 34/75 immediate learning (List A) and 
completed Trail A in 23.41 seconds.  The first raw test score (Verbal Fluency) 
is entered into the following equation: 
z-score = (subjects’ score - controls’ mean)/controls’ SD 
The Verbal Fluency score of 53 would be entered as follows: z-score 
= (53-40.8438)/12.14724 where; 40.8438 is the control’s mean for Verbal 
Fluency and 12.14724 is the control’s SD.  Rounded control means (and SDs) 
can be found in Tables 7.16 and 7.17 for cognitive domain 5 (verbal ability).  
This produces a z-score of +1.00 and shows normal performance in Verbal 
Fluency skills. 
Consider the raw score of 34 on total new learning (List A) from the 
RAVLT.  This score would be entered as follows: z-score=(34-
43.9688)/8.5628.  This produces a z-score of -1.16 and shows deficits in 
episodic memory.  For variables in which higher scores indicate poorer 
performance, the subject’s score and control mean were reversed.  The z-
score equivalent is (control mean-subject score)/control SD.  The Trail A 
score of 43.4 would be entered as follows: (31.8063-43.4)/11.73939.  This 
produces a z-score of -1.00 and shows deficits in visuomotor speed. 
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 In summary, z-scores provide a convenient way to assess test results 
that use different units of measurement based on a standardized normal 
population.  The degree of difference from the standardized mean to define 
‘abnormality’ case-ness is based on probability theory (Dawson-Saunders & 
Trapp, 1994).  It is proposed that 66.7% of the normal population will have 
scores between –1 and 1 and only 2.5% of the population will have scores 
below 1.96.  As a rule, z-scores are most commonly used to compare 
different attribute/test profiles and interpreting individual performance based 
on percentile difference of the population mean. 
 
7.8.2 Cognitive function 
 In this section two analyses were used to examine cognitive function 
in those with and without SMC and those grouped by aMCI (Controls, SMC, 
and aMCI).  The raw data means and SDs for each cognitive test are 
summarized in Tables 7.16 and 7.17 together with the z-scores for each of 
the nine cognitive domains.  As shown in Table 7.16, subjects with SMC 
scored significantly lower than subjects without SMC on working memory 
(p=.032), verbal recall (p=.038) and visuo-motor speed (p=.044). 
Analysis of the data by three groups (Table 7.17) showed significant 
group differences on six of the nine cognitive domains.  Post hoc analysis 
showed that the aMCI group scored significantly lower than the control and 
SMC groups on verbal learning F(2,83)=14.6, p=.000, verbal recall 
F(2,83)=29.5, p=.000, verbal ability F(2,83)=5.4, p=.006, visuo-motor 
speed F(2,83)=5.5, p=.005 and executive functioning F(2,83)=9.2, p=.000.  
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The aMCI group also had significantly lower scores on visual recall compared 
to the SMC group.  There were no significant group differences in working 
memory and visuo-spatial ability.  The aMCI group scored lower on IQ 
compared to the other two groups, but this was not significant (p=.060). 
Table 7.16 Summary profile of performance on different cognitive domains (Z 
transformed) and raw test scores for each domain in subjects with and without 
SMC (mean ± SD) 
 
Cognitive domain and tests 
 
No SMC 
(n=32) 
SMC 
(n=54) 
P 
 value 
    
1. Intellectual functioning -0.00 ± 1.00 -0.41 ± 1.12 .088 
Full scale IQ (NART) 117.7 ± 5.4 115.5 ± 6.0  
    
2. Working memory (WM) -0.00 ± 0.80 -0.39 ± 0.79 .032* 
Digit span (forward) 10.3 ± 2.1 9.6 ± 2.4  
Digit span (backward) 8.3 ± 2.3 7.2 ± 2.4  
Serial 7’s          1.1 ± .10 0.76 ± .97  
    
3. Verbal learning (VbL) -0.00 ± 1.00 -0.36 ± 1.34 .189 
RAVLT: trials 1-5 44.0 ±8.6 40.9 ± 11.5  
    
4. Verbal recall (VbR) -0.00 ± 0.74 -0.42 ± 0.96 .038* 
RAVLT: immediate recall 9.2 ± 2.9 7.8 ± 3.8  
RAVLT: delayed recall 9.2 ± 2.7 7.4 ± 3.8  
List A recognition 13.8 ± 1.6 13.3 ± 2.0  
Non-word list recognition 2.7 + 2.2 
 
3.2 + 2.8 
 
 
5. Verbal ability (VbA) -0.00 ± 0.84 -0.36 ± 0.91 .072 
F A S (total) 40.8 ± 12.1 35.1 ± 12.8  
Boston naming test  54.3 ± 5.9 52.9 ± 6.8  
    
6. Visual recall (VsR) -0.00 ± 1.00 0.20 ± 1.15 .433 
REY complex figure test  
(recall) 
14.7 ± 5.8 15.8 ± 6.7  
7. Visuo-spatial ability (VsA) -0.00 ± 1.00 -0.11 ± 1.11 .634 
Rey complex figure test  
(copy) 
35.5 ± 1.2 35.3 ± 1.4  
    
8. Visuomotor speed (VmS) -0.00 ± 1.00 -0.57 ± 1.40 .044* 
Trail Making-A 31.8 ± 11.7 38.5 ± 16.3  
    
9. Executive functioning (EF) 0.00 ± 1.00 -0.16 ± 1.10 .506 
Trail Making-B 92.3 ± 50.1 100.2 ± 54.5  
*Statistically significant at p<.05 
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Table 7.17 Summary profile of performance on different cognitive domains (Z 
transformed) and raw test scores for each domain (mean ± SD) by three groups 
 
Cognitive domain and tests 
 
Controls 
(n=32) 
SMC 
(n=42) 
aMCI 
(n=12) 
P 
value 
     
1. Intellectual functioning -0.00 ± 1.00 -0.28 ± 0.97 -0.86 ± 1.50  .060 
Full scale IQ (NART) 117.7 ± 5.4 116.2 ± 5.2 113.1 ± 8.02  
     
2. Working memory (WM) -0.00 ± 0.80 -0.38 ± 0.83 -0.41 ± 0.68 .100 
Digit span (forward) 7.0 ± 1.2 6.5 ± 1.6 6.7 ± .89  
Digit span (backward) 5.0 ± 1.4 4.5 ± 1.5 4.1 ± 1.1  
Serial 7’s          1.1 ± 1.0 .74 ± .96 .83 ± 1.0 
 
 
3. Verbal learning (VbL) -0.00 ± 1.00 0.04 ± 1.21 -1.78± 0.65a,b .000 
RAVLT: trials 1-5 44.0 ± 8.6 44.3 ± 10.3 28.8 ± 5.6 
 
 
4. Verbal recall (VbR) -0.00 ± 0.74 -0.05± 0.72 -1.71± 0.48a,b .000 
RAVLT: immediate recall 9.2 ± 2.9 9.0 ± 3.4 3.8 ± 1.9  
RAVLT: delayed recall 9.2 ± 2.7 8.8 ± 3.0 2.3 ± 1.2  
List A recognition 13.8 ± 1.6 13.9 ± 1.3 11.3 ± 2.6  
Non-word list recognition 2.7 ± 2.2 
 
2.9 ± 2.4 
 
4.4 ± 3.9 
 
 
5. Verbal ability (VbA) -0.00 ± 0.84 -0.20± 0.72 -0.95± 1.30a,b .006 
F A S (total) 40.8 ± 12.1 37.0 ± 11.9 28.3 ± 14.1  
Boston naming test  54.3 ± 5.9 53.9 ± 5.5 49.3 ± 9.6 
 
 
6. Visual recall (VsR) -0.00 ± 1.00 0.41 ± 1.10 -0.56 ± 1.11b .017 
REY complex figure test  
(recall) 
14.7 ± 5.8 17.1 ± 6.2 11.5 ± 6.4 
 
 
     
7. Visuo-spatial ability 
(VsA) 
-0.00 ± 1.00 0.01 ± 0.84 -0.56 ± 1.75 .237 
Rey complex figure test (copy) 35.5 ± 1.2 35.5 ± 1.0 34.8 ± 2.2  
     
8. Visuomotor speed  -0.00 ± 1.00 -0.34± 1.10 -1.40± 2.01a,b .005 
(VmS) 
Trail Making-A 31.8 ± 11.7 35.8 ± 12.6 47.9 ± 23.6 
 
 
9. Executive functioning 
(EF) 
0.00 ± 1.00 0.14 ± .67 -1.20± 1.60a,b .000 
Trail Making-B 92.3 ± 50.1 85.3 ± 33.8 152.3 ± 79.2 
 
 
 a Statistically significant at p<.05 compared to the control group (post-hoc test). 
 b Statistically significant at p<.05 compared to the SMC group (post-hoc test). 
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Figure 7.4 Median z-scores for each cognitive domain for the three groups.  By definition, 
scores for the control group have a mean of 0 and a standard deviation of 1 (dotted line). 
 
Figure 7.4 illustrates the median z-score profile of cognitive 
functioning for the SMC and aMCI groups in comparison to the control group 
(dotted line).  The median scores are displayed for the cognitive domains, as 
they are less prone to skewed data.  Visual examination of the profiles 
suggests that the aMCI group scored more poorly on seven of the cognitive 
domains and had pronounced deficits (<-1) on IQ, verbal learning, verbal 
recall and visuo-motor speed.  None of the SMC group scored <.05 SD below 
the group mean for any of the cognitive domains. 
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7.9 Cognitive profiles and age 
Figure 7.5 illustrates that age is a strong predictor of cognitive 
function based on results of a neurocognitive test battery.  The vast majority 
of subjects under the age of 70 had normal cognitive function on formal 
testing.  For those over 70 years of age, about 60% had deficits (below 1.0 
SD of norm z-score) in two or more cognitive domains and more domains 
were affected if they fulfilled the aMCI criteria. 
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Figure 7.5 Graph showing the relationship between age and the number of domains with 
cognitive deficits greater than one SD of the norms for each of the three groups. Dotted line 
indicates line of best fit for the control group (open circles), dashed line for the SMC group 
(open boxes) and the solid line for the aMCI group (stars). 
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The Pearson correlation coefficients of the relationship between age 
and each of the cognitive domains are presented in Table 7.18 and 
illustrated in Figures 7.6 to 7.13.   
Table 7.18 shows many of the cognitive domains were highly inter-
correlated (for example verbal learning and verbal recall (D3 and D4) had a 
correlation of 0.84 and the trail making tasks A and B (D8 and D9) had an r 
value of 0.53.  Full IQ and working memory (Domains 1 and 2) were 
unrelated to age (r=.04 and -0.02, p>.05) (Table 7.18 and Fig 7.6).  In 
contrast, age was significantly and negatively related to verbal learning 
(Domain 3, r= -0.51, p<.01, Fig. 7.7), verbal recall (Domain 4, r= -0.42, 
p<.01, Fig 7.8), verbal ability (Domain 5, r= -0.37, p<.01, Fig 7.9) and 
visual recall (Domain 6, r= -0.28, p<.05, Fig 7.10).  Age was not related to  
 
Table 7.18 Correlation matrix (Pearson r values) summarizing the association 
between age and the nine cognitive domains (D1-D9, n=86) 
Variable  D1 D2 D3 D4 D5 D6 D7 D8 
 Age IQ WM VbL VbR VbA VsR VsA VmS 
D1-IQ .04 -----        
D2-WM -.02 .50** ------       
D3-VbL -.51** .10 .12 ------      
D4-VbR -.42** .04 .05 .84** ------     
D5-VbA -.37** .52** .43** .36** .31** ------    
D6-VsR -.28* .05 -.09 .30** .30** .35** ------   
D7-VsA -.21 .12 .18 .26* .24* .16 .18 ------  
D8-VmS -.47** .07 .21 .33** .29** .43** .28** .19 ------ 
D9-EF -.31** .25* .30** .36** .31** .45** .24* .23* .53** 
*Statistically significant at p<.05, **p<0.01, Bonferroni corrected probabilities. 
   see Table 7.17 for explanation of abbreviations for each of the domains. 
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Figure 7.6 (above) Graph showing that age was unrelated to working memory (z-scores).  
Dotted line indicates control mean.  Scores above the line indicate better performance.  See 
Table 7.17 for further explanation of domains and tasks used to quantify z-scores. 
 
Figure 7.7 (below ) Graph showing that age was related to deficits in verbal learning.  
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Figure 7.8 (above) Graph showing that age was related to deficits in verbal recall.   
Figure 7.9 (below ) Graph showing that age was related to deficits in verbal ability.  
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Figure 7.10 (above) Graph showing that age was related to deficits in visual recall.   
 
Figure 7.11 (below ) Graph showing that age was unrelated to visuo-spatial ability.  
Approximately half the subjects had a maximal score which explains the similar scores above 
the line (ceiling effect).  
                                                                           Chapter 7 - Results-Initial assessment 
__________________________________________________________________________ 
 178 
50 55 60 65 70 75 80
Age
-4
-3
-2
-1
0
1
2
Do
m
ai
n 
8 
- V
isu
m
ot
or
 s
pe
ed
 (z
 s
co
re
s) aMCI (n=12)
SMC (n=42)
no SMC (n=32)
Groups
50 55 60 65 70 75 80
Age
-5
-4
-3
-2
-1
0
1
2
Do
m
ai
n 
9 
- E
xe
cu
tiv
e 
fu
nc
tio
n 
(z
 s
co
re
s)
 
Figure 7.12 (above) Graph showing that age was related to deficits in visuomotor speed.  
 
Figure 7.13 (below ) Graph showing that age was related to deficits in executive function.  
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Figure 7.14 Relationship between age and global average (mean z-score cognitive domains 
2 to 9).  
 
visuo-spatial ability (Domain 7, r= -.21, p>.05, Fig 7.11), however age was 
significantly and negatively related to visuo-motor speed (Domain 8, 
r= -0.47, p<.01, Fig 7.12), and executive function (Domain 9, r= -.31, 
p<.01, Fig 7.13).   
Figure 7.14 illustrates the relationship between age and the average 
z-score for cognitive domains two to nine for the three subject groups.  Age 
was unrelated to average z scores for the Control group (r=-.220, p>.001), 
but was related to the SMC (r=-.581, p<.001), and aMCI groups (r=-.692, 
p<.001).   
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7.10 Impaired cognitive domains 
In this section, a Pearson Chi-square test was used to identify the 
number of subjects in each group scoring within the impaired range (more 
than one SD below the mean).  Based on evidence that premorbid IQ 
remains stable in early Alzheimer’s disease (as measured by NART) and that 
IQ was not significant in Tables 7.16 and 7.17, IQ was not a variable of 
interest and was thus excluded from multiple regressions in Table 7.19.   
 
Table 7.19 Number of cognitive domains with scores below 1 SD of control mean 
on initial assessment 
 
 
Cognitive Domain 
Controls  
(n=32) 
n (%) 
SMC 
(n=42) 
n (%) 
aMCI 
(n=12) 
n (%) 
2. Working memory 3 (9%) 12 (29%) 2 (17%) 
3. Verbal learning 4 (13%) 10 (24%) 10 (83%) 
4. Verbal recall  4 (13%) 4 (10%) 11 (92%) 
5. Verbal ability 4 (13%) 5 (12%) 5 (42%) 
6. Visual recall  4 (13%) 4 (10%) 3 (25%) 
7. Visuo-spatial ability 4 (13%) 8 (19%) 3 (25%) 
8. Visuomotor speed 2 (6%) 8 (19%) 5 (42%) 
9. Executive functioning 3 (9%) 3 (7%) 5 (42%) 
Total (summed over domains 2-9)     
0  16 (50%) 17 (41%) 1 (8%) 
1 8 (25%) 9 (21%) 0 
2 5 (16%) 10 (24%) 2 (17%) 
3 2 (6%) 1 (2%) 4 (33%) 
4-5 1 (3%) 5 (12%) 2 (17%) 
6+ 0 0 3 (25%) 
 
Table 7.19 shows the number and percentage of subjects in each 
group who scored one SD below the control mean (z-score<–1) on each of 
the cognitive domains and the group aggregate for the number of impaired 
domains (2-9).  A higher percentage of subjects with aMCI (92%) and SMC 
(38%) had multiple domain deficits compared to the control group (25%).  
The aMCI group had a high percentage of subjects with impairments on 
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tests of verbal learning (83%) and verbal recall (92%).  Twenty-four percent 
of the SMC group had impairments in verbal learning. 
 
7.11 Assessment of risk factors for dementia on global functioning 
The following analysis was undertaken to assess which variables 
accounted for the variation in global functioning.  A multiple regression 
analysis was performed with global z-score averaged over domains 2-8 as 
the dependent variable.  Cognitive domain 1 was omitted from the global 
function z-score due to reasons discussed in section 7.10.  A summary of the 
multiple regression analysis is presented in Table 7.20.  The independent 
variables were age, education years, SMC, family history of Alzheimer’s 
disease and minor depression (from GDS and PAS).  The latter three 
variables were coded as present (coded 1) or absent (coded 0).  ApoE status 
was not used in the analysis as only 56 cases provided blood and this would 
have reduced the number of cases to too few. 
 Table 7.20 shows the correlations between the variables (first five 
rows and columns), the unstandardized regression coefficients (B) and 
intercept, the standardized regression coefficients (β, beta), the semi-partial 
correlations (sr2) and R2, and adjusted R2.  The overall R for regression 
(.612) was significantly different from zero, F(5,80)=9.60, p=.001.  Age was 
the only factor which significantly contributed to the prediction of global 
cognitive functioning whilst SMC, family history and depression did not 
contribute significantly to the equation.  Although the correlation between 
years of education and global functioning was .31, education did not 
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contribute significantly to the regression.  Presumably, the relationship 
between education and global functioning is influenced by the subject’s age.   
Table 7.20 Standard multiple regression of age, subjective memory complaint 
(SMC), family history of AD, education years and depression using global 
cognitive functioning (average of Z-scores Domains 2-8) as the dependent 
variable 
 Global 
(DV) 
Age SMC AD 
FHx 
Education 
Years 
Depn B beta sr2 
Unique 
Age -.54      0.039** -.502 .222 
SMC -.20 .06     -0.225 -.168 .027 
AD FHx .20 -.16 .06    0.148 .115 .018 
Edu 
years 
.31 -.25 -.17 .10   0.022 .135 .016 
Depn -.04 -.19 -.09 .02 -.05  -.309 -.139 .018 
      Intercept 2.09   
Mean -.17 63.1 0.63 0.48 13.8 .09  R2 0.375 
SD .65 8.4 .48 .50 4.1 .30  Adj 
R2 
0.336 
        R 0.612 
n=86, *p<0.05, **p<0.01 
       unique variability =.301, shared variability = .074 
       subjective memory complaint, AD family history and minor depression were coded 0=absent, 1 = present 
 
Moreover, as illustrated in Figure 7.15, the regression analysis 
showed a good fit between the predicted and observed cumulative 
probabilities.  Inspection of the residual analysis (Figure 7.16) showed that 
assumptions of normality, linearity and homoscedasticity were met as these 
were not correlated to the residuals. 
Therefore, age was the only variable which contributed significantly to 
prediction of global cognitive functioning, age (sr2=0.222).  Together the five 
predictor variables contributed .301 in unique variability and another .074 in 
shared variability.  In combination these explained 38% of the variability in 
global functioning. 
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Figure 7.15  Probability plot of the multiple regression analysis shown in Table 7.20.  
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Figure 7.16 Scatterplot of standardized residuals and predicted values for the multiple 
regression analysis.  
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In summary, of the five variables examined (age, education years, 
SMC, family history of Alzheimer’s disease and depression) in the multiple 
regression analysis, age was by far the largest predictor of global 
functioning.  This effect was independent of SMC, family history and 
depression.  For those without a memory complaint or a family history, 
significant changes would not be expected between assessments spaced 5-
10 years apart (0.20 and 0.39 change in global z-scores).  Conversely, 
changes greater than -0.5 SD units would indicate a significant decline in 
cognitive functioning between tests conducted a few years apart.  This issue 
will be taken up in the next chapter describing follow-up assessments.   
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Chapter 8: 
Results, 
Follow -up assessment 
 
8.1 Introduction  
This chapter presents data for 43 subjects who returned for a follow-
up test after an average period of three years.  A high proportion of subjects 
did not attend for follow-up testing.  A total of 50% declined to be re-tested 
or were unable to be contacted.  The reasons and implications of the follow-
up response rate are considered in the discussion.  None of the subjects who 
returned for follow-up testing had experienced a relevant medical or 
psychiatric illness over the intervening period.  Nor had any commenced a 
medication that could compromise their performance.  The same 
neuropsychological test battery that was administered at the initial 
assessment was employed for the follow-up assessment. 
 The first section analyzes the characteristics of subjects who returned 
and those who did not attend a follow-up test to identify areas of potential 
bias.  Comparisons were made between subjects with SMC (n=28) and 
without SMC (n=15) on different demographic variables to examine group 
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differences between assessments.  Two separate analyses were carried out; 
one examined group differences between assessments.  The other analysis 
assessed change over time in subjects with amnestic mild cognitive 
impairments (aMCI) compared to the control and SMC groups (repeated 
measures).   
The influence of the ApoE ε4 allele on cognitive function in the 
context of risk factors such as age, family history of Alzheimer’s disease, 
depression and level of education was then examined.  A multiple regression 
analysis was performed to assess the influence of these factors on global 
cognitive performance as measured by the global z-score of 8 cognitive 
domains at time 2. 
 
8.2 Follow-up interviews 
The follow-up tests took place between February 2002 and November 
2005.  As shown in Table 8.1, the follow-up sample consisted of 43 subjects 
(50% of the total study sample) who consented to a second memory test.  
The mean follow-up period between tests was 3.2 years. 
A total of 43 persons did return for a second test.  As advised by 
relatives, one of the subjects died from cancer (subject #1, a 68 year old 
female).  Twenty subjects declined to be re-tested; four of these subjects 
stated they were unable to take time off work.  Four of the subjects had 
their initial test after October 2004 and consequently did not complete the 2-
3 year interval required for re-testing.  Sixteen subjects did not respond and 
were considered non-contactable (lost to follow-up). 
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Table 8.1 Demographic and clinical characteristics of subjects who returned for a 
follow-up test compared with those who did not return for a follow-up test 
(mean ± SD) 
 
 
Characteristics 
Not  
followed-up 
(n=43) 
Had 
a follow-up test 
(n=43) 
 
 
P value 
Age (years) 62.1 ± 8.7 64.1 ± 8.0 .275 
   (range) (50-79) (51-79)  
Gender    
   Male 17 (40%) 16 (37%) .825 
   Female 26 (60%) 27 (63%)  
Education (years) 13.7 (4.0) 13.8 (4.1) .906 
Family history positive 19 (44%) 22 (51%) .517 
Subjective memory complaint 26 (61%) 28 (65%) .665 
Depression    
   GDS total (n=43) 2.3 (2.1) 2.0 (2.3) .644 
(rated as mildly depressed) 4 (9%) 4 (9%) 1.0 
Dementia Rating Scale 132.1 ± 6.7 134.1 ± 5.5 .140 
   (range) (109-141) (121-142)  
   (rated < 121) 5 (12%) 2 (5%) .237 
7 Minute Screen (total score) -13.7 ± 10.7 -13.4 ± 11.7 .896 
    (range) (-39 to 23) (-33 to 32)  
Abnormal 7MS (>1) 2 (5%) 4 (9%) .397 
       
According to the reports of relatives, one subject (#12) was 
diagnosed as having Alzheimer’s disease by her treating specialist.  It is likely 
that this subject had dementia, but in the absence of a full assessment and 
rigorous application of dementia criteria, such a diagnosis cannot be 
confirmed.  At last contact, this patient was residing in a nursing home.  
Another subject (#75) was rated as having clinical signs of depression 
according to the Psychogeriatric Assessment Scale (PAS) and was excluded. 
To identify potential bias in the follow-up sample, the characteristics 
of subjects who returned for a follow-up test were compared to those who 
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did not attend a follow-up test.  As shown in Table 8.1, there were no 
demographic or clinical differences between the groups for any of the 
variables.  Both groups had similar mean ages and proportions with a 
positive family history, and SMC (61% VS. 65%).  Both groups had four 
subjects who were rated as having mild depressive symptoms. 
On the DRS, five (12%) subjects who dropped out of the study scored 
below the threshold for dementia.  Whilst two subjects (5%) who returned 
for a follow-up test scored below the threshold for dementia.  On the 7MS, 
two (5%) subjects who dropped out of the study scored within the abnormal 
range.  Whilst four (9%) subjects who returned for a follow-up test scored 
within the abnormal range.  Moreover, based on the similarities between the 
two groups, subjects in the follow-up cohort were considered to be 
representative of the total sample of subjects who had an initial test.  
 
8.3 Subjective memory complaint 
The data on SMC are based on information collected from the baseline 
assessment.  As can be seen in Table 8.2, there were no demographic 
differences between subjects with SMC and subjects without SMC.  On initial 
testing, subjects with SMC had lower DRS scores, F(1,41)=7.76, p=.008, but 
not on follow-up testing, F(1,41)=2.78, p=.103.  Two subjects (7%) with 
SMC had abnormally low DRS scores on both tests.  On the 7MS, there were 
no significant differences between subjects with SMC and subjects without 
SMC at either time point.  Four (14%) subjects with SMC scored within the 
abnormal range on initial testing and one (4%) on follow-up testing. 
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Table 8.2 Characteristics of subjects in the follow-up sample with and without 
subjective memory complaint (mean ± SD)   
 
Characteristics 
No SMC  
(n=15) 
SMC 
(n=28) 
 
P value 
Age 63.2 ± 8.2 64.6 ± 8.0 .606 
Gender 
   Male 
 
8 (53%) 
 
11 (39%) 
 
.377 
   Female 7 (47%) 17 (61%)  
Months-between tests 38.5 ± 5.9 37.5 ± 7.8 .646 
Years of education 14.9 ± 3.6 13.2 ± 4.3 .191 
Family history positive AD 10 (67%) 18 (64%) .876 
Stroke score >1 (T1 & T2) 0 1 (4%) .459 
Geriatric depression (Test 1) 1.2 ± 2.2 1.5 ± 1.9 .604 
Geriatric depression (Test 2) 1.5 ± 2.0 1.8 ± 2.0 .562 
Dementia Rating Scale (Test 1) 137.1 (3.5) 133.0 (5.8) .008* 
   (range) (129-142) (121-142)  
   DRS+ (rated < 121) 0 2 (7%) .289 
Dementia Rating Scale (Test 2) 136.3 ± 4.0 132.9 ± 7.5 .103 
   (range) (129-141) (105-142)  
   DRS+ (rated < 121) 0 2 (7%) .289 
7 Minute Screen total (Test 1) -17.7 ± 4.3 -11.1 ± 13.7 .076 
   (range) (-23 to -7) (-33 to 32)  
Abnormal 7MS (>1) 0 4 (14%) .124 
7MS total (Test 2) -16.7 (5.9) -14.9 (13.6) .626 
   (range) (-24 to –6) (-34 to 35)  
Abnormal 7MS (>1) 0 1 (4%) .459 
    *Statistically significant at p <.05 
 
8.4 Cognitive changes on dementia screening tests 
In this section, the results for change on two dementia screening 
tests (DRS and 7MS) are presented in Tables 8.3 and 8.4.  Initial analyses 
that compared those with and without SMC did not reveal any group 
differences between testing, nor were there any changes over time.  
Therefore, data are reported using three groups.  To investigate change over 
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time, a MANOVA was performed on each variable.  If significant differences 
were obtained for any of the variables, further one-way analyses of variance 
(ANOVA) were used to identify group differences (this contrast feature is not 
available on SPSS using MANOVA). 
The analysis of change over time showed a decline on two of the DRS 
subtests (Table 8.3).  The control group had significantly lower scores on 
attention F(1,40)=5.58, p=.023, whilst the aMCI group had significantly 
lower scores on initiation F(1,40)=9.25, p=.004. 
 
Table 8.3 Assessment of change in global functioning as measured by the DRS 
(mean ± SD)  
 
Dementia Rating Scale 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change 
Over time 
Controls (n=15)    
Total Score 137.1 ± 3.5 136.3 ± 4.0 __ 
    a) attention 17.9 ± .52 17.5 ± .52 d 
    b) initiation 36.1 ± 1.4 34.7 ± 2.7 __ 
    c) construction 6.0 6.0 __ 
    d) conceptualisation 35.6 ± 2.6 36.5 ± 2.5 __ 
    e) memory 41.4 ± .83 41.6 ± .83 __ 
SMC (n=23)    
Total Score 133.5 ± 5.4  134.6 ± 4.7 __ 
    a) attention 17.8 ± .52 17.9 ± .42 __ 
    b) initiation 33.1 ± 4.5 34.1 ± 3.6 __ 
    c) construction 6.0 6.0 __ 
    d) conceptualisation 35.7 ± 2.4 35.3 ± 2.0 __ 
    e) memory 41.2 ± 1.0 41.3 ± .89 __ 
aMCI (n=5)    
Total Score 127. 8 ± 5.6a,b 124.8 ± 12.7a,b __ 
    a) attention 17.8 ± .45 17.8 ± .45 __ 
    b) initiation 30.8 ± 4.2a 27.0 ± 5.2a,b d 
    c) construction 6.0 6.0 __ 
    d) conceptualisation 33.8 ± 1.6 34.0 ± 4.7 __ 
    e) memory 39.4 ± 2.3a,b 40.0 ± 2.8a,b __ 
            a indicates significant difference from controls at Time 1 or Time 2 
            b indicates a significant difference from SMC group at Time 1 or Time 2 
        d indicates a significant decline over time within a group 
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The analysis of group differences at time 1, showed the aMCI group 
had significantly lower scores on the DRS total score, F(2,40)=7.2, p=.002 
and memory subtest F(2,40)=6.1, p=.005 compared to the control and SMC 
groups.  Also at time 1, the aMCI group had significantly lower scores on the 
initiation subtest compared to the control group, F(2,40)=4.9, p=.012. 
 At time 2, the aMCI group had significantly lower scores on the DRS 
total score, F(2,40)=7.6, p=.002, initiation F(2,40)=9.9, p=.001, and 
memory F(2,40)=3.3, p=.045 compared to the control and SMC groups.  On 
the memory subtest, the difference was very small as noted by the mean 
score (40.0). 
The analysis of change over time showed a change on several 7MS 
subtests (Table 8.4).  The aMCI group had significantly lower scores on 
enhanced cued recall (ECR), F(1,40)=13.56, p=.001 and animal fluency, 
F(1,40)=4.30, p=.045.  The aMCI also had a significantly higher score on the 
7MS total score, F(1,40)=6.98, p=.012, indicating a decline in cognitive 
ability.  The SMC group had significantly higher scores on temporal 
orientation (error), F(1,40)=5.17, p=.028, animal fluency, F(1,40)=5.84, 
p=.020, and the 7MS total score F(1,40)=13.20, p=.001.   
The analysis of group differences at time 1 showed the aMCI group 
had significantly lower scores compared to the other two groups on clock 
drawing.  At time 2, the aMCI group had significantly lower scores compared 
to the control and SMC groups on temporal orientation, enhanced cued recall 
(ECR), and animal fluency and the 7MS total score. 
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Table 8.4 Assessment of change in global functioning as measured by the 7-
Minute Screen (mean ± SD)  
 
7-minute screen (7MS) 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change 
Over time 
Temporal orientation (error)   
   Controls (n=15) .33 ± .82 .13 ± .35  - 
   SMC (n=23) 1.3 ± 3.4 .04 ± .21 c 
   aMCI (n=5) .40 ± .90 1.4 ± 3.1a,b - 
Enhanced cued recall (ECR)   
   Controls (n=15) 15.9 ± .26 15.9 ± .26 - 
   SMC (n=23) 15.7 ± .54 15.9 ± .34 - 
   aMCI (n=5) 15.6 ± .55 13.4 ± 4.2a,b d 
Clock drawing    
   Controls (n=15) 6.9 ± .26 7.0 (0) - 
   SMC (n=23) 7.0 ± .21 7.0 ± .21 - 
   aMCI (n=5) 6.6 ± .55 a,b 6.8 ± .45 - 
Animal fluency    
   Controls (n=15) 20.2 ± 2.4 18.9 ± 3.9 - 
   SMC (n=23) 18.1 ± 6.2 20.1 ± 6.7 c 
   aMCI (n=5) 14.8 ± 4.9 11.2 ± 3.5a,b d 
7MS total    
   Controls (n=15) -17.7 ± 4.3 -16.7 ± 5.9 - 
   SMC (n=23) -11.4 ± 14.7 -18.5 ± 9.4 c 
   aMCI (n=5) -9.3 ± 8.7 1.6 ± 18.9a,b d 
            a indicates significant difference from controls at time 1 or time 2 
            b indicates a significant difference from the SMC group 
            c indicates an improvement over time within a group 
             d indicates a decline over time within a group 
 
Pearson’s correlation coefficient was used to assess the relationship 
between age, the 7MS and DRS for the three groups.   As illustrated in 
Figures 8.1 and 8.2, age was positively related to lower scores on the 7MS 
(higher scores indicating impairment) (r=0.50, p=.001) and negatively 
related to the DRS (lower scores indicating impairment) (r=-0.45, p=.003).  
This indicated age had a significant effect on both screening tests. 
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Figure 8.1 (above) Graph showing the relationship between age (T2) and performance on 
the 7MS on follow-up assessment.  Scores above the line indicate poorer performance. 
Figure 8.2 (below ) Graph showing the relationship between age (T2) and performance on 
the DRS on follow-up assessment.  Scores above the line indicate better performance. 
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Figure 8.3 Graph showing the strong correspondence (r= -0.84) between the 7MS and DRS 
on follow-up assessment. Dotted lines indicate threshold values for the two measures. 
 
In agreement with initial testing (see Figure 7.3, page 160) Figure 
8.3 illustrates a strong negative linear correlation between the 7MS and DRS 
(r= -0.84, p=.001).  Higher scores on the 7MS were associated with lower 
scores on the DRS.   
 
8.5 Neuropsychological changes over time 
This section presents results for change on individual tests grouped by 
cognitive domain for the three groups (controls, SMC, aMCI).  These are 
presented in Tables 8.5 and 8.10.  Two analyses were used.  One 
investigated change over time on each of the 8 cognitive domains.  If 
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significant differences were obtained for any of the cognitive domains, 
further one-way ANOVAs were used to identify group differences. 
 
Working memory (Domain 2) 
As can be seen in Table 8.5, the analysis of change over time in 
working memory showed the SMC group had significantly higher scores on 
digit span forward, F(1,40)=4.30, p=.045, whilst the control group had a 
significant decline in performance on digit span backwards, F(1,40)=5.36, 
p=.026.   
 
Table 8.5 Assessment of change in working memory (domain 2) (mean ± SD) 
 
Working memory 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change 
Over time 
Digits forward    
   Controls (n=15) 6.7 ± .96 6.6 ± 1.1 __ 
   SMC (n=23) 6.3 ± 1.7 6.8 ± 1.3 c 
   aMCI (n=5) 6.4 ± .55 6.2 ± 1.5 __ 
Digits backward    
   Controls (n=15) 4.7 ± 1.3 4.0 ± 1.3 d 
   SMC (n=23) 4.8 ± 1.5 5.0 ± 1.6 __ 
   aMCI (n=5) 4.4 ± .55 4.2 ± .84 __ 
Serial 7’s (errors)    
   Controls (n=15) .87 ± 1.0 .67 ± .98 __ 
   SMC (n=23) .70 ± .97 1.1 ± 1.0 __ 
   aMCI (n=5) .80 ± 1.1 .40 ± 0.90 __ 
            c indicates a significant improvement over time within a group 
      d indicates a significant decline over time within a group 
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Verbal learning (Domain 3) 
As can be seen in Table 8.6, the analysis of change over time in 
verbal learning showed the SMC group had significantly higher scores on 
verbal learning, F(1,40)=6.17, p=.017.   
 
Table 8.6 Assessment of change in verbal learning (domain 3) (mean ± SD)  
 
Verbal learning 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change 
Over time 
Trials 1-5    
   Controls (n=15) 43.5 ± 9.0 46.1 ± 7.0 __ 
   SMC (n=23) 41.9 ± 9.1 45.2 ± 11.2 c 
   aMCI (n=5) 27.4 ± 6.2a,b 28.2 ± 5.9a,b __ 
               a indicates a significant difference from controls 
               b indicates a significant difference from SMC group 
               c indicates a significant improvement over time within a group 
          Trials 1 –5 = total learning over trials on the Rey Auditory Verbal Learning Test 
 
The analysis showed the aMCI group scored significantly lower on 
verbal learning compared to the control and SMC groups at both time points, 
F(2,40)=6.63, p=.003 (Time 1) and F(2,40)=7.41, p=.002 (Time 2). 
 
Verbal recall (Domain 4) 
As can be seen in Table 8.7, the analysis of change over time in 
delayed recall showed the SMC group had significantly higher scores on 
delayed recall, F(1,40)=5.06, p=.030. 
The analysis of group differences at time 1, showed the aMCI group 
had significantly lower scores on immediate recall, F(2,40)=9.37, p=.001 
(T1), delayed recall, F(2,40)=17.23, p=.001 (T1), and recognition of List A 
words F(2,40)=6.1, p=.005 compared to the control and SMC groups.   
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Table 8.7 Assessment of change in verbal recall (domain 4) (mean ± SD) 
 
Verbal recall 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change 
Over time 
Immediate recall    
   Controls (n=15) 9.9 ± 2.2 9.4 ± 2.2 __ 
   SMC (n=23) 8.0 ± 3.5 9.0 ± 3.0 __ 
   aMCI (n=5) 3.2 ± 2.4a,b  2.8 ± 2.6a,b __ 
Delayed recall    
   Controls (n=15) 9.3 ± 2.6 9.3 ± 3.5 __ 
   SMC (n=23) 8.1 ± 2.4 9.2 ± 3.0 c 
   aMCI (n=5) 2.2 ± 1.3a,b 2.6 ± 2.4a,b __ 
List A: recognition    
   Controls (n=15) 13.9 ± 1.8 14.1 ± 1.8 __ 
   SMC (n=23) 13.9 ± 1.3 14.0 ± 1.3 __ 
   aMCI (n=5) 11.0 ± 3.2a,b 9.2 ± 6.3a,b  __ 
List B: recognition    
   Controls (n=15) 5.1 ± 3.0 6.5 ± 3.8 __ 
   SMC (n=23) 7.2 ± 2.5 7.0 ± 3.6 __ 
   aMCI (n=5) 5.0 ± 2.0 5.2 ± 4.6 __ 
                 a indicates a significant difference from controls 
                 b indicates a significant difference from SMC group 
                 c indicates a significant improvement over time within a group 
           RAVLT = Rey Auditory Verbal Learning Test  
 
At time 2, the aMCI group had significantly lower scores on immediate 
recall F(2,40)=12.45, p=.001, delayed recall, F(2,40)=9.92, p=.001 (T2) 
recognition of List A words F(2,40)=8.40, p=.001 compared to the other two 
groups. 
 
Verbal ability (Domain 5) 
As can be seen in Table 8.8, the analysis of change over time in 
verbal ability showed the SMC group had significantly higher scores on FAS 
word generation, F(1,40)=13.15, p=.001.   
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Table 8.8 Assessment of change in verbal ability (domain 5) (mean ± SD) 
 
Verbal ability 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change over 
time  
BNT    
   Controls (n=15) 53.0 ± 8.2 54.7 ± 5.9 __ 
   SMC (n=23) 54.7 ± 5.5 55.5 ± 4.6  __ 
   aMCI (n=5) 47.4 ± 10.4  47.6 ± 10.6a,b __ 
FAS (total)    
   Controls (n=15) 40.1 ± 12.7 39.3 ± 15.4 __ 
   SMC (n=23) 36.9 ± 12.7 43.5 ± 13.7 c 
   aMCI (n=5) 23.8 ± 10.3a,b 22.8 ± 15.2a,b __ 
                 a indicates a significant difference from controls 
            b indicates a significant difference from SMC group 
           C indicates a significant improvement over time within a group 
           FAS = Letter fluency; BNT = Boston Naming Test 
 
The analysis of group differences at time 1, showed the aMCI group 
had significantly lower scores on FAS word generation, F(2,40)=, p=.050 
compared to the control and SMC groups.  At time 2, the aMCI group had 
significantly lower scores on FAS word generation, F(2,40)=4.21, p=.022 
and on the BNT, F(2,40)=3.68,p=.034 compared to the other two groups. 
 
Visual copy and recall (Domains 6 and 7) 
As can be seen in Table 8.9, the analysis of change over time in 
visual copy and recall showed the aMCI group’s recall performance increased 
on the second assessment, but this was not significant (p=.058).   
Analysis of group differences at time 1, showed the aMCI group 
obtained significantly lower scores on visual copy, F(2,40)=4.2, p=.026, and 
visual recall, F(2,40)=4.4, p=.018, respectively compared to the control and 
SMC groups. 
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Table 8.9 Assessment of change in visual copy (domain 6) and recall (domain 7) 
(mean ± SD) 
 
Visual copy and recall 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change 
over time 
ROCFT: Copy    
   Controls (n=15) 35.7 ± .60 35.7 ± .70 __ 
   SMC (n=23) 35.5 ± .85 35.7 ± .69 __ 
   aMCI (n=5) 34.0 ± 3.1a,b 35.2 ± 1.8 __ 
ROCFT: Recall    
   Controls (n=15) 16.2 ± 5.0 17.6 ± 6.5 __ 
   SMC (n=23) 18.2 ± 5.9 18.7 ± 5.6 __ 
   aMCI (n=5) 9.7 ± 8.0a,b 15.5 ± 11.7 __ 
                            a indicates a significant difference from controls 
                            b indicates a significant difference from SMC group 
                  ROCFT = Rey-Osterrieth Complex Figure Test 
 
Visuomotor speed and executive functioning (Domains 8 and 9) 
 As can be seen in Table 8.10, the analysis of change over time in 
visuomotor speed and executive functioning (Trail A and B) showed no 
changes over time for any of the three groups. 
Table 8.10 Assessment of change in visuomotor speed (domain 8) and executive 
functioning (domain 9) (mean ± SD) 
Visuomotor speed &  
Executive functioning 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change over 
time 
Trail A    
   Controls (n=15) 29.5 ± 7.7 29.6 ± 9.2 __ 
   SMC (n=23) 34.8 ± 14.1 34.2 ± 16.3 __ 
   aMCI (n=5) 52.7 ± 34.3a,b 60.1 ± 30.1a,b __ 
Trail B    
   Controls (n=15) 93.3 ± 62.1 73.1 ± 17.5 __ 
   SMC (n=23) 85.0 ± 33.3 86.1 ± 56.3 __ 
   aMCI (n=5) 166.3± 80.0a,b 176.2 ± 92.0a,b __ 
                   a indicates a significant difference from controls 
                   b indicates a significant difference from SMC group 
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Analysis of group differences at time 1, showed the aMCI had 
significantly higher scores compared to the other two groups on Trails A and 
B, F(2,40)=4.07, p=.025 and F(2,40)=5.29, p=.009, respectively.  At time 2, 
the aMCI group had significantly higher scores compared to the other two 
groups on Trails A and B, F(2,40)=6.71, p=.003 and F(2,40)=7.71, p=.001, 
respectively.  The large SDs on Trail B indicates two subjects did not 
complete the task and obtained a score of 300 (sec). 
 
Assessment summary of individual tests 
On the brief screening tests, the aMCI group showed greater decline 
over time on the 7MS total score and two subtests; verbal fluency and 
enhanced cued recall.  The SMC group obtained significantly higher scores 
on the 7MS total score, verbal fluency and temporal orientation.  On the 
DRS, the aMCI showed minimal change over time.  However, in the analysis 
of group differences, the aMCI group had significantly lower scores on the 
DRS total score, initiation and memory compared to the other two groups. 
 On the composite cognitive domain tests, the analysis of change over 
time showed the SMC group had higher scores on working memory, verbal 
learning, verbal recall and verbal ability, whilst the aMCI group declined on 
working memory.  The aMCI group had consistently lower scores compared 
to the other two groups on all of the cognitive domains and maintained a 
stable performance over time. 
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8.6 Profile of neuropsychological impairment at follow-up 
This section provides a summary profile of change over time, using 
repeated measures MANOVA for the individual cognitive domains expressed 
as z scores.  The subjects are grouped by SMC (Table 8.11), and also by 
aMCI (Table 8.12).  Analysis of the data by two groups (Table 8.11) 
showed significant changes on four of the nine cognitive domains.  Both 
subjects with and without SMC had significantly higher scores on intellectual 
functioning F(1,41)=14.24, p=.001 and F(1,41)=16.35, p=.001, respectively.  
The SMC group had significantly higher scores on working memory, 
F(1,41)=6.67, p=.013, verbal learning, F(1,41)=18.84, p=.000 and verbal 
ability, F(1,41)=10.70, p=.002. 
Analysis of the data by three groups (Table 8.12) showed significant 
group differences on four of the nine cognitive domains.  All three groups 
had significantly higher scores on intellectual functioning (IQ), 
F(1,40)=16.67, p=.001 (controls), F(1,40)=8.33, p=.006 (SMC), and 
F(1,40)=8.00, p=.007 (aMCI).  The SMC group had significantly higher 
scores on working memory, F(1,40)=13.08, p.001, verbal learning, 
F(1,40)=14.32, p=.001, and verbal ability, F(1,40)=14.20, p=.001.  The 
aMCI group had significantly higher scores on verbal learning, F(1,40)=4.15, 
p=.048.  This contrasted with the aMCI group’s performance on verbal 
recall, which remained stable.  The aMCI group had a slight decrease in 
performance in visuomotor speed as noted by the one point change in the 
SD, but this was not significant.   
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Table 8.11 Summary profile of changes in each cognitive domain (Z transformed) 
in subjects with and without SMC on initial and follow-up assessment (mean ± 
SD) 
 
 
Cognitive domain and tests 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change 
over 
time 
    
1. Intellectual functioning    
   No SMC (n=15) .00 ± 1.0 .43 ± .70 c 
   SMC (n=28) .00 ± 1.1 .30 ± .96 c 
    
2. Working memory (WM)    
   No SMC (n=15) .00 ± .69 -.11 ± .58 __ 
   SMC (n=28) -.04 ± .89 .23 ± .96 c 
    
3. Verbal learning (VbL)    
   No SMC (n=15) .00 ± 1.0 .19 ± 1.2 __ 
   SMC (n=28) -.85 ± 1.2 -.23 ± 1.3 c 
    
4. Verbal recall (VbR)    
   No SMC (n=15) .00 ± .69 -.32 ± .98 __ 
   SMC (n=28) -.90 ± 1.0 -.74 ± 1.3 __ 
 
5. Verbal ability (VbA)    
   No SMC (n=15) .00 ± .88 .07 ± .84 __ 
   SMC (n=28) -.19 ± .72 .05 ± .91 c 
    
6. Visual recall (VsR)    
   No SMC (n=15) .00 ± 1.0 .27 ± 1.3 __ 
   SMC (n=28) .10 ± 1.4 .38 ± 1.4 __ 
    
7. Visuo-spatial ability 
(VsA) 
   
   No SMC (n=15) .00 ± 1.0 .00 ± 1.2 __ 
   SMC (n=28) -.81 ± 2.6 -.15 ± 1.6 __ 
    
8. Visuomotor speed 
(VmS) 
   
   No SMC (n=15) .00 ± 1.0 -.01 ± 1.2 __ 
   SMC (n=28) -1.1 ± 2.6 - 1.2 ± 2.8 __ 
    
9. Executive functioning 
(EF) 
   
   No SMC (n=15) .00 ± 1.0 .33 ± .28 __ 
   SMC (n=28) -.10 ± .86 -.14 ± 1.1 __ 
    
                          c indicates a significant improvement over time within a group 
 
 
 
 
                                                                   Chapter 8 – Results – Follow-up assessment 
__________________________________________________________________________ 
 203 
Table 8.12 Summary profile of changes in each cognitive domain by three groups 
on initial and follow-up assessment (mean z score ± SD) 
 
Cognitive domain and tests 
Initial 
(Time 1) 
Follow-up 
(Time 2) 
Change 
over time 
1. Intellectual functioning (IQ)    
   Controls (n=15) .00 ± 1.0  .43 ± .70 c 
   SMC (n=23) .16 ± .93 .41 ± .85 c 
   aMCI (n=5) -.76 ± 1.4 -.24 ± 1.3 c 
    
2. Working memory (WM)    
   Controls (n=15) .00 ± .69 -.11 ± .58 __ 
   SMC (n=23) -.03 ± .95 .36 ± .98 c 
   aMCI (n=5) -.08 ± .55 -.35 ± .68 __ 
    
3. Verbal learning (VbL)    
   Controls (n=15) .00 ± 1.0 .19 ± 1.2 __ 
   SMC (n=23) -.44 ± .92 .16 ± 1.0 c 
   aMCI (n=5) -2.7 ± .51a,b -2.0 ± .81a,b c 
    
4. Verbal recall (VbR)    
   Controls (n=15) .00 ± .70 -.32 ± .98  __ 
   SMC (n=23) -.62 ± .85 -.34 ± .93 __ 
   aMCI (n=5) -2.2 ± .59a,b -2.5 ± .94a,b __ 
    
5. Verbal ability (VbA)    
   Controls (n=15) .00 ± .88 .07 ± .84 __ 
   SMC (n=23) -.02 ± .59 .29 ± .69 c 
   aMCI (n=5) -.98 ± .81a,b -1.0 ± 1.1a,b __ 
    
6. Visual recall (VsR)    
   Controls (n=15) .00 ± 1.0  .27 ± 1.3 __ 
   SMC (n=23) .40 ± 1.2  .50 ± 1.1 __ 
   aMCI (n=5) -1.3 ± 1.6 -.15 ± 2.3 __ 
    
7. Visuospatial ability (VsA)    
   Controls (n=15) .00 ± 1.0 .00 ± 1.2 __ 
   SMC (n=23) -.36 ± 1.4 .01 ± 1.2 __ 
   aMCI (n=5) -2.9 ± 5.2  -.90 ± 3.0 __ 
    
8. Visuomotor speed (VmS)    
   Controls (n=15) .00 ± 1.0 -.01 ± 1.2 __ 
   SMC (n=23) -.70 ± 1.8  -.62 ± 2.1 __ 
   aMCI (n=5) -3.0 ± 4.5a,b  -4.0 ± 3.9a,b __ 
    
9. Executive functioning (EF)    
   Controls (n=15) .00 ± 1.0 .33 ± .28 __ 
   SMC (n=23) .13 ± .54  .12 ± .91 __ 
   aMCI (n=5) -1.2 ± 1.3a,b  -1.3 ± 1.5a,b  __ 
      a indicates a significant difference from the control group 
         b indicates a significant difference from the SMC group 
         c indicates a significant improvement over time within a group 
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Figure 8.4 illustrates the mean z-score profile of neuropsychological 
functioning for both the SMC and aMCI groups in comparison to the control 
group on re-testing.  Examination of Figure 8.4 shows that most of the 
control and SMC groups obtained a similar or higher score on re-testing 
three years later.  Whilst the aMCI group did not decline, their performance 
significantly contrasted with the control and SMC groups in a number of 
cognitive domains, including verbal learning, verbal recall, verbal ability, 
visuomotor speed and executive functioning 
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Figure 8.4 Mean z-scores for each cognitive domain for the three groups on initial (T1) and 
follow-up assessment (T2).  Scores for the control group (represented by the zero line) have 
a mean of 0 and a standard deviation of 1.  Scores below –1 indicate significantly lower 
functioning. 
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8.7 Impaired cognitive domains 
In this section, a Pearson Chi-square test was used to identify the 
number of subjects in each group scoring within the impaired range (more 
than one SD below the mean) on both assessments. 
Table 8.13 shows the number and percentage of subjects in each 
group who scored one SD below the control mean (z-score<–1) on each  
of the cognitive domains and the group aggregate for the number of 
impaired domains (2-9).   
 
Table 8.13 Number of cognitive domains with scores below 1 SD of control mean 
on initial and follow-up assessment (mean ± SD) 
 
 
 
Cognitive Domain 
Controls  
Time 1 
(n=15) 
(n=%) 
SMC 
Time 1 
(n=23) 
(n=%) 
aMCI 
Time 1 
(n=5) 
(n=%) 
Controls 
Time 2 
(n=15) 
(n=%) 
SMC 
Time 2 
(n=23) 
(n=%) 
aMCI 
Time 2 
(n=5) 
(n=%) 
2. Working memory  1 (7%) 5 (22%) 0 0 1 (4%) 1 (20%) 
3. Verbal learning  1 (7%) 7 (30%) 4 (80%) 1 (7%)  3 (13%) 4 (80%) 
4. Verbal recall  1 (7%) 8 (35%) 5(100%)  3 (20%) 6 (26%) 5(100%) 
5. Verbal ability   3 (20%)  1 (4%) 3 (60%)  2 (13%) 0 3 (60%) 
6. Visual recall   3 (20%)  3 (13%) 2 (40%)  3 (20%)  2 (9%) 2 (40%) 
7. Visuospatial ability   3 (20%) 6 (26%) 2 (40%)  2 (13%)  3 (13%) 1 (20%) 
8. Visuomotor speed  2 (13%) 2 (26%) 3 (60%)  4 (27%)  9 (39%) 3 (60%) 
9. Executive functioning  1 (7%) 0 2 (40%)  0  2 (9%) 2 (40%) 
Total (sum of 2-9)        
0  8 (53%) 7 (30%) 0 6 (40%) 10(44%) 0 
1 4 (26%)  7 (30%) 0 5 (33%) 6 (26%) 1 (20%) 
2  1 (7%) 3 (13%) 1 (20%) 3 (20%)  4 (17%) 0 
3  1 (7%) 3 (13%)  1 (20%) 0  2 (9%) 1 (20%) 
4-5 0 3 (13%) 1 (20%)  1 (7%)   0 2 (40%) 
6+ 1 (7%) 0 2 (40%) 0 1 (4%) 1 (20%) 
 
At follow-up, the percentage of subjects in each group with multiple 
domain deficits remained higher for the aMCI (100% at T1 vs. 80% at T2) 
and SMC groups (39% at T1 vs. 30% at T2) compared to the control group 
(39% at T1 vs. 27% at T2).  On both assessments, the aMCI group had a 
high percentage of subjects with impairments on tests of verbal learning 
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(80%), verbal recall (100%), verbal ability (60%) and visuomotor speed 
(60%). 
Figure 8.5 shows that at follow-up, age remained a strong predictor 
of cognitive function based on the number of domain deficits on formal 
testing (r=0.43, p=.003).  The vast majority of control subjects under the 
age of 70 had normal cognitive function with few deficits on formal testing.  
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 Figure 8.5 Graph showing the relationship between age and the number of domains with 
cognitive deficits greater than one SD of the norms for each of the groups on follow-up 
assessment.  Dotted line indicates line of best fit for control group (open circles), dashed 
line for the SMC group (open boxes) and the solid line for the aMCI group (stars). 
 
8.8 Apolipoprotein-ε4 (ApoE-ε4) 
 Table 8.14 shows the characteristics of subjects with and without the 
ApoE-ε4 allele on initial and follow-up assessment.  Three subjects were not 
tested for the ApoE-ε4. 
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Table 8.14 Characteristics of subjects with and without the ApoE-ε4 allele on 
follow-up assessment (mean ± SD) 
 
 
Characteristics 
Non ApoE-ε4 
(2/3, 3/3) 
(n=26) 
ApoE-ε4 
(2/4, 3/4, 4/4) 
(n=14)a 
 
P 
value 
Age 64.4 ± 8.0 65.0 ± 8.1 .840 
Gender    
   Male 13 (50%) 4 (29%) .191 
   Female 13 (50%) 10 (71%)  
Years of education 13.3 ± 3.6 14.8 ± 4.8 .279 
Family history of AD 15 (58%) 10 (71%) .392 
Subjective memory complaint 18 (69%) 8 (57%) .445 
7 Minute screen total (Test 1) -11.8 ± 12.9 -17.1 ± 9.3 .184 
   (range) (-26 to 32) (-33 to -2)  
Abnormal 7MS 3 (12%) 0 .186 
7 Minute screen total (Test 2) -14.5 ± 13.0 -17.3 ± 9.3 .470 
   (range) (-34 to 35) (-31 to -1)  
Abnormal 7MS 1 (4%) 0 .457 
Dementia Rating Scale (Test 1) 134.1 (4.7) 134.3 (6.6) .925 
   (range) (123-142) (121-142)  
rated < 121 0 2 (14%) .048* 
Dementia Rating Scale (Test 2) 133.2 ± 6.9 135.2 ± 6.4 .363 
   (range) (105-142) (119-142)  
rated < 121 1 (4%) 1 (7%) .648 
            * Statistically significant at p<.05   
        a Includes one subject who had a copy of the ApoE-ε2/ε4 allele 
 
 
Fourteen subjects (35%) carried at least one ApoE-ε4 allele.  There 
were no statistically significant differences between ApoE-ε4 and non-ApoE-
ε4 carriers for the majority of the demographic and clinical variables.  At 
time 1, a slightly higher percentage of ApoE-ε4 (14%) carriers compared to 
none in the non- ApoE-ε4 carriers had a DRS score below the threshold for 
dementia (<121), which reached significance at, χ2=3.9; df=1; p=.048. 
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Figure 8.6 Relationship between mean z-scores for each cognitive domain for 
Apolipoprotein-ε4 status on initial (time 1) and follow-up assessment (time 2).  Scores for 
the control group (represented by the zero line) have a mean of 0 and a standard deviation 
of 1.  Scores below –1 indicate significantly lower functioning. 
 
Figure 8.6 summarizes the pattern of cognitive ability and ApoE-ε4 
status on initial and follow-up testing.  Examination of the graph shows that 
ApoE-ε4 status had little effect on the mean z-scores for any of the cognitive 
domains.  In most cases performance improved or remained stable on 
retesting regardless of ApoE-ε4 genotype.  
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8.9 Assessment of risk factors for dementia on global functioning 
To assess which variables contributed to global functioning at time 2, 
a multiple regression analysis was performed with global z-score averaged 
over domains 2-8 as the dependent variable.  The independent variables 
tested were age, education years, SMC, family history of Alzheimer’s disease 
and mild depressive symptoms.  The latter three variables were coded as 
present (coded 1) or absent (coded 0).  The results of the multiple 
regression analysis are summarised in Table 8.15.  One case (#59) was not 
included due to outlier values on the global z-score. 
 
Table 8.15 Standard multiple regression of age, subjective memory complaint, 
family history and education years on global cognitive functioning (average of Z-
scores Domains 2-8) on follow-up assessment 
 Global  
(DV) 
Age SMC AD 
FHx 
Education 
Years 
Depn B Beta sr2 
Unique 
Age (yrs) -.53**      -.063* -.647 .388 
SMC  -.09 .04     -.127 -.083 .007 
AD FHx .22 .07 .00    .467* .299 .088 
Edu years -.09 -.23 -.19 .00   -.051* -.284 .073 
Depression -.26 -.09 .10 .09 -.10  -.679** -.360 .125 
      intercept  4.71   
Mean -.04 66.9 .64 .67 13.9 .12  R2 .535 
SD 0.74 7.7 .49 .48 4.1 .40  Adj R2 .470 
        R .731 
n=42, **p<0.05 
unique variability =.681, shared variability = .05 
subjective memory complaint, AD family history and minor depression were coded 1= Yes, 2= No 
 
The multiple regression analysis showed a significant contribution of 
four risk factors to the variance in global z scores, R2= .535; (p=.001).  As 
can be seen from the regression coefficients four factors, age (beta=-.647; 
p=.001), depression score (beta=-.360; p=.004), family history (beta=..299; 
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p=.013) and education (beta=-.284; p=.023) explained the largest 
proportion of variance in global cognitive function.  The presence of SMC did 
not contribute significantly to the regression model.  Examination of the 
residual analysis (Figure 8.7) showed that assumptions of normality, 
linearity and homoscedasticity were met as these were not correlated to the 
residuals. 
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Figure 8.7 Scatterplot of standardized residuals and predicted values for the multiple 
regression analysis.  
 
In summary, the multiple regression analysis indicates that 
collectively, four variables (age, minor depression, AD family history and 
education years), accounted for 54% of the total variance in global cognitive 
functioning.  Together the four predictor variables contributed .681 in unique 
variability and another .05 in shared variability.  Closer inspection of the 
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correlations and beta value sizes indicate inverse relations between global z-
scores and years of education and minor depression.   
A further multiple regression analysis was performed using change in 
global z scores between assessment 1 and 2, using the same variables, but 
this was not significant.  
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Chapter 9: 
Discussion 
 
9.1 General overview 
The main aim of the present study was to determine whether SMC 
predict the development of cognitive impairment in a younger cohort of 
subjects, many of whom were under the age of 70 years (73%), based on 
their risk profile and neuropsychological assessment.  In order to purse this 
line of inquiry, this study was conducted in two parts.  The initial cross-
sectional design examined in detail the role of SMC as well as established 
risk factors (i.e. age, family history and verbal learning deficit) on cognitive 
function.  The follow-up component was implemented to examine whether 
the presence of SMC affects the 3-year cognitive outcome of subjects. 
In this chapter, the principal findings will be drawn together and a 
discussion of the results will be presented in the following sections: 1) Cross-
sectional findings; 2) Longitudinal findings.  In addition, the results will be 
addressed in terms of their clinical significance for the early detection of 
Alzheimer’s disease.  They will also raise methodological issues relevant to 
this study and provide directions for future research. 
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I. Initial assessment 
9.2 Summary  
 The initial analysis suggested a relationship between SMC and 
cognitive impairment in a younger cohort of subjects.  This was documented 
by impaired performance on two screening tests for dementia (e.g. 7MS and 
DRS) and neuropsychological assessment.  This relationship occurred 
independently of depression.  Further analysis of the data showed that when 
a group of subjects with SMC (n=12) demonstrated impairment on tests of 
delayed recall and animal fluency.  Once these subjects were removed from 
the SMC group to form the aMCI group, the relationship between SMC and 
cognitive impairment in younger subjects was no longer apparent.   
These initial findings are important as they indicate that SMC in 
younger subjects are less likely to be related to cognitive impairment.  In 
isolation, SMC are unlikely to be useful for identifying cases with significant 
cognitive impairment.  In particular, the use of sensitive tests such as animal 
fluency and delayed recall are more reliable indicators of cognitive 
impairment compared to current brief screening methods for subjects with 
SMC.  Subjective memory complaints were more likely to be associated with 
cognitive impairment in older subjects (>70 years).  Many current studies do 
not adequately screen for objective memory impairment in persons with 
memory complaints.  This is likely due to the use of simple measures of 
global cognitive functioning, such as the MMSE.  
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Subjective memory complaints 
 Prior to comparing the present study with the literature on memory 
complaints, the concept of measuring and quantifying SMC needs to be 
acknowledged.  A straight forward comparison between studies is precluded 
by the fact that a range of questions and scales (e.g., Cognitive Difficulties 
Questionnaire; MacNair Scale) has been used across studies.  There is no 
agreement or uniformity on the choice of these methods.  Additionally, the 
questions to identify memory difficulties have varied widely, with many 
tapping into different aspects of cognitive functioning and time frames.  
 The obvious repercussion of the usage of various measurements of 
memory complaints is that a meaningful comparison and interpretation of 
results is less readily achievable.  The main reason for this difficulty is that 
there exists no strong evidence of a correlation between these different 
techniques in measuring the same construct (Mitchell, 2008a).  Ahmed et al. 
(2008) reported that patients with Semantic Dementia frequently endorse 
semantic complaints, such as word finding difficulty and understanding the 
meaning of names (Ahmed et al., 2008).  These same authors reported that 
the “worried well” and patients with Alzheimer’s disease could not be 
distinguished on the basis of their memory complaints.  This suggests that 
the use of differing questions may fail to identify cases of significant 
cognitive impairment or dementia syndromes.  Thus, it is important to 
consider these issues when comparing the relationship between SMC and 
cognitive functioning across different studies. 
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Depression 
 It is important to emphasize that SMC is frequently linked to major 
depression (Cargin et al., 2008; Jessen et al., 2007; Jorm et al., 2004; 
Lautenschlager et al., 2005).  It is well documented that impaired memory 
and concentration difficulties are part of the core symptomatology of major 
depression (APA, 2000; Steffens and Potter, 2008).  Whilst some reports 
indicate that major depression is a prodrome to dementia (Wilson et al., 
2008), major depression may also appear co-morbidly with an underlying 
dementia.  Undoubtedly, the relationship between SMC, depression and 
dementia is rather complex.  This is demonstrated by several lines of inquiry 
into correlates of SMC indicating relations with both depression and cognitive 
impairment (e.g., Jessen et al., 2007; Minett et al., 2008).   
In the present study, those with scores on the GDS and PAS in the 
depression range were excluded.  Subjects with a self-reported previous 
history of major depression were also excluded.  Subjects taking 
medications, such as corticosteroids and anti-depressants which could 
influence mood and potentially affect cognitive functioning were also 
excluded.  However, subjects with mild depressive symptoms were not 
excluded as this was unlikely to significantly affect cognitive performance.   
  
Prevalence of SMC 
In the present study, 63% of subjects reported SMC as defined by a 
single question.  This proportion is higher than the 10.6% to 21% reported 
in several previous community studies that have also used a single question 
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(Geerlings et al., 1999; Jungwirth et al., 2004; St. John and Montgomery, 
2002).  The relatively high rate of subjects reporting a memory complaint in 
the present study was likely due to the advertisement requesting subjects 
with memory difficulties. 
However, the variation in the reported rates of SMC might also be 
related to the methods used to define and quantify SMC.  Purser et al. 
(2006) showed that when community-dwelling subjects were asked in more 
detail about their memory difficulties using a memory scale, rather than a 
single question requiring a “Yes” or “No” response, a prevalence of 32% was 
observed.  Thus, the variation in the reported rates of SMC may also be the 
result of the different techniques used to quantify SMC.  Nevertheless, the 
rate of memory complaints in the present study is comparable to a recent 
community study by Cargin et al. (2008).  They reported an average rate of 
67.5% in normal controls and memory declining groups.  
 
9.3 Subjective memory complaints  
Hypothesis 1: Subjects with SMC will demonstrate significant cognitive 
impairment on formal neuropsychological assessment compared to those 
without SMC. 
  The present study initially showed that in this cohort of predominantly 
younger subjects with SMC (73%), a simple question “Do you have problems 
with your memory?” was associated with cognitive impairment on formal 
neuropsychological assessment.  This was demonstrated by the use of two 
brief screening tests and neuropsychological assessment (Tables 7.5, and 
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7.16).  This observation is further discussed below. 
 
9.3.1 Brief screening tests findings 
In subjects with SMC, the 7MS and DRS identified an overall global 
cognitive deficit, including sub-clinical deficits on attention, initiation, 
memory and animal fluency compared to the No SMC group. 
Moreover, seven subjects in the SMC group had DRS total scores 
below the threshold for impairment compared to none in subjects without 
SMC.  Similarly, six subjects in the SMC group scored above the abnormal 
threshold on the 7MS compared to none of the subjects without SMC. 
 
9.3.2 Neuropsychological findings 
 The SMC group could be differentiated from the No SMC group on 
tests in three of the eight cognitive domains, including working memory; 
verbal recall and visuomotor speed (see Table 7.16, page 170).  These 
deficits occurred independently of depression as shown in the multiple 
regression analysis (Table 7.20, page 182).  This analysis showed that 
depression was a non-significant predictor of global cognitive function.  
 
Relevant literature findings 
The present observation of a relationship between SMC and cognitive 
impairment is in agreement with a recent community-based study by Rouch 
et al. (2008).  Rouch et al. (2008) investigated the association between SMC, 
affective disorders and objective memory in 937 non-demented community-
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dwelling subjects (mean age=65).  Memory complaints were quantified using 
the MacNair scale, which is a self-rating scale exploring memory difficulty in 
everyday life.  Their results showed a significant association between 
memory complaints and lower scores on verbal memory (Free and Cued 
Selective Reminding Test) and executive function (Digit Symbol Substitution 
Test, Trail Making B).  Similar to our study, the association occurred 
independently of affective disorders, such as depression and anxiety.   
However, in the study by Rouch et al. (2008), animal fluency did not 
correlate with memory complaints, but rather with depression.  This finding 
contrasts with the results of the present study.  Both studies were 
comparable regarding mean age (63 yrs and 65 yrs, respectively).  The 
discrepancy may be explained by two methodological issues.  Firstly, Rouch 
et al. (2008) allowed their subjects 2 minutes to generate animals, whilst in 
the present study only a 1 minute time period was allowed.  Another factor 
that might explain the difference is sample size.  Namely, sample size which 
was much larger for Rouch et al. compared to the present study (n=937 and 
n=86, respectively). 
 However, other studies have failed to support the present finding: 
Minett et al. (2008) studied the relationship between SMC, cognitive function 
and depression in 114 non-demented subjects (aged > 50 years).  Their 
results showed a relationship between SMC and depression, but not with 
cognitive function.  Despite the lack of association, these authors reported 
that subjects with a memory complaint had significantly lower scores on 
animal fluency compared to subjects without a complaint.   
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Another study, by Jessen et al. (2007), also failed to report a 
relationship between SMC and cognitive function.  These authors reported a 
relationship between SMC and depression in 2389 non-demented subjects 
(mean age=80 years).  In addition to this finding, an association between 
SMC and verbal delayed recall was also reported.  The use of the MMSE as a 
simplistic screening test might have precluded both Minett and Jessen from 
observing any difference between subjects with SMC and those without SMC.  
The lack of association might also be attributed to the different techniques 
used by Minett and Jessen to measure SMC.  Namely, both authors used a 
combination of questions and scales to define the presence of SMC.  
Nevertheless, both Minett and Jessen observed impairments on animal 
fluency and verbal delayed recall, which are part of the 7MS.  This 
observation reinforces the greater sensitivity of the 7MS (Solomon et al., 
1998; Del Ser et al., 2006) to identifying cognitive impairment compared to 
the MMSE. 
The results of the present study provide limited support for the 
hypothesis that SMC are associated with impairments in several cognitive 
domains amongst community dwelling subjects over the age of 50 years.  
However, the regression analyses presented in tables 7.20 and 8.15 
found that when age is taken into account, SMC were insignificant in the 
prediction of global cognition.  This is discussed further in section 9.4. 
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9.4 The role of age 
 The present study was able to show significant neuropsychological 
evidence of cognitive impairment in subjects identified as having SMC and 
aMCI (Table 7.8; page 174).  This observation was more strongly related to 
age, as shown by the more rapid decline in cognitive function in subjects 
with aMCI with advanced age (Figure 7.5, page 173).   
The relationship between age, SMC and cognitive function is clearly 
an important area for investigation.  With the exception of several 
investigators known to target younger populations, such as Jorm and 
Christensen, much of the literature has focused on older subjects (e.g., 
Jungwirth et al., 2008; Howieson et al., 2008; Palmer et al., 2003).  Thus, 
whether SMC can be used to help identify subjects at an earlier age is not 
well known.  However, this area is fraught with difficulties, as the effects of 
normal ageing begin from the age of 60 onwards.  There is considerable 
debate within the literature to say when age-related cognitive decline begins 
(Salthouse, 2009).  Normal ageing is characterized by a decrease in the 
efficiency by which information is processed and retrieved.  From the mid 
70s onwards (De Ronchi et al., 2005) cognitive decline occurs on tasks of 
new learning, speed and flexible adjustments to new situations. This needs 
to be taken into consideration, especially when evaluating studies examining 
older subjects. 
The relationship between age, SMC and global cognitive functioning is 
further illustrated in Figure 7.14 (page 179).  It was observed that the 
association between age, SMC and global cognitive function differed 
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according to whether there was evidence of SMC and/or cognitive 
impairment (i.e. the subject group).  In control subjects, there was no 
association between age and global cognitive functioning as indicated by the 
non-significant correlation.  In subjects with SMC and aMCI, age was 
significantly and negatively correlated to global cognitive functioning, 
commencing from the age of approximately 65 onwards.  This indicated that 
increasing age was accompanied by lower cognitive functioning.  More 
specifically, verbal learning, verbal recall, verbal ability, visuomotor speed 
and executive functioning significantly correlated with age (Figures 7.7 to 7.9 
and 7.12, 7.13, pages 175-176 and 178).   
Furthermore, Figure 7.5 (page 173) showed that subjects with SMC 
had on average deficits in two or more cognitive domains (below 1SD of the 
control group mean), commencing from the age of 60 onwards.  The 
multiple regression analysis (Table 7.20, page 182) showed that of the five 
variables examined (age, SMC, family history of AD, education and 
depression), age was the best predictor of global cognitive functioning (z 
scores) accounting for 39% of the variance.  
 
Relevant literature findings 
The present observation of an association between age, SMC, aMCI 
and lower global cognitive functioning is consistent with the findings of 
Wang et al. (2004a).  Wang et al. (2004a) examined the association 
between SMC and future dementia in 1,883 community subjects (mean 
age=74.6).  Subjects had no baseline objective cognitive impairment as 
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defined by a score of >91 on the Cognitive Ability Screening Instrument.  
Wang et al. (2004a) defined a memory complaint as being present in 
subjects who scored 20 or more on a 5-point Likert scale.  Despite the 
different measurement techniques, Wang et al. (2004a) also identified the 
age of 70 as a beginning of cognitive decline in subjects with memory 
complaints.  
As 73% of our sample was under 69 years (Table 7.4, page 147), our 
study shows that in subjects identified as having either SMC or aMCI, 
multiple cognitive deficits can appear between the ages of 60 to 65.  
Compared to Wang et al’s (2004a), our study has identified an earlier age 
when cognitive impairment begins to manifest in those with memory 
complaints. 
It is important to emphasize that the aMCI group in the present study 
were slightly older (mean age=70) and had fewer years of education (mean 
years 11).  Thus, the demographic profile of our aMCI group (Table 7.7, 
page 153) is consistent with the profile reported by previous studies linking 
older age to clinical conditions, such as MCI (e.g., Gallassi et al., 2008).  In 
the study by Gallassi et al. (2008) patients with SMC who developed MCI 
after a period of 9 months, were older (mean age=71.1) and had lower 
levels of education (8 years) and lower global cognitive function based on 
the MMSE scores.   
However, other studies have failed to support the present findings: 
Park et al. (2007) investigated the association between SMC and objective 
cognitive function in 9477 subjects with a mean age of 72.6.  Their results 
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showed that age was associated with SMC, irrespective of the cognitive 
status of the individual.  These authors reported no association between 
SMC and advanced age in subjects with cognitive impairment, but observed 
an association in elderly subjects without cognitive impairment.  
The inconsistency between both studies is likely due to two 
methodological issues.  Namely sample size and the manner in which the 
variable depression was treated.  Firstly, Park et al’s. (2007) study had a 
larger sample size compared to our study (n= 9477 and n=86, respectively).  
Thus, the discrepancies between the present results and Park et al.’s (2007) 
might be reflective of the size difference between the two studies.  
More significantly, the lack of measurement of an important variable 
such as depression by Park et al. (2007) might have contributed to the 
authors observing an association between SMC and elderly subjects without 
cognitive impairment.  This would help to explain the high percentage of 
their sample reporting a memory complaint (57.3%).  Given the reported 
associations between SMC and depression, it is possible that this percentage 
included subjects with undiagnosed depression.   
 
9.5 Screening for cognitive impairment 
 One aim of the present study was to identify sensitive testing 
methods for early case detection.  In the quest to achieve this, the present 
study was able to demonstrate a novel finding.  After the initial analysis 
between subjects with and without SMC, all subjects were further screened 
for cognitive impairment using a well-validated and widely used verbal 
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memory test (Rey, 1964).  It was observed that approximately one-quarter 
(n=12; 22%, Table 7.6, page 151) of the SMC group (n=54) demonstrated 
cognitive impairment as measured by performance 2SDs below the control 
group mean on delayed recall (Guarch et al., 2008).  These subjects were 
subsequently re-classified as having aMCI. 
Further analysis clearly showed that after the removal of these 12 
subjects from the SMC group, the cognitive differences between subjects 
with SMC and without SMC was no longer apparent on neuropsychological 
assessment (Tables 7.8 and 7.17, pages 155 and 171).  In fact, the means 
and SDs of both the control and SMC groups were almost identical on both 
the DRS and 7MS and cognitive domains.  Whilst previous studies have 
identified subjects with SMC, they have not excluded those with SMC and 
concurrent cognitive impairment, (e.g. Dufoil et al. 2005 and Kim et al., 
2006).  A discussion of these concerns commences on page 225, Section 
9.5.2. 
Hypothesis 2: There is in existence screening tests that are both sensitive 
and relatively easy to administer and can be used to potentially identify 
subjects with MCI. 
The present study was unable to identify sensitive screening to 
identify cognitive impairment in subjects with MCI. 
 
9.5.1 Brief screening tests findings 
 There were discrepancies in identifying impairment based on standard 
thresholds for the 7MS and DRS (see Table 7.8, page 155).  It is noteworthy 
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that on the DRS, seven subjects in the SMC group had DRS total scores 
below the threshold for impairment compared to none in the No SMC group.  
This highlights the sensitivity of the DRS as a screening tool for dementia.  
Similarly, on the 7MS total score, six subjects in the SMC group had 7MS 
total scores above the threshold for dementia compared to none in the No 
SMC group.  Although SMC had good specificity (100%), it had unacceptably 
low sensitivity (< 15%).   
Figure 7.3 (page 157) shows there was strong disagreement between 
the two screening tests for two SMC subjects.  Two subjects in the aMCI 
group had abnormal scores on both tests (see filled stars quadrant 1).  
The aMCI group had significantly lower global cognitive functioning 
compared to the SMC group on both the DRS and 7MS.  At the level of each 
subtest, the aMCI group had significantly lower scores on DRS total score, 
memory, conceptualisation, enhanced cued recall and clock drawing 
compared to the other two groups. 
 
9.5.2 Neurocognitive profile of impairment  
 The aMCI group could be differentiated from the control and SMC 
groups by significantly lower scores on tests of verbal learning, verbal recall, 
verbal ability, visual recall, visuo-motor speed and executive function (Table 
7.17, Figure 7.4, pages 171-1172).  Figure 7.4 shows that the aMCI group 
had greater deficits (-1SD below mean) on 4 of the 9 cognitive domains (IQ, 
verbal learning, verbal recall and visuomotor speed) compared to the other 
two groups. 
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A higher percentage of subjects with aMCI (92%) and SMC (38%) 
had multiple domain deficits compared to the control group (25%), (Table 
7.19, page 180).  The aMCI group had a high percentage of subjects with 
impairments on tests of verbal learning (83%) and verbal recall (92%).  In 
comparison, 24% of the SMC group had impairments in verbal learning.  
 These findings are consistent with reports of lower global cognitive 
functioning and additional deficits beyond episodic memory in subjects with 
aMCI and those with early Alzheimer’s disease (Archer et al., 2006; Bäckman 
et al., 2004; Ribero et al., 2006; Saxton et al., 2004).  The present 
observation is in agreement with the findings of Archer et al. (2006).  Archer 
et al. (2006) examined whether symptoms of memory impairment predict 
future cognitive impairment in 21 subjects with MCI, 37 subjects with 
symptoms of memory loss but no cognitive impairment (SNCI) and 33 
healthy volunteers.  Comparable to our study, the mean age of the three 
groups was (63.6 years) and all underwent a thorough neuropsychological 
assessment.  These authors found that the MCI group could be distinguished 
from the SNCI and controls on tests of memory, at a group level, they also 
obtained lower scores on IQ, naming and executive function.  The SNCI 
differed from the control group on tests of delayed recall, ROCFT (immediate 
and delayed recall), and Trail making B test. 
Another study also found multiple cognitive deficits in subjects with 
MCI (Saxton et al., 2004).  Saxton et al. (2004) investigated cognitive 
impairment in 693 non-demented subjects (mean age=76 years) prior to 
developing Alzheimer’s disease over a mean interval of 7.4 years using a 
                                                                                                 Chapter 9 – Discussion 
__________________________________________________________________________ 
 227 
standard neuropsychological assessment battery.  After a median follow-up 
of 4.5 years, a total of 72 subjects were diagnosed with Alzheimer’s disease.  
These authors reported that whilst performance on episodic memory was 
consistently identified, this was frequently accompanied by other deficits, 
such as semantic memory and executive function.   
In so far as the results of the present study can be compared to 
previous studies, the present observation of inadequate screening for 
cognitive impairment has implications for studies that have used simple 
screening measures, such as the MMSE.  This was apparent in many studies, 
especially in those studies that used subjects with cognitive impairment 
(Crowe et al., 2006; Kim et al., 2006).  It was equally apparent in the 
diversity of cut-off scores to define cognitive impairment.  One can question 
their results based on the limited sensitivity and specificity of these testing 
methods.   
Some relevant literature examples of this are: Dufouil et al. (2005) 
examined whether SMC could predict future decline in 733 subjects (aged 59 
to 71) with baseline MMSE scores of 27.6 + 2.1, (range 18-30) and reported 
a positive association between the two.  Clearly, with such a wide range, 
many of their subjects are likely to have had dementia at baseline.   
Kim et al. (2006) also examined the association between SMC and 
cognitive decline in 686 subjects (mean age=71.0), that included 133 
subjects with MMSE scores < 21 and reported a positive association.  Once 
again, many subjects have dementia at the onset. 
Snitz et al. (2008) examined the association between SMC and 
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memory function in 276 primary care outpatients (mean age=73.2) with 
MMSE scores >19 and also found a positive association.  
Crowe et al. (2006) examined the association between SMC and 
future cognitive decline in 55 subjects with their own definition of aMCI 
(mean age=76 years) with mean MMSE scores of 26.1 and reported a 
positive association.  Amnestic MCI was identified using a psychometric 
algorithm based on a composite memory score derived from three episodic 
memory tests (two verbal learning tests and one paragraph recall subtest).  
Subjects who scored < 7th percentile on the composite memory score and 
were not impaired on composite scores for reasoning or perceptual speed 
were considered to have aMCI.  Whilst the present study used one verbal 
memory test and the presence of a memory complaint to classify subjects, 
Crowe et al. (2006) did not consider SMC to be a compulsory inclusion 
criterion.  However, similar to our study, Crowe et al. (2006) did not collect 
functional performance data.   
To complicate the issue, a wide range of cut-off scores to define 
cognitive impairment using the MMSE (e.g Dufoil et al., 2005; Geerlings et 
al., 1999; Jungwirth et al., 2008) has been used.  Thus, allowing groups with 
different cognitive abilities to be formed and compared.  For example, the 
“normal subjects” in the study by Geerlings as defined by an MMSE cut-off 
score of 26, would be considered to have “questionable impairment” 
according to the study of Jungwirth et al. (2008).  Jungwirth used an MMSE 
cut-off score of >28 to define normal cognition.  The implication of this for 
the study by Geerlings, would be that the observed differences may not be 
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valid given the likelihood that subjects with baseline MMSE scores between 
26 and 28 may well not be “normal” either the differences would disappear 
or would be relatively weakened.  Indeed, when Kim et al. (2006) excluded 
their patients with cognitive impairment (MMSE <19) the previous observed 
association between SMC and cognitive decline was weakened. 
Furthermore, whilst the outcome of studies using patients with 
objective cognitive impairment or aMCI (e.g., Crowe et al., 2006; Kim et al., 
2006) suggests they have some insight into their memory problems; they 
cannot draw conclusions regarding the role of SMC in subjects with no 
objective impairment.  By definition, aMCI is a clinical condition that involves 
objective impairment and may or may not involve subjective impairment 
depending on the criteria used (e.g. Petersen versus Winblad).  
Therefore, these findings do not provide further information on the 
role of SMC when no cognitive impairment is apparent.  However, the 
question arises as to whether it is meaningful to include subjects with 
cognitive impairment to identify differences between subjects with and 
without SMC.  The present study suggests that when cognitive impairment is 
removed from the equation SMC have limited prognostic value. 
 
9.6 Other screening tests to identify cognitive impairment  
 The present study was able to identify a number of other sensitive 
neuropsychological tests that can be used to identify cognitive impairment in 
subjects with SMC. 
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9.6.1 Delayed verbal recall 
The present study used Rey’s (1964) verbal delayed recall test to 
categorize subjects with SMC as having aMCI.  The observation of 
impairment on verbal memory in patients with an increased risk of future 
dementia due to their profile is consistent with a large body of evidence 
implicating impairment in delayed recall as a significant predictor of future 
Alzheimer’s disease. (e.g., Andersson et al., 2006; Cargin et al., 2007 and 
2008; Estevez-Gonzalez et al., 2003; Guarch et al., 2008; Saxton et al., 
2004).  Episodic memory is a highly sensitive cognitive test and its 
deterioration is characteristic of preclinical stages of a dementia syndrome of 
the Alzheimer’s type (Bäckman et al., 2004; Perri et al., 2007). 
Andersson et al. (2006) used the delayed recall test to identify 
subjects at high risk of developing Alzheimer’s disease.  These authors 
retrospectively assigned 224 subjects (mean age=61 years) to one of three 
memory groups, using their baseline results on the Delayed Recall.  These 
authors found that 84% of the subjects in the severe impairment memory 
group (defined by a delayed recall score of < 6) had significant cognitive 
deficits in memory (and at least two non-memory domains).  These included 
significant impairments in language, visuospatial function, and executive 
function and subsequently progressed to Alzheimer’s disease at a high rate 
(64%) after an interval of 3 years.   
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9.6.2 Animal naming 
The present study further identified animal naming as a simple and 
easy to use test for identifying cognitive impairment in subjects with SMC.  
Animal naming was part of the 7MS.  According to Monsch et al. (1992), 
animal naming is a highly sensitive test capable of distinguishing between 
normal controls and patients with Alzheimer’s disease.  By using published 
thresholds (<14), the task with the best sensitivity and specificity was animal 
naming.  In the present study, animal naming identified deficits in 36% of 
subjects with SMC compared to 50% of subjects with aMCI (Table 7.9, page 
158).   
  Impairment on semantic memory, especially animal naming is 
increasingly being identified in subjects with an increased risk of Alzheimer’s 
disease (Amieva et al., 2005; Hodges et al., 2006; Jorm et al., 2005b; 
Lehrner et al., 2005; Palmer et al., 2004).  Category fluency is a highly 
sensitive test (Salmon et al., 2002) showing impairment in the pre-dementia 
phase of Alzheimer’s disease (Raoux et al., 2008) and in the absence of 
other semantic deficits (Monsch et al., 1992).  Support for the use of animal 
naming as a sensitive test is provided by Hodges et al. (2006).  Hodges et al. 
(2006) examined the cognitive course of 10 patients with MCI from a 
memory clinic over a minimum period of 6 years.  Hodges et al. (2006) also 
used detailed neuropsychological assessment to examine a wide array of 
cognitive domains.  Despite the mean age difference between the study by 
Hodges et al. (2006) and the present study (72.8 and 63.1, respectively), 
these authors observed a consistent and early impairment on category 
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fluency (8 out of 10 patients) in the presence of episodic memory deficits 
within the first year of assessment.  After an interval of 10 years, all the 
patients developed Alzheimer’s disease and three were autopsy confirmed.   
Sager et al. (2006) examined the usefulness of three brief screening 
tests (Animal Naming, Clock Drawing and the MMSE) in detecting dementia 
and mild cognitive impairment in 364 subjects (aged > 50 years).  This 
group of subjects consisted of 34 normal controls; 69 patients with MCI; 140 
patients with Alzheimer’s disease and 121 with other dementia syndromes 
from a memory clinic.  By using the standard cut-off score of <24 on the 
MMSE, they were able to identify 60% of patients with dementia and 1% 
with MCI.  However, by using the recommended cut-off score <14 words per 
minute (Monsch et al., 2006); on animal naming they identified 85% of 
patients with dementia with a low (12%) false positive rate.  Similar to the 
present study, they also identified 54% of patients with MCI. 
II. Follow-up assessment 
9.7 Introduction 
 The present study employed a comprehensive neuropsychological test 
battery to examine in more detail the role of SMC on cognitive function over 
time in community-dwelling subjects, aged 50 to 79 years.  When this study 
initially commenced in 1999, SMC were only beginning to be examined (e.g., 
Geerlings et al., 1999; Jonker et al., 1996; Schmand et al., 1997; Schofield 
et al., 1997; Tobiansky et al., 1995).  Since this time, there has been a 
substantial increase in the number of longitudinal studies examining the role 
of SMC on cognitive function and Alzheimer’s disease (Cargin et al., 2008; 
                                                                                                 Chapter 9 – Discussion 
__________________________________________________________________________ 
 233 
Jungwirth et al., 2008).  As mentioned previously, a longitudinal approach is 
invaluable as it provides further information regarding the stability of any 
relationship between SMC and cognitive function observed in cross-sectional 
studies.  It is also valuable for identifying subjects in the very early stages of 
a dementia syndrome, such as Alzheimer’s disease. 
 Fifty percent (50%) of the subjects returned for a follow-up test after 
an average interval of three years.  Whilst this is considered to be a low 
follow-up response rate, these results would need to be replicated by a 
larger sample with a higher follow-up rate.  This would provide more 
substantive evidence concerning the role of SMC in relation to cognitive 
function over time.  Nevertheless, the author was interested in examining 
cognitive change over time in subjects with SMC in an attempt to identify 
early cases of cognitive impairment suggestive of Alzheimer’s disease. 
 
9.8 Subjective memory complaints 
 By analysing subjects with SMC who participated in both the initial 
and follow-up assessment, the present study was unable to demonstrate a 
significant relationship between SMC and cognitive function after an interval 
of 3 years.  The low subject number and short follow-up interval meant that 
only relationships with large effect sizes could be identified.   
The present observation of no significant relationship between SMC 
and cognitive functioning is not in accordance with results previously 
reported by others (e.g., Gallassi et al., 2008; Geerlings et al., 1999; van 
Oijen et al., 2007).  Using a similar question and time interval, Geerlings et 
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al. reported an association between memory complaints and cognitive 
decline in subjects with normal baseline cognition.  One of the major 
differences between these two studies, which likely explain the inconsistency 
between these two studies, was the sample size.  The sample size in the 
present study was 43, while the sample size in the study by Geerlings et al. 
was 2169. It is likely that the current study’s relatively small sample of 
subjects did not provide sufficient statistical power to demonstrate this 
association or the effect is of a small magnitude between memory 
complaints and cognitive decline or Alzheimer’s disease among subjects.  
However, whilst many studies support a relationship between SMC 
and cognitive decline (e.g., Jungwirth et al., 2008; van Oijen et al., 2007; 
Gallassi et al., 2008), several studies are discordant with these reports (e.g., 
Cargin et al., 2008; Mol et al., 2006).  Mol et al. (2006) examined the 
association between SMC and cognitive function in 557 healthy subjects 
(mean age=67.7) with baseline MMSE scores >24.  On baseline testing, 
these authors reported an association between SMC and lower scores on 
both the information processing speed task and delayed recall task.  
However, over a mean interval of six years and after controlling for baseline 
MMSE scores, SMC was no longer associated with change in cognitive 
function in subjects with and without SMC.  Rather, these authors observed 
that SMC had stronger associations with symptoms of depression and 
anxiety than to cognitive decline.   
The discrepant findings are likely due to the difference in sample size 
between the study by Mol et al. (2006) and the present study (n=557 and 
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n=46, respectively).  However, the differences are also likely to be due to 
the different methods used to measure SMC.  Although, Mol et al. (2006) 
used a single question to measure SMC, subjects that were not worried or 
hindered by their forgetfulness were excluded.  This resulted in the exclusion 
of 78 subjects that may have developed cognitive decline at follow-up. 
 
9.9 Cognitive change in subjects with SMC and aMCI 
Hypothesis 3: Subjects with SMC will demonstrate evidence of worsening 
cognitive function over a 3-year interval. 
 
9.9.1 Brief screening tests 
The present study was able to show evidence of worsening cognitive 
function over time in subjects with aMCI on two brief screening tests (7MS 
and DRS; Tables 8.3 and 8.4, pages 190 and 192).  Moreover, the aMCI 
group showed greater decline on the 7MS total score and two subtests; 
animal fluency and enhanced cued recall.  Interestingly, compared to the 
aMCI group, the SMC group obtained significantly higher scores on the 7MS 
total score, verbal fluency as well as temporal orientation.  The fluctuating 
course associated with the SMC group is a common finding (Glodzik-
Sobanska et al., 2008) and a major cause for concern due to its inclusion in 
the criteria for MCI (Mitchell, 2008a and 2008b).  The time frame for 
memory complaints to evolve into significant cognitive impairment has been 
estimated to take at least 7 years (Reisberg et al., 2008).   
The present observation of decline on animal fluency and enhanced 
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cued recall in subjects with aMCI is consistent with the findings of Howieson 
et al. (2008).  Howieson et al. (2008) examined the clinical and 
neuropsychological predictors of MCI and dementia in 156 cognitively intact, 
community dwelling older subjects (mean age=83 years).  Mild cognitive 
impairment was defined as two consecutive observations with a CDR > 0.5.  
Despite the difference in the mean follow-up interval between the two 
studies (7 years and 3 years, respectively), these authors found statistically 
significant cognitive loss at least 3 to 4 years prior the diagnosis of MCI on 
tests of verbal memory, animal fluency as well as visuospatial constructions.  
These findings are consistent with a large body of evidence implicating 
multiple cognitive domain deficits in the evolution towards Alzheimer’s 
disease (Bäckman et al., 2004; Fleisher et al., 2007).  It is possible that 
these impairments represent a stage of early cognitive decline suggestive of 
Alzheimer’s disease but requires a large sample, sufficient follow-up interval 
to illustrate this change and a formal baseline assessment of dementia. 
 
9.9.2 Neuropsychological tests  
The present study did not find the predicted change in cognitive 
function over time in subjects with SMC and aMCI.   The analysis of change 
over time examining cognitive domains showed that the majority of subjects 
(both SMC aMCI) either remained stable or improved their cognitive 
performance (Table 8.12, page 199).  The SMC group had significantly 
higher scores on intellectual functioning, working memory, verbal learning, 
verbal recall and verbal ability.  The aMCI group had significantly higher 
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scores on intellectual functioning and verbal learning.  Although these 
changes are significant, closer inspection of the data shows the change was 
only .05 SD below the mean.   
However, in interpreting these findings, one must keep in mind the 
low sample size and short follow-up interval of the present study.  It is likely 
that these factors contributed to the present observation of no change in 
cognitive function over time.  As larger studies using longer follow-up 
intervals have supported significant cognitive decline in subjects with SMC 
and aMCI (e.g., Gallassi et al., 2008).   
Gallassi et al. (2008) examined the clinical and neuropsychological 
predictors of no cognitive impairment and MCI according to the criteria of 
Winblad et al. (2004) in 92 non-demented outpatients (mean age=67.4; 
SD=10.4).  After an interval of 9 months, these authors found that self-
reported SMC, measured with the Memory Assessment Clinic Questionnaire 
predicted MCI in 49 subjects with SMC.  The high percentage (53%) of 
subjects who declined might be explained by the source of recruitment.  The 
subjects in the Gallassi et al. (2008) study were recruited from a tertiary 
setting and were likely to be more impaired.  Additionally, despite the 
differences in sample sizes between the present study and Gallassi et al. 
(2008) (n=43 and n=92, respectively) the two aMCI groups shared similar 
demographic features.   
It is important to emphasize that although the subjects in the aMCI 
group in the present study did not decline on follow-up testing, they failed to 
show improvement across a range of neurocognitive tests.  The lack of 
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improvement upon retesting has been noted by others as a diagnostically 
useful finding (Galvin et al., 2005).  Galvin et al. (2005) identified 
histopathologic AD in one-third (34%) of their patients who did not have 
dementia at death and did not show improvement on tests of episodic and 
semantic memory upon retesting.  These authors suggested that the 
cognitive impairment that preceded preclinical Alzheimer’s disease is clinically 
indistinguishable from subjects without dementia, except for the observation 
of a lack of improvement upon retesting. 
In reconciling this conflicting finding, it is important to remember that 
this may have occurred because of the small sample size.  Another issue 
relevant to this study appears to be the fluctuating course frequently 
associated with SMC and that screening tests lack the sensitivity to capture 
this.  This is evident as by the better performance of the SMC group on the 
7MS compared to the aMCI group’s decline in performance on this test. 
Essentially, a full neuropsychological evaluation is the current gold standard 
of cognitive performance and is more reliable compared to the results on the 
screening tests which produce more false positives and false negative 
results. 
 
9.10 The role of age on SMC and cognitive functioning 
A further interesting observation is shown in Figure 8.5 (page 206), 
which shows that age remains a strong predictor of cognitive functioning, 
especially for those over the age of 70 years, irrespective of cognitive status.  
However, closer inspection of Figure 8.5 clearly shows that subjects with 
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cognitive impairment (e.g., aMCI) have a steeper decline in cognitive 
function from the age of 70 onwards.  Also, subjects with SMC aged between 
60 and 65 years begin to show deficits in at least 2 cognitive domains.  This 
suggests a potential point for early intervention by identifying individuals at 
risk of developing Alzheimer’s disease at an earlier age. 
The observation of a more rapid decline in cognitive function in older 
subjects with either SMC or aMCI is consistent with several studies (Crowe et 
al., 2006; Gallassi et al., 2008; Wang et al., 2004a).  Crowe et al. (2006) 
examined the relationship between SMC and cognitive decline in subjects 
with baseline aMCI (mean age=74 years).  In this study, SMC was not a 
compulsory inclusion criterion.  However, subjects with baseline SMC had a 
statistically significant decline on MMSE scores. 
 
9.11 The apolipoprotein ε4 (ApoE ε4) allele 
Hypothesis 4: Subjects with SMC and the ApoE e4 allele will show evidence 
of worsening cognitive function over time. 
The present study was unable support a role of the ApoE ε4 in 
cognitive change for carriers of the ApoE ε4 allele.  Carriers of the ApoE ε4 
allele did not have a larger magnitude of cognitive decline on follow-up 
assessment as demonstrated by the general stability of the groups (Figure 
8.6, page 208).  The analysis showed that ApoE ε4 status had no affect on 
the multiple regression and similar correlations were found between age and 
number of impaired domains and ApoE ε4 groups (Figure 8.6).  In most 
cases performance improved or remained stable on retesting regardless of 
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ApoE ε4 genotype.  However, this observation is limited by the small sample 
size (n=43).  The ApoE ε4 allele is associated with a very small effect size 
and very large samples are required to find associations.  
Whilst we were unable to show a significant effect of the ApoE ε4 
allele on cognitive function, several studies using larger sample sizes provide 
support for a role of the ApoE ε4 on cognitive function  (Caselli et al., 2004; 
Christensen et al., 2008; Estevez-Gonzalez et al., 2004; Fliesher et al., 
2007). 
 Caselli et al. (2004) investigated memory loss in 180 cognitively 
normal community subjects (mean age=60 years) with ApoE ε4 allele prior 
to the onset of MCI.  After an interval of 33-months, carriers of the ApoE ε4 
had poorer performance on multiple measures of verbal memory tests 
including (total score on Auditory Verbal Learning Test (AVLT); delayed 
recall; and Selective Reminding Test (SRT), free and cued recall) compared 
to non-ApoE ε4 carriers.  Additionally, these authors reported that carriers of 
the ApoE ε4 aged between 50 to 59 showed greater declines on the AVLT 
delayed recall, SRT free and cued recall, and Complex Figure Test.  This 
study suggests that prior to the onset of MCI or dementia, ApoE ε4 carriers 
show a modest decline in memory skills commencing from the age of 50 
onwards. 
 Similarly, Christensen et al. (2008) also reported that ApoE ε4 carriers 
have a greater vulnerability to cognitive decline in the presence of other risk 
factors at the age of 65-69 years.  These authors showed that after an 
interval of 4-years, significant effects of the ApoE ε4 on cognitive decline 
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occurred on the MMSE and Symbol-Digit Modalities test, after controlling for 
risk factors, such as previous head injury or low education.   
However, not all studies provide support for a role of the ApoE ε4 in 
cognitive function (Fliesher et al., 2007).  Fliesher et al. (2007) examined 
predictors of Alzheimer’s disease in 539 patients (aged between 55-90 years) 
with aMCI recruited from a clinical drug trial study.  All patients received 
comprehensive assessment.  Fliesher et al. (2007) observed that progression 
from aMCI to Alzheimer’s disease was best predicted by a combination of 
ApoE status and cognitive domain testing (being delayed episodic recall, 
executive functioning and a composite measure of global cognition).  These 
authors observed that the inclusion of the ApoE ε4 in their model did not 
enhance the prediction of Alzheimer’s disease above that predicted by tests 
of memory and executive functioning.   
 
9.12 Methodological limitations 
Results from the present study must be considered in light of several 
important methodological limitations.  Each of these is addressed below: 
 
Experimental tests 
 Firstly, it is important to recognise that performance on each test and 
differences between groups might also be caused or attenuated by 
situational factors.  It is likely that the experimental situation itself, 
particularly anxiety associated with neuropsychological assessment, produces 
stress in individuals, which may influence cognitive function.  The 
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neuropsychological interview was rather demanding in nature and would 
have induced a certain degree of stress, possibly compromising subjects’ 
performance.  This issue would be more pertinent for the initial assessment 
due to unfamiliarity with the experimental situation.  
 
Sample Size and follow-up response rate 
The cross-sectional subject number was relatively small (n=86).  Such 
a small sample size may result in subtle differences between groups being 
overlooked.  The differences detected between the SMC and aMCI groups 
might have become statistically significant with larger study numbers. 
The follow-up response rate was equally low (n=43).  This limited the 
potential of addressing the important issue of whether SMC are associated 
with cognitive decline over time.  Relatively smaller subject numbers may 
result in subtle differences between groups being lost.  Differences detected 
between the SMC and aMCI groups might have become statistically 
significant with larger study numbers. 
The time interval between testing may have contributed to the low 
follow-up response rate.  It is likely that a yearly assessment would have 
increased the follow-up response rate.  Thus, the small sample size and low 
follow-up rate limits the generalisation of these findings to other populations.  
Replication using a larger sample size and follow-up response rate (>85%) is 
required before more definitive conclusions can be drawn. 
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Amnestic Mild Cognitive Impairment (aMCI) classification 
Another consideration for the implication of the present results was 
the classification of aMCI.  The present classification of aMCI was based on a 
test of delayed recall (Rey, 1984), rather than a clinically based diagnosis.  It 
was also based on the presence of a memory complaint by self-report, 
normal orientation, apparent adequate social functioning within the 
community and no evidence of longitudinal cognitive decline was collected.  
Also, no functional data were collected.   
Whilst it is not unusual for different authors to modify aspects of the 
criteria (e.g., Crowe et al., 2006), in large scale studies it is important to 
collect this information before assigning a classification, such as aMCI 
(Winblad et al., 2004).  Consequently, the results should be interpreted with 
caution. 
To minimise the possibility that subjects had a dementia syndrome, 
exclusion criteria were applied.  Based on the subjects’ cognitive testing, 
there was evidence of mild cognitive impairment.  The exclusion criteria for 
the study made it unlikely that subjects classified as having aMCI had a 
dementia syndrome.   
Additionally, the term MCI could have been used to refer to the 
subjects with aMCI, however the candidate chose to use the term aMCI 
because of its association with progression to Alzheimer’s disease (Guarch et 
al., 2008). 
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Medical History 
Another feature that could possibly be confounding the present 
conclusion is that no medical illness data were collected (e.g., 
hypothyroidism, vitamin B12 deficiency), and there was limited coverage of 
past psychiatric history (e.g., delirium).  It is important to exclude this 
information as SMC or cognitive impairment may be a consequence of an 
underlying medical or psychiatric illness.  However, the aforementioned 
medical problems still remain a relatively rare cause of overall significant 
dementia level cognitive impairment.  Additionally, subjects with delirium are 
usually acutely unwell and would be unlikely to present and attend for the 
lengthy (several hours) process of our neuropsychological assessment. 
However, prior to entry into the study, the candidate made a 
reasonable attempt to exclude subjects whose complaints were likely to have 
been due to current medical, psychiatric or drug and alcohol issues.   
It would have been ideal to have had a full psychogeriatric 
assessment (by a medical specialist) to exclude depressive syndromes, 
delirium and relevant medical illnesses on all subjects.  However, this was 
logistically not possible for the present community-based study.  Importantly 
since MCI is relatively new field of enquiry (having evolved over the past 10 
years) it is unclear whether medical illness, in the absence of delirium, is a 
cause of cognitive impairment. 
 
 
 
                                                                                                 Chapter 9 – Discussion 
__________________________________________________________________________ 
 245 
Selection bias 
 The participants in the present study were a volunteer sample who 
selected themselves for participation in response to an advertisement.  The 
voluntary nature of the study sample may have resulted in recruiting 
subjects who were healthier than those in the general population.  Thus, the 
study sample is not representative of the general population and this limits 
the generalization of the results.  
 Furthermore, subjects who returned for a follow-up test did not differ 
from subjects who did not return for a follow-up test (Table 8.1, page 187). 
 
Practice effects 
 The importance of the practice effect is likely to be minimal given the 
somewhat lengthy interval between testing and re-testing. 
 
Major Depression 
 Considering the age range of the sample (50 to 79 years), the 
decision to use two depression scales for geriatric populations was 
unfortunate.  A more suitable self-rating scale of depression such as the 
Beck Depression Scale or Hospital and Anxiety Depression Scale would have 
been a better choice given the large number of middle-aged subjects.  It is 
noteworthy that a high inter-correlation has been reported between the 
Geriatric Depression Scale and the Beck Depression Scale (Bass et al., 2008) 
and both are valid and reliable tools to screen for depression. 
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Subjective memory complaints 
 Firstly, instead of being spontaneously referred, the SMC was elicited 
by a flyer.  This may have encouraged some subjects to complain, 
consequently influencing differences between complainers and non-
complainers in the cognitive testing. 
 Whilst it is preferable to have corroborative evidence about short-term 
memory from a reliable informant (e.g., spouse) (Winblad et al., 2004), this 
was not possible in the present study as it did not include carers or family 
members. 
It would have been of great interest to collect information on SMC at 
follow-up and not only on baseline assessment”.  Kim et al. (2006) identified 
that subjects with SMC at baseline and follow-up had a 4.8 times greater risk 
of dementia compared to a risk of 2.3 times in subjects who had SMC only at 
baseline.  Kim et al. (2006) also found that dementia was not associated 
with new complaints at follow-up.  Therefore, whilst SMC may persist or 
disappear at follow-up, this suggests that baseline memory complaints carry 
more weight in determining dementia, especially when present at both 
points.  It also suggests that SMC that is no longer present at follow-up may 
have been related to anxiety.  Nevertheless, collecting information on SMC at 
both baseline and follow-up is an important consideration for future studies. 
A potentially confounding effect in the present study is the lack of 
measurement of traits such as stress, anxiety and personality factors.  
Research has shown that psychoaffective factors can influence the subject’s 
perception of their memory and lead to an overestimation of cognitive 
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difficulties.  Indeed, studies show that SMC are more related to factors such 
as depression than to cognitive impairment (Cargin et al. 2008).  However, 
in contrast to some studies (Kumar et al., 2006), none of the aMCI subjects 
in the present had mild depressive symptoms based on their PAS or GDS 
scores”.  Nevertheless, the possibility remains that persons that are 
concerned about their memory to the extent they respond to an 
advertisement are likely to have an anxiety disorder.  Thus, due to the lack 
of appropriate measurements the results need to be interpreted with 
caution. 
 
The Mini- Mental State Examination 
 Considering the extensive nature of the assessment, the MMSE was 
considered redundant, because the majority of the questions within the 
MMSE were in the neuropsychological test battery.  The decision not to 
include the MMSE was unfortunate, because this would have facilitated 
further comparison between studies using the MMSE and the two screening 
tools (7MS; DRS) in identifying cognitive impairment. 
 
The apolipoprotein ε4 (ApoE ε4) allele 
 The lack of association between ApoE ε4 and change in global 
functioning between assessments may be attributed to several factors.  Only 
one subject had a ε4/ε4 genotype which is associated with the largest 
effects of ApoE.  A large sample size of over 1000 subjects would be 
required to recruit a sufficient number of ε4/ε4 carriers to demonstrate a 
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more rapid decline in cognitive functioning based on ApoE genotyping.   
 
Alzheimer’s disease 
 The present study set out to investigate the relationship between SMC 
and cognitive impairment; it did not set out to determine the aetiology of the 
cognitive impairment.  Certainly, whilst the profile of impairment observed in 
subjects with aMCI was generally consistent with that observed in the 
literature, the conclusions are limited by the lack of sufficient medical, 
psychiatric and functional data.  Thus, other causes for the cognitive 
impairment cannot be ruled out. 
 Moreover, Alzheimer’s disease is the most common cause of 
substantive cognitive impairment in non-depressed community samples 
(Brookmeyer et al., 2007). 
  
9.13 Clinical significance and future directions 
 The current findings have clinical, as well as research implications for 
early case detection using SMC.  Firstly, the present findings suggest that in 
isolation, SMC are unlikely to be useful for identifying cases with significant 
cognitive impairment.  This is particularly relevant for younger subjects 
under the age of 70 years.  However, for subjects over the age of 70 years, 
SMC are likely to identify significant cases with neuropsychological 
assessment (such as animal fluency and delayed recall).   
 Secondly, it seems that a combination of SMC and neuropsychological 
assessment (especially cognitive domain tests, such as delayed recall and 
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animal fluency) is likely to be more effective in screening community 
subjects for dementia and identifying those who would benefit from further 
neuropsychological assessment.  It is not economically feasible to provide 
frequent full neuropsychological evaluations to a large proportion of the 
population who complain about their memory without objective evidence of 
cognitive impairment.  This approach can also be useful for monitoring at-
risk individuals. 
Therefore, based on the available evidence within the dissertation, the 
following information may be helpful to the clinician.  Further 
neuropsychological investigation is warranted in patients with all the 
following characteristics: aged over 65 years, a memory complaint 
(preferably an informant, e.g., spouse or GP) and is currently residing within 
the community.  The best tests to screen the individual would be the delayed 
recall (RAVLT) and the animal naming test.  Poor performance on both of 
these tests as indicated by the cut-offs coupled with a memory complaint 
would warrant further investigation. 
Thirdly, as dementia (and in particular Alzheimer’s disease) is 
reaching epidemic proportions in Australia (Jorm, 2005), it is of interest to 
identify individuals in the earliest stage of dementia or when symptoms first 
appear to test potential disease modifying therapies (Cummings et al., 
2007).  This could provide crucial opportunities for early intervention and 
treatment of these individuals.  It could also potentially reduce the significant 
costs associated with caring for patients with Alzheimer’s disease. 
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 Considering the complex array of factors that may be related to 
memory complaints, (e.g., depression, anxiety, personality), future research 
should identify ways of quantifying SMC that are free of psychological 
conditions.  This could be achieved by developing questions that are 
sensitive to different underlying aetiologies.   
 Prevention is the best cure for Alzheimer’s disease.  In order to help 
identify those at the greatest risk of developing dementia, easy to administer 
tools (in particular animal fluency) that could be completed by a general 
practitioner within a few minutes would be a worthwhile.  This could be done 
quite quickly in combination with the MMSE.  Several recent studies 
(Scarmeas et al., 2006; Lautenschlager et al., 2008) have advocated the 
beneficial effects of diets and moderate exercise in improving cognitive 
function and potentially reducing the risk of developing dementia.  These 
measures may have significant benefit in reducing the number and severity 
of AD cases within the community.  In particular, the earlier identification of 
those at risk of AD or actual early cases of AD would likely represent a group 
who would be better treatment responders. 
 
9.14 Final conclusions 
 Whilst the notion of a relationship between SMC and cognitive 
function seems intuitively appealing, there has been ongoing controversy 
regarding the precise role of SMC in cognitive function.  The present study 
was a quantitative attempt to clarify this relationship.  In pursuing this line of 
inquiry, this study has provided some valuable information regarding the 
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clinical utility of using SMC to identify individuals at risk of developing 
cognitive impairment suggestive of Alzheimer’s disease within the 
community. 
By addressing some of the methodological issues in previous studies 
(such as, the use of predominantly older subjects, limited cognitive testing), 
the present study demonstrated that SMC used in isolation is a poor 
predictor of cognitive function, especially in younger subjects (i.e., < 70 
years). 
The present study provides evidence that selected and relatively quick 
to administer formal neuropsychological assessment of cognitive function (in 
particular tests of animal fluency and delayed recall) can better identify those 
at risk of developing future Alzheimer’s disease compared to current brief 
testing strategies (often only using the MMSE alone).  This combination of 
cognitive domain testing and risk profile (e.g., age, SMC) could be used to 
identify individuals at risk of developing Alzheimer’s disease at an earlier age, 
thus exposing a cohort with likely better treatment responsiveness. 
 Future (hopefully more efficacious) treatment strategies would be 
targeted at these individuals resulting in a major alleviation in the current 
substantial public health expense of Alzheimer’s disease. 
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 A1 
Appendix 
BRIEF TELEPHONE SCREENING INTERVIEW 
1. Do you have a problem with your memory? 
2. Are you over 50 years of age? 
3. Do you have a family history of Alzheimer’s disease? 
4. Have you ever been hospitalised for a psychiatric illness? (e.g. 
depression) 
5. Have you ever had a stroke? 
6. Have you ever had an automobile accident? 
7. Have you ever had a drug problem? 
8. Have you ever had to go into detoxification? 
- how many drinks do you have a day? 
- have you ever blacked out? 
- has anyone ever told you that you have a drinking problem? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                              
 
 A2 
DEMOGRAPHIC INFORMATION 
 
 
Questions Response 
1. What is your name?  
2. What year were you born in?  
3. How old are you?  
4. What country were you born in?  
5. Sex of subject  
6. Age when left school  
7. Years of education  
8. Highest level of education attained?  
9. Occupational background  
10. Do you have a family history of 
Alzheimer’s disease? 
 
11. If yes to (10.) who?  
12. Are you currently taking any 
medication? 
 
If yes to (12.) what medication?  
 
                                                              
 
 A3 
STROKE SCALE 
Have you ever had or been told that you had: 
S1. A stroke? 
 No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
S2. A series of mini-strokes or transient ischaemic attacks (or TIAs)? 
No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
Have you ever: (include present condition in recording responses) 
S3. … had a sudden weakness on one side which got better? 
 No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
S4. … had a sudden difficulty with speaking? 
No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
S5. … had a sudden severe difficulty with your vision? 
No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
S6. … had a sudden severe difficulty with your memory? 
No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
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DEPRESSION SCALE (PAS) 
Have you ever had or been told that you had: 
D1. In the last two weeks, have you been feeling depressed or sad at all?  
 No …………………………………………………………………………… 0 
 Depends on situation ………………………………………………….  0 
 Yes ………………………………………………………………………….. 1 
 Does not know ………………………………………………………….. ? 
D2. Have you had trouble sleeping over the past 2 weeks? 
No …………………………………………………………………………… 0 
 Depends on situation ………………………………………………….  0 
 Yes ………………………………………………………………………….. 1 
 Does not know ………………………………………………………….. ? 
D3. In the past two weeks, have you been taking anything to help you sleep? 
 No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
D4. In the last two weeks, have you been worn out or had too little energy, 
even when you haven’t been doing a lot? 
No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
D5.  In the last two weeks, have you talked or moved more slow ly than is 
normal for you? 
No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
 Does not know …………………………………………………………. ? 
 
D6. In the last two weeks, have you had to be moving some part of your  
body all the time – that is, you were so restless you couldn’t sit still?  
No …………………………………………………………………………… 0 
 Yes ………………………………………………………………………….. 1 
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 Does not know …………………………………………………………. ? 
 
D7. In the past tw o w eeks, how  frequently have you felt lacking in self-
confidence or felt inadequate? 
No …………………………………………………………………………… 0 
 Depends on situation ………………………………………………….  0 
 Yes ………………………………………………………………………….. 1 
 Does not know ………………………………………………………….. ? 
 
Now I’d like to ask you about your thinking. 
D8. In the last two weeks, has your thinking been much slower than usual? 
No …………………………………………………………………………… 0 
 Depends on situation ………………………………………………….  0 
 Yes ………………………………………………………………………….. 1 
 Does not know ………………………………………………………….. ? 
 
D9. In the last two weeks, have you had trouble concentrating? 
No …………………………………………………………………………… 0 
 Depends on situation ………………………………………………….  0 
 Yes ………………………………………………………………………….. 1 
 Does not know ………………………………………………………….. ? 
 
D10. In the last tw o weeks, do your thoughts seem to get mixed up that you 
cannot get them sorted?  
No …………………………………………………………………………… 0 
 Depends on situation ………………………………………………….  0 
 Yes ………………………………………………………………………….. 1 
 Does not know ………………………………………………………….. ? 
 
D11. In the last two weeks, have you had difficulty making decisions? 
No …………………………………………………………………………… 0 
 Depends on situation ………………………………………………….  0 
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 Yes ………………………………………………………………………….. 1 
 Does not know ………………………………………………………….. ? 
 
As they get older, some people find their thoughts turning to death more 
than in earlier life. 
 
D12. In the last two weeks, have you felt as if you wanted to die?  
No …………………………………………………………………………… 0 
 Depends on situation ………………………………………………….  0 
 Yes ………………………………………………………………………….. 1 
 Does not know ………………………………………………………….. ? 
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GERIATRIC DEPRESSION SCALE (SHORT FORM) 
 
 
1. Are you basically satisfied with your life?    Yes No 
2. Have you dropped many of your activities or interests?  Yes No 
3. Do you feel that your life is empty?     Yes No 
4. Do you often get bored?      Yes No 
5. Are you in good spirits most of the time?    Yes No 
6. Are you afraid something bad is going to happen to you? Yes No 
7. Do you feel happy most of the time?    Yes No 
8. Do you often feel helpless?      Yes No 
9. Do you prefer to stay home, rather than go out and do 
 new things?       Yes No 
10. Do you feel that you have more problems with memory 
 than most?       Yes No 
11. Do you think that it is wonderful to be alive now?  Yes No 
12. Do you feel pretty worthless the way you are now? Yes No 
13. Do you feel full of energy?     Yes No 
14. Do you feel that your situation is hopeless?   Yes No 
15. Do you think that most people are better off than you are?Yes No 
 
Depression Score:         /15 
Code answers as Yes or No; Score one point for “No” to question 1, 5, 7, 11, and 13 
Score one point for “Yes” to other questions. 
3 ± 2 = normal 
7 ± 3 = mildly depressed 
12 ± 2 = very depressed 
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REY-OSTERRIETH COMPLEX FIGURE TEST 
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7 MINUTE SCREEN 
 
ORIENTATION 
TEST 
Correct 
Answer 
Patient 
Response 
Scoring System Score 
MONTH 
(Ask: What month us 
it now?) 
  5 points for each 
month off 
(max. score = 30) 
 
DATE 
(Ask: What is today’s 
date?) 
  1 point for each 
date off 
(max. score = 15) 
 
YEAR 
(Ask: What year is 
it?) 
  10 points for each 
year off 
(max. score = 60) 
 
DAY OF THE WEEK 
(Ask: What day of 
the week is it?) 
  1 point for each 
day off 
(max. score = 3) 
 
TIME 
(Ask: What time is it 
now?) 
  5 points for each 
30 minutes off 
(max. score = 5) 
 
 
 
    
Score 
Total (sum of all 5 scores; maximum = 113) 
Insert the current month, date, year, day of the week, and time 
If the patient does not respond or responds “I don’t know”, encourage him or her to guess.  
If he or she will not guess, give the maximum score for that question 
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ENHANCED CUED TEST SCORE SHEET 
 
MEMORY TEST SCORE SHEET 
            Delayed Recall 
Category Word Uncued Cued Score 
Piece of fruit Grapes    
Animal Tiger    
Body part Foot    
Piece of furniture Desk    
Tool  Screwdriver    
Article of clothing Shoe    
Musical instrument Guitar    
Type of vehicle Motorcycle    
Toy Top    
Vegetable Tomato    
Insect Spider    
Kitchen utensil Pot    
Ship Sailboat    
Part of a building Door    
Bird Eagle    
Weapon Cannon    
 
     Total Recall     ________ +________ = _______ 
 
Scoring Instructions 
1. Total the number of uncued responses 
2. Total the number of cued responses 
The sum of the cued plus uncued responses is the score 
(maximum = 16) 
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CLOCK DRAWING 
 
SAY: “I want you to draw the face of a clock with all the numbers on it.  
Make it large.” 
 
After the patient has drawn the face of a clock,  
SAY: “Now draw the hands, pointing at 20 minutes before 4 o’clock” 
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ANIMAL FLUENCY 
 
SAY: “I will say a category name.  Then I want you to give me as many words that fit in 
that category as quickly as you can.  For instance, if I say vegetables, you might give me 
corn, spinach, lettuce, etc.  Any questions” 
SAY: “Begin when I name the category.  The category is animals.  Go ahead” 
Allow 60 seconds for this test 
Make a check mark [√] for each correct response in the lines below.  Each check [√] = 1 
point. 
 
1. ______________  16. ______________ 31. ______________ 
2. ______________  17. ______________ 32. ______________ 
3. ______________  18. ______________ 33. ______________ 
4. ______________  19. ______________ 34. ______________ 
5. ______________  20. ______________ 35. ______________ 
6. ______________  21. ______________ 36. ______________ 
7. ______________  22. ______________ 37. ______________ 
8. ______________  23. ______________ 38. ______________ 
9. ______________  24. ______________ 39. ______________ 
10. ______________ 25. ______________ 40. ______________ 
11. ______________ 26. ______________ 41. ______________ 
12. ______________ 27. ______________ 42. ______________ 
13. ______________ 28. ______________ 43. ______________ 
14. ______________ 29. ______________ 44. ______________ 
15. ______________ 30. ______________ 45. ______________ 
 
 
 
Scoring: Record the number of the last  
line checked in the score box 
  
 
 
Score 
 
                                                              
 
 A13 
VERBAL FLUENCY 
DIRECTIONS: I will say a letter of the alphabet.  Then I want you to give me as many 
words that begin with that letter as quickly as you can.  For instance, if I say ‘B’ you might 
give me ‘bad’, ‘battle’, ‘bed’… I do not want you to give me words that are proper names 
such as ‘Brisbane’, ‘Bob’, or ‘Brycreem’ and no numbers.  Also do not use the same word 
again with a different ending such as ‘rain’, ‘rained’, and ‘raining’. 
 
Any questions? (Pause) 
 
Begin when I say the first letter.  The first letter is ‘F’.  Go ahead. 
 
Allow 1 minute for each letter (F, A and S).  Say Fine or Good after each 1 minute 
performance  
 
 
 
F 
 
A 
 
S 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total: 
 
Total: 
 
Total: 
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TRAIL-MAKING A TEST 
Please connect the numbers in ascending order starting with number 1. 
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TRAIL-MAKING B TEST 
Please connect the circles in the following order: start at one and then draw 
a direct line to the circle marked “A”; then draw a line to the circle marked 
“2”, then connect to B, as so forth until you reach the last circle marked 13.  
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MATTIS DEMENTIA RATING SCALE  DRS 
Scoring Form   Steven Mattis 
Name                                         Age  Sex Date 
Occupation                            Education   
Diagnosis    
 
Scale 
Raw Score Cut-off 
SDAT Sample 
% ile    T Score 
Attention    
Initiation/Perseveration    
Construction    
Conceptualization    
Memory    
DRS TOTAL SCORE    
Constitution and scores of the five subtests: 
Attention subtest 
 Digit span (forwards and backwards) 
 Two-step commands 
 One-step commands 
 Imitation of commands 
Initiation subtest 
 Fluency for supermarket items 
 Fluency for clothing items 
 Verbal repetition (e.g. bee, key, gee) 
 Double alternating movements 
 Graphomotor (copy alternating figures) 
Construction subtest 
 Copy geometric designs 
Conceptualization subtest 
 Similarities 
 Inductive reasoning 
 Detection of different item 
 Multiple choice similarities 
 Create a sentence 
Memory subtest 
Orientation (e.g. date, place)  
Counting of A’s 
 Counting randomly arranged A’s 
Recall a sentence 
 Recall a self-generated sentence 
Read a word list 
 Verbal recognition  
 Figure recognition 
 Match figures 
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NATIONAL ADULT READING TEST (NART) 
 
 Errors   Errors 
Chord   Superfluous   
Ache   Simile  
Depot   Banal  
Aisle   Quadruped  
Bouquet   Cellist  
Psalm   Facade  
Capon   Zealot  
Deny   Drachm  
Nausea   Aeon  
Debt   Placebo   
Courteous   Abstemious  
Rarefy   Détente  
Equivocal   Idyll  
Naïve   Puerperal  
Catacomb   Aver  
Gaoled   Gauche  
Thyme   Topiary  
Heir   Leviathan  
Radix   Beatify  
Assignate   Prelate  
Hiatus    Sidereal  
Subtle   Demesne  
Procreate   Syncope  
Gist   Labile  
Gouge   Campanile  
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MENTAL CONTROL (WMS-R) 
 
1. Directions: Months Backwards (Time limit 76 seconds).  Say, I want to see 
how quickly you can remember the months of the year backwards from 
December to January, like this – December, November – all the way back to 
January. 
Repeat the directions if necessary, but give no aid during the examinee’s 
effort. 
Record the time in seconds 
 
Dec Nov Oct Sept Aug Jul Jun  
May Apr Mar Feb Jan     _____ _____ 
 
Note: Months Backwards was used as a distracter task and was not scored. 
 
2. Directions: Serial 7’s (Time limit 76 seconds).  Say, Now I want you to 
subtract 7 from 100, and then subtract 7 from the answer you get, and keep 
subtracting 7 until I say stop. 
Repeat the directions if necessary, but give no aid during the examinee’s 
effort. 
Record the time in seconds 
 
100 93 86 79 65 58 51 44     _____ _____ 
37 30 23 16 9 2 
 
Scoring: Give 2 points if completed in time limit, and subtract one point for 
each error.  Maximum 2, /Minimum 0 
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DIGIT SPAN (WAIS-R) 
DIRECTIONS: (Digits Forward) Start with Item 1. Say, 
I am going to say some numbers.  Listen carefully, and when I am through say them right 
after me.  The digits should be given at the rate of one per second.  Let the pitch of voice 
drop on the last digit of each trial.  Administer both trials of each item, even if the subject 
passes Trial 1. 
Item 1 example 2-7-5 
 
DIRECTIONS: (Digits Backward) Say,  
Now I am going to say some more numbers, but this time when I stop I want you to say 
them backwards.  For example, if I say 7-1-9, what would you say? (Pause for examinee) 
If the examinee responds correctly (9-1-7), say, That’s right, and proceed to Trial 1 of Item 
1.  Say, Now listen to these numbers, and remember you are to say them backwards. 
 
However, if the examinee fails the example, say, No, you would say 9-1-7.  I said 7-1-9, so 
to say it backwards you would say 9-1-7.  Now try these numbers.  Remember, you are to 
say them backwards, 3-4-8.  Give no help on this second example or any of the items that 
follow.  Whether the examinee succeeds or fails with the second example (3-4-8), proceed 
to Trial 1 of Item 1. 
*Discontinue after failure on both trials of any item 
 
Forward         (0,1,2) 
   (0,1)     (0,1) 
1.   5-8-2  ____  6-9-4   ____  ____ 
2.   6-4-3-9  ____  7-2-8-6   ____  ____ 
3.   4-2-7-3-1  ____  7-5-8-3-6  ____  ____ 
4.   6-1-9-4-7-3  ____  3-9-2-4-8-7  ____  ____ 
5.   5-9-1-7-4-2-8 ____  4-1-7-9-3-8-6  ____  ____ 
6.   5-8-1-9-2-6-4-7 ____  3-8-2-9-5-1-7-4  ____  ____ 
7.   2-7-5-8-6-2-5-8-4 ____  7-1-3-9-4-2-5-6-8 ____  ____    
                  Forward Span  ____ /9        Total Forward  ____ /14 
 
Backward         (0,1,2) 
   (0,1)     (0,1) 
1.   2-4   ____  5-8   ____  ____ 
2.   6-2-9  ____  4-1-5   ____  ____ 
3.   3-2-7-9  ____  4-9-6-8   ____  ____ 
4.   1-5-2-8-6  ____  6-1-8-4-3  ____  ____ 
5.   5-3-9-4-1-8  ____  7-2-4-8-5-6  ____  ____ 
6.   8-1-2-9-3-6-5 ____  4-7-3-9-1-2-8  ____  ____ 
7.   9-4-3-7-6-2-5-8 ____  7-2-8-1-9-6-5-3  ____  ____ 
           Forward Span  ____ /9        Total Forward  ____ /14 
                                         GRAND TOTAL  ____/28 
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REY AUDITORY VERBAL LEARNING TEST 
 DIRECTIONS: For Trial 1, say I am going to read a list of words.  Listen carefully, for when I 
stop, you are to say back as many words as you can remember.  It doesn’t matter in what 
order you repeat them.  Just try to remember as many as you can.  Read List 1 words at 1 
second intervals (rate of 1 per second).  Check off the words recalled, using numbers to 
keep tack of the patient’s pattern of recall.  No feedback should be given regarding the 
number of correct responses, repetitions or errors.  If the patient asks if they have said a 
word before, examiner may tell them. 
 
When the examinee indicates that he/she can recall no more words, the examiner rereads 
the list after giving a second set of instructions:  Now I am going to read the same words 
again, and once again when I stop, I want you to tell me as many words as you can 
remember, including words you said the first time.  It doesn’t matter in what order you say 
them.  Just say as many words as you can remember, whether or not you said them before. 
 
The list is reread for trials 3-5, using trial 2 instructions each time.  The examiner may 
praise the examinee as he or she recalls more words.  On completion of trial 5, the 
examiner tells the examinee:  Now I am going to read a second list of words.  This time, 
again, you are to say back as many words of this second list as you can remember.  Again, 
the order in which you say the words does not matter.  Just try to remember as many words 
as you can.  Examiner reads List 2. 
 
Immediately following the reading and recall of List 2, without an additional presentation, 
subjects are asked to recall the words from the original list (List 1).  After a 20 minute delay, 
the subject is again asked to recall the words from the original list (List 1). Immediately 
following this, the subject is given the Recognition page and is asked to identify as many of 
the list words as they can (by ticking boxes as indicated) and, if possible, the specific list of 
origin (1 or 2) (i.e., to write a 1 or 2 in the box next to the appropriate word). 
 
List 1 Trial 
1 
Trial 
2 
Trial 
3 
Trial 
4 
Trial 
5 
List 2 List 2 
Recall 
List 1 Immed 
recall 
20 
Min 
Recall 
DRUM      DESK  DRUM   
CURTAIN      RANGER  CURTAIN   
BELL      BIRD   BELL   
COFFEE      SHOE  COFFEE   
SCHOOL      STOVE  SCHOOL   
PARENT      MOUNTAIN  PARENT   
MOON      GLASSES  MOON   
GARDEN      TOWEL  GARDEN   
HAT      CLOUD  HAT   
FARMER      BOAT  FARMER   
NOSE      LAMB  NOSE   
TURKEY      GUN  TURKEY   
COLOUR      PENCIL  COLOUR   
HOUSE      CHURCH  HOUSE   
RIVER      FISH  RIVER   
Totals           
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RECOGNITION TEST 
 
 
 
√ Tick if 
read to 
you 
1 = List 1 
2 = List 2 
 √ Tick if 
read to you 
1 = List 1 
2 = List 2 
1  bell   26  gun   
2  window   27  crayon   
3  hat    28  church   
4  barn   29  turkey   
5  ranger   30  fountain   
6  nose   31  boat   
7  weather   32  hot   
8  school   33  parent   
9  hand   34  water   
10 pencil   35  farmer   
11 home   36  rose   
12 fish   37  cloud   
13 moon   38  house   
14 tree   39  stranger   
15 balloon   40  garden   
16 bird   41  glasses   
17 mountain   42  stocking   
18 coffee   43  shoe   
19 mouse   44  teacher   
20 river   45  stove   
21 towel   46  nest   
22 curtain   47  children   
23 flower   48  drum   
24 colour   49  toffee   
25 desk   50  lamb   
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SIMILARITIES (WAIS-R) 
DIRECTIONS: Start with Item 1. Say, In what way are an ORANGE and a BANANA 
alike? If the subject replies that they are both fruit, say, Good and proceed to the next 
item.  If the subject gives a 1-point answer to Item 1, give an example of a 2-point 
response.  For example, If the subject answers “You eat them both”, say That’s right, you 
do eat them both.  Also, they are both fruit.  Then go onto the next item.  If the 
subject fails to respond to Item 1 or gives an incorrect answer (a 0-point response), say, 
They are both fruit, you eat them both, and go onto the next item. 
Item 2 and subsequent items should be phrased in the same way as the first item.  For Item 
2 say, In what way are a DOG and a LION alike?  Give no further help on this or any 
subsequent item.  However, if a response is unclear or ambiguous, say, What do you 
mean? Or Tell me a little more, or make a similar neutral inquiry. 
Record, verbatim, the subject’s response to each item in the appropriate space below. 
Discontinue after 4 successive failures 
 
1. Orange – Banana                                                                              
 
 
 
 
2. Dog – Lion                                                                                        
 
 
 
 
 
3. Coat – Suit 
 
 
 
 
 
4. Boat – Car  
 
 
 
 
 
5. North – West  
 
 
 
 
 
6. Table – Chair  
 
 
 
 
 
7. Work – Play 
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PRAXIS 
DIRECTIONS: Tell the patient “I am going to ask you to do some things, try and do them as 
well as you can”.  If the patient fails to perform the command well, then show him or her 
how (imitate the action).  If this fails, then give the patient the real object, where applicable 
(asterisks).  Allow for variations in normal performances.  Score 3 points for a good 
performance in the command column.  Score 2 points for approximate performance or good 
performance on imitation only.  Score 1 point for approximate performance on imitation or if 
performed with the actual object.  If the patient uses a body part for an object, score 2 
points (e.g., fingers used as a comb through the hair). 
 
Examples: “Whistle” If the patient purses his or her lips and blows, but there is no sound, 
score 2 points for an approximate performance.  If the patient declares that he or she 
cannot do it or purses his or her lips but does not blow, then demonstrate.  If the patient 
then purses his or her lips and blows, score 1 point for approximate performance on 
imitation.  If the patient fails to exhale then score (no points).  “Sniff” If the patient 
grimaces or inhales through the mouth, score 1 point only.  If performance improves on 
imitation, score 2 points.  If the patient does it only with a flower, score 1 point only.  If the 
patient rubs the flower on his or her nose, score 0 (no points) 
 
 
 
 
Command Imitated With Object 
Upper Limb 
 
   
1 Make a fist    
2 Salute    
3 Wave goodbye    
4 Scratch your head    
5 Snap your fingers    
Facial 
 
   
6 Put out your tongue    
7 Close your eyes    
8 Whistle    
*9 Sniff a flower    
*10 Blow out a match    
Instrumental 
 
   
*11 Use a comb    
*12 Use  toothbrush    
*13 Use a spoon to eat    
*14 Use a hammer     
*15 Use a key    
Complex 
 
   
16 Pretend to drive a car    
17 Knock at door and open it    
*18 Pretend to fold a paper     
19 Pretend to light a cigarette    
20 Pretend to play the piano    
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BOSTON NAMING TEST 
DIRECTIONS: Say, Now I am going to show you some pictures and I want you to say the 
name of each picture.  For each picture ask:  What is the name of this object? Or Can you 
name this?  No semantic or phonetic cuing should be used.  A non specific prompt can be 
used if the response is too general.  For example, if the response to the “canoe” item is 
“boat” say, Is there another name for that?  You may not ask, Isn’t that a special kind of 
boat?  If the test administrator uses a prompt after too general a response (i.e. “boat”) only 
the specific response (i.e. “canoe”) is counted correct. 
 
General Instructions for All Subjects  
The pictures are presented in order, allowing up to 20 seconds for response, unless the 
subject says he does not know the word before 20 seconds have gone by.  If the answer is 
correct, score 1 in column (1) if they responded within 5 seconds and column (2) if it was 
>5 seconds but <20.  Record verbatim any response other than the correct one.  If their 
response is incorrect, score 0 in columns (1) or (2), and proceed with stimulus, letter and 
phonemic cueing, if appropriate, as outlined below. 
 
Starting and Stopping points.  Begin with item 1 for all subjects, and discontinue after 6 
consecutive failures (Score>3) 
 
Picture       
       
1. Bed …………………..       
2. Tree ………………….       
3. Pencil ………………..       
4. House ……………….       
5. Whistle ……………..       
6. Scissors …………….       
         .       
         .       
55. Sphinx …………….       
56. Yoke ……………….       
57. Trellis ………………       
58. Palette …………….       
59. Protractor ………       
60. abacus …………….       
 
Summary of Scores 
  1. Number of spontaneously correct responses   ____ ____ 
 2. Number of correct responses following a stimulus cue  ____ ____ 
 3. Number of times a stimulus cue was required   ____ ____ 
 4. Number of correct responses following phonemic cue  ____ ____ 
               TOTAL CORRECT (1+2) ____/60 
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VOLUNTEERS NEEDED FOR A STUDY ON AGEING 
AND ALZHEIMER’S DISEASE 
 
 
Researchers at Concord and Royal Prince Alfred Hospital are 
conducting a study to identify early indicators for Alzheimer's 
disease (AD).  Volunteers should be over 50 years of age with no 
history or current evidence of clinical depression or major 
psychiatric disorder, stroke, head injury or significant drug and 
alcohol problems.  We are interested in recruiting people with or 
without memory difficulties, especially if they have a family 
history of Alzheimer’s disease.  Participants are asked to complete 
a number of simple memory tests and provide a small sample of 
blood.  If you are interested in participating in the study please 
phone Concetta Tarantello on 9767-5106, 9515-5873 or (mobile 
0404 498 653) during working hours. 
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VOLUNTEERS NEEDED FOR A STUDY ON AGEING 
AND ALZHEIMER’S DISEASE 
Researchers at Concord and Royal Prince Alfred Hospital are 
conducting a study to identify early indicators for Alzheimer's 
disease (AD).  Volunteers should be over 50 years of age with no 
history or current evidence of clinical depression or major 
psychiatric disorder, stroke, head injury or significant drug and 
alcohol problems.  We are interested in recruiting people with or 
without a memory complaint, especially if they have a family 
history of AD.  Participants will be asked to complete a number of 
simple memory tests and have a brain scan.  If you are interested 
in participating in the study please phone Concetta Tarantello on 
9767-5106, 9515-5873 or (mobile 0404 498 653) during working 
hours. 
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Telephone: (02) 9767 5106              [on letterhead] 
Mobile: 0404 498 653 
 
 
A RESEARCH STUDY INTO  
COGNITIVE DECLINE IN NORMAL AGEING AND PRECLINICAL ALZHEIMER’S 
DISEASE: A COMMUNITY-BASED STUDY 
INFORMATION FOR PARTICIPANTS 
BACKGROUND INFORMATION 
You are invited to participate in a research study about Alzheimer’s disease 
(AD) and memory function.  The aim of this study is to identify different 
patterns of memory capability in people aged over 50 years with and without 
mild memory complaints and in people with possible dementia seen by 
community mental health teams.  A further aim is to examine the 
relationship between current memory ability and carriers of a particular gene 
(ApoE e-4 allele) thought to increase the chance of developing dementia 
later in life.  The study is being conducted by Concetta Tarantello (PhD 
student), Dr. Glenn Hunt (Senior Research Fellow), and Dr. Richard White 
(Consultant Psychiatrist) in the Department of Psychological Medicine at 
Concord and Royal Prince Alfred Hospital. 
 
WHAT DOES THE STUDY INVOLVE? 
If you agree to participate in this study, you will be asked to provide a 5 ml 
blood sample drawn from a vein in your forearm, and to take part in a 
clinical assessment.  The clinical assessment will involve a number of simple 
tests (mostly paper and pencil tests) examining all aspects of memory and 
will take about 1 to 2 hours to complete. 
 
DISCOMFORT/RISKS 
The collection of blood may involve some discomfort at the site of the needle 
puncture and the possibility of mild bruising afterwards.  If this occurs, it 
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should go away within a couple of days.  You may become tired during the 
clinical assessment.  If this happens, you are welcome to ask for one or 
more short rest breaks.  
BENEFIT 
While we intend that this research study furthers medical knowledge and 
may improve treatment and assessment of Alzheimer’s disease in the future, 
it may not be of direct benefit to you.  Your blood sample will only be used 
for the purpose of this study (ApoE testing) and no portion will be stored for 
future use.  You can obtain the results of the ApoE blood test but the results 
cannot be used to determine if you will develop dementia in later life, 
presently ApoE typing is of research interest only.  If you would like more 
information on ApoE testing, we can give you a fact sheet of frequently 
asked questions or arrangements can be made for you to see a genetic 
counsellor if you want further advice.  
 
PARTICIPATION AND CONFIDENTIALITY 
Participation in this study is entirely voluntary, you are in no way obliged to 
participate and if you do participate you can withdraw at any time.  
Whatever your decision, please be assured that it will not affect your medical 
treatment, any present or future insurance policies or your relationship with 
medical staff (where applicable).  All aspects of the study, including results, 
will be strictly confidential and only the investigators named above will have 
access to the information.   A report of the study may be submitted for 
publication, but individual participants will not be identifiable.  If you are 
currently being seen by a community health worker and you give your 
consent, a short summary of your current memory function may be placed in 
your health folder (community medical record), as it may be helpful to the 
people looking after you.    
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FURTHER INFORMATION 
This information sheet is for you to keep.  Concetta Tarantello will answer 
any further questions you may have about this study; you can contact her on 
9767-5106 during working hours.  This study has been approved by the 
Human Research Ethics Committee (RPAH and CRGH Zone) of the Central 
Sydney Area Health Service.  Anyone with concerns or complaints about the 
conduct of the research study can contact the Secretaries of these 
committees on (02) 9515-6766 or 9767-6233.  Alternatively, if you wish to 
speak with an independent person about any problems or queries about the 
way in which the study was conducted, contact the Concord Hospital Patient 
Representative on (02) 9767-7488. 
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Some answers to frequently asked questions 
about Alzheimer’s disease and ApoE 
 
What is my risk of developing Alzheimer’s disease? 
It is worth pointing out that we are all at some risk of developing Alzheimer’s 
disease (dementia) provided that we live long enough.  More people are 
likely to develop dementia over the next 20 years because more people are 
living into their 80’s and 90’s.  Recent studies suggest that the prevalence of 
dementia in first-world populations doubles every five years between the 
ages of 65 and 85.  Stated more clearly, the chance of developing dementia 
at the age of 65 is about 1.5% and by the age of 85 this increases to 13.6% 
and if you live to the mid-nineties the rate is around 30-40%.   
 
What causes Alzheimer’s disease? 
Alzheimer’s disease (dementia) is caused by the formation of tiny plaques in 
the brain over many years.  The presence of these plaques (or tangles) 
interrupts the flow of information between different parts of the brain.  This 
results in loss of function especially for remembering things.  Progressively, 
the person becomes more and more forgetful to the point where they can no 
longer look after themselves.  Presently, we do not know what causes 
dementia or why these plaques form in some people; it may be part of the 
normal ageing process.  The majority of cases of Alzheimer’s disease do not 
result from single gene mutations; it appears to be caused by a number of 
different genetic risk factors together with environmental factors.  Recent 
research has identified one of the risk factors linked to Alzheimer’s disease to 
be a gene called ApoE. 
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What is ApoE? 
ApoE is short for apolipoprotein E.  It is a protein derived from our DNA 
(genes) that has a role in fat metabolism and tissue repair.  It is primarily 
synthesised (made) in the liver.  There are three forms of ApoE known as 
apoE2, apoE3 and apoE4.  Most of us know there are three different blood 
types-A, B and O.  People differ in the type of ApoE they inherit just like 
people have different blood types. 
A gene has two parts called alleles.  We inherit one copy from our 
mother and one copy from our father.  Together they form 2 copies (alleles) 
that determine our ApoE type.  For example, if you inherited a copy of the 
ApoE e2 gene from your mother and an ApoE e3 allele from your father, 
your ApoE status would be ApoE (e2/e3).  Since the ApoE alleles are 
different they are said to be heterozygous.  If you inherited similar ApoE 
copies from each parent (for example, both e3 or both e4), this is said to be 
homozygous.  Therefore, when you get your results they will be one of six 
possibilities. Either homozygous for which there are three types (e2/e2; 
e3/e3 or e4/e4) or heterozygous which there are also three types (e2/e3, 
e2/e4, or e3/e4).  Research has shown that the majority of people will be 
carriers of the Apo e3 gene (e2/e3, e3/e3 or e3/e4).  It is less common to be 
homozygous for the ApoE e2 (e2/e2) or the ApoE e4 (e4/e4) gene.  
 
What is the association between ApoE and 
Alzheimer’s disease? 
In 1993, an important study was published showing that the frequency of 
ApoE e4 in people with Alzheimer’s disease (namely 30-50%) was greater 
than the ApoE e4 frequency (namely 10-15%) in age-matched controls 
without dementia.  This association showing that people with two copies of 
the ApoEe4 gene (homozygotes e4/e4) have higher rates of dementia than 
non-e4 carriers has been replicated several times in different racial groups.  
The consensus of opinion is that ApoE genotype determines ‘when’ rather 
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than ‘whether’ one develops dementia in later life.  That is, carriers of the 
ApoE e4/e4 type develop dementia about 5 to 6 years earlier than non-e4 
carriers.   
Knowledge about your family history of dementia is of much greater 
importance than knowing your ApoE genotype in predicting who will develop 
Alzheimer’s disease.  It seems that people with two copies of the ApoE e4 
gene (e4/e4) have, on average, about a 50% chance of developing dementia 
by age 90 years (compared to the population average of 32%).  Also, many 
people who are non-carriers of ApoE e4 gene will go on to develop 
dementia, so this test can not be used to rule-in or rule-out the likelihood of 
developing dementia in later life.  In medical terms the test is said to have 
poor predictive value and should not be used as a diagnostic tool.  Thus, this 
test seems to have negligible diagnostic benefit so you should not be overly 
concerned about your test result.   
 
In conclusion 
At the moment we do not how ApoE e4 and the apoE4 protein influence the 
pathophysiology (cause) of Alzheimer’s disease.  The aim of this study is 
examine if there is an association between ApoE types, age and memory 
capability.  Hopefully this study will shed some light on this subject.  In 
conclusion, you should not be overly concerned about the type of ApoE you 
inherited from your parents.  It is more important to look at your family 
pedigree to see if there are several members over many generations that 
developed Alzheimer’s disease at an early age (<55 years).  If this is the 
case, you may want the advice of a genetic counsellor.  We can help arrange 
an appointment for you, if you wish. 
 
